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ABSTRACT
DESIGN, SYNTHESIS AND BIOLOGICAL SCREENING OF NOVEL CUCSINSPIRED ESTRONE ANALOGS TOWARDS TREATMENT OF PANCREATIC
ADENOCARCINOMA
KHALED MOHAMMED ALSEUD
2019
Pancreatic cancer is currently the fourth most deadly type of cancer globally. It is expected
to become the second by 2030, due to its poor prognosis and its resistance to the current
standard treatment, Gemcitabine. Moreover, the survival rate after treatment is low
compared to other cancer types, which suggests an urgent need for new potent and safe
treatment agents. Recently, the triterpenoid, cucurbitacin, has shown promising
antiproliferative activity against human pancreatic cancer cells in a dose- and timedependent manner, and decreased pancreatic tumor size in combination with gemcitabine
in vivo. However, the use of cucurbitacin in clinical studies has been hindered by its low
yield from natural sources and challenging total chemical synthesis. In order to overcome
this obstacle, we have developed molecular-modeling based strategy that resulted in the
installation of cucurbitacin pharmacophores onto an estrone scaffold to generate novel
hybrid analogs that showed a promising antiproliferative activity. In-silico drug design
results showed that modification of these compounds at C11 possessing high binding
affinity towards more than one of pancreatic molecular targets such as EGFR, and Erk,
kinase domains. Based on that total of 25 novel analogs have been synthesized by adopting
multiple step organic synthesis. The ant proliferation activities of the novel analogs were
biologically investigated against PANC-I, AsPC-I, and BXPC-3 pancreatic cell lines in 2D

xiii
and 3D models using MTT and CellTiter assays, respectively. Five analogs showed potent
IC50 values compared to gemcitabine and cucurbitacin B, and were further studied for cell
cycle inhibition, EGFR signaling and caspase 3/7 activity in 2D models. Additional studies
showed these analogs arrested the cell cycle in the G1 phase, inhibited activation of EGFR
and the downstream MAP kinase Erk. The present study shows, for the first time, that C11
modified cucurbitacin-estrone hybrid analogs possess more antiproliferative activities than
the standard chemotherapy regimen against pancreatic cancer cell lines and provide
potential drug candidates for preclinical application.

1
Chapter One
General Introduction

1.1. Drug Discovery and Development
Drug discovery research has contributed to the progress of medicine more than the research
in other medical fields.1 The drug discovery process is very complicated and requires a
development period of 10-15 years and a cost estimated to be more than $1-3 billion
dollars.2 Moreover, 95% of these drug candidates fail to receive approval from NIH during
the early or late stages of drug discovery or during the clinical phases.3 The drug discovery
process starts with the identification of a medical problem that needs to be treated, followed
by identification of the molecular targets used to treat that disease and the screening of
many compounds in vitro against these targets. Thousands of compounds are produced
during this screening stage. Following this stage, the drug candidates undergo a preclinical
studies where they are tested in vivo. Many disciplines contribute to this long process
where the pharmacological activity and toxicity profile of these drugs are tested, mostly in
mice. This stage will determine if the drug will be moved to clinical trials after approval
from the FDA; at that point, it will obtain an investigational new drug (IND) license that
allows researchers to start the clinical trial process. In the clinical trial stage, the
pharmacological and toxicity effects are studied in healthy human subjects, as well as in
human subjects who are affected by the targeted disease. This stage is divided into four
phases.4
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Figure 1.1. Timeline for the general stages of drug discovery and development.5
By benefiting from the failed drugs, medicinal chemists develop drug design concepts
through which they can identify the functional groups that increase the binding to the
targets compared to existing groups and groups that are known to be toxic, such as nitro
groups. Also, an understanding of molecular targets facilitates the drug discovery process,
especially since the advancements in bioinformatics. Through bioinformatics and genetic
sequences, the researcher is able to identify the genetic mutations in biological molecules
in different cancer types before they are overexpressed in vitro, and use them as targets for
screening small molecules.5 Through NMR spectroscopy, x-ray crystallography, and
computational in-silico design programs, a better understanding of ligand-target
interactions is gained and the first stage of the drug discovery process has been effectively
minimized.6
One of the strategies used in the drug discovery process is in-silico drug design, where a
library of small molecules is screened against a three-dimensional structure of a
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macromolecule. In this strategy, small molecules are fitted into the space that is docked by
the original ligand that crystalized with that macromolecule.7 The first step in molecular
docking includes the generation of a large library of small molecules and all possible
conformers of these ligands by rotating the angles between their atoms. Then, the most
stable conformer is chosen by using one of the force fields, such as UFF, GAFF or
MMFF94.8 After the preparation of the virtual library, docking programs with different
parameters rank the binding of the molecules.9 Docking programs such as FRED, Surflex
and DOCK will run the exhaustive docking process that is used to rank the ligands based
on different functions, such as shapeguass, PLP, chemgauss3, chemscore, and screenscore.
These functions rank the ligands based on the molecular interactions between the ligand
and the macromolecule. For example, all of these mentioned forces consider the fitting of
the molecule in the pocket and the hydrogen bonding between the ligand and the target
(with the exception of the chemguass function). Some interactions are unique to a specific
function, such as desolvation which is used by chemguass3 but not the others. These
scoring functions also vary in terms of their speed, exhaustive docking and optimization.
After running the docking experiments, these compounds will be ranked according to a
calculated consensus score that depends on the functions used in the docking. The lowest
consensus score will be the ligand that best binds to the target. The promising candidates
will be obtained either by purchasing, if they are commercially available, or by
synthesizing them chemically.
After synthesizing the candidate compounds and testing their biological activity in vitro,
another important step is necessary to gain information that might not be predicted by
molecular modeling. Information such as the transport of the drug to the cell or the export
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of the drug by a certain resistance mechanism requires that other kinds of optimization are
performed to overcome the obstacles found in the biological evaluations of these
candidates. These optimizations have different aspects, including changing the polarity of
some functional group or completely changing the pharmacophores.
Many aspects of optimization have been carefully studied, leading to the development of
drug discovery rules. For example, the Lipinski rule of five suggests that a compound
should not exceed 5 hydrogen bond donors and 10 hydrogen bond acceptors, and its
molecular weight should be less than 500 Daltons with a partition coefficient in terms of
log P less than 5.10 These rules are focused on the chemical and physical properties of the
compound which affect its binding to the target and its bioavailability. Although these rules
are not essential in determining if a drug will be a good candidate, it is important to take
them into consideration and use them as an initial guide in designing drugs, thus keeping
synthesized compounds within the mentioned ranges.
Another aspect of drug optimization uses a bioisosterism concept where a chemical group
can be substituted with a different group having similar chemical properties to obtain better
pharmacological activity or less toxic effects. Bioisosterism is based on the biological
activity derived from a biological evaluation of previously known lead compounds and
their derivatives.11 Sometimes, bioisosterism is applied not only to change the biological
activity of compounds, but to change their physical properties to improve their
bioavailability, thus maintaining or improving the potency of the drug.
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1.2. Natural products as an inspired source for drug discovery
Statistical studies regarding approved drugs indicate that natural products play an important
role in drug discovery. Natural products contain unique pharmacophores, as noted through
their complex stereochemistry. An example of a natural product-inspired drug is
temsirolimus, which is an mTOR inhibitor with anticancer activity against renal cell
carcinoma. It was developed from the natural product rapamycin.12

Figure 1.2. a diagram for the sources of the approved from the period of 1981-2011
shows that almost two thirds are derived from natural products.13

1.3. Cucurbitacins as Potential Natural Compounds Targeting Different Molecular
Targets
Cucurbitacins are four-ring tetraterpenoid compounds that exist in very small amounts in
Cucurbitaceae plants, such as Cayaponia tayuya, and Citrillus colocynthis.14 This group of
compounds, which consists of 18 types, was traditionally used as an anti-inflammatory and
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anticancer agent are example of natural products that has been used for different
pharmacological uses till today.15
1.3.1. Chemistry of Cucurbitacins
Cucurbitacins are tetracyclic triterpenes are characterized by high number of oxygen atoms
and similar to steroids in structure (Figure 1.3). One of the common features of
cucurbitacins and steroids, such as cholesterol and estrone, is the presence of the four ring
system.16 However, some differences and additional functional groups are found in
cucurbitacin (cuc) that result in its unique pharmacological activities compared to steroids,
such as the gem-dimethyl group at ring A, C4, the methyl that exists between rings B and
C, and C9. In some cuc types, such as cuc A, C11 is hydroxylated, which is thought to be
responsible for the selectivity of cuc A as it loses its anti-STAT3 inhibition activity.17
Another feature of cucurbitacins is the presence of α-β-unsaturated ketone in the side chain,
which is one of the major pharmacophores responsible for the antiproliferative activity of
cucurbitacins. Upon comparing nine commonly found cucs compounds, common
functional groups can be used to distinguish cuc family of compounds from the other fourmembered ring steroidal compounds. These characteristics include the double bond
between C5 and C6 and ring B, α-hydroxyl group at ring D, C16, the hydroxyl group at C2,
and the ketone at C3 of ring A. In all cucs compounds, except for cucs C and F, the ketone
group is reduced to hydroxyl groups, while C2 of cuc C is attached to hydrogen instead.
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Figure 1.3. General structures of cucurbitacin and steroid.

The α-β-unsaturated ketone side chain of cucurbitacins either contains the tertiary
hydroxylated group, as in cucs D and F-J, or are acetylated, as in the rest of cucs.
Experimental data confirms the presence of acetyl-transferase enzyme as expressed in the
gene biosynthetic cluster of these cucs types.18
1.3.2. Pharmacological Activities of Cucurbitacins
The unique oxygenated and unsaturated four rings of cucurbitacins, which differentiate
them from the other steroidal scaffolds, give them unique biological and pharmacological
activities.19 Cucs were traditionally known for their anti-inflammatory activity, but
recently, they became efficient antiproliferative agents for the treatment of different cancer
types, such as lung, breast, colon, and pancreatic cancers.17 Moreover, cucs have been
reported to have antiviral activity, which opened another avenue of investigation for
pharmacological uses for cucurbitacins.20
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Cucurbitacins have been traditionally used as an anti-inflammatory agent by applying it
topically. In this type of application, it has been proved to inhibit cyclooxygenase 2 (COX2). Cyclooxygenase enzymes are involved in the biosynthesis of prostaglandins and
thromboxane, so their inhibition relieves the symptoms of inflammation and pain.21
Comparing cucs with the non-steroidal anti-inflammatory (NSAIDs) COX inhibitors,
Recio et al. indicated that the COX-2 inhibitory rate of cucs is lower than NSAIDs. On the
other hand, cucs are more selective COX-2 inhibitors. Other reports demonstrated that the
saturation of carbons 23, 24 of cucs increased the inhibitory COX-2 activity.22
Cuc B has demonstrated comparable antiviral activity to acyclovir when it was examined
against the enveloped-DNA virus Herpesviridae, with IC50 values of 0.94 and 1.74 μM,
respectively.23 The anti-HSV-1 activity of cucs against enveloped-DNA viruses, which are
responsible for many antiviral infections, indicate other potential antiviral activities for
these compounds. Moreover, cuc B showed a mono- and synergistic effect with
tetracycline and oxacillin against Staphylococcus aureus (S. aureus). As a result, cucs may
be used in combination with antibiotics for the treatment of staphylococcal infections.23
Currently, cucs are being investigated for their anticancer activity in different cancer cell
lines. Moreover, many in-vivo studies demonstrate the antiproliverative activity of cucs in
combination with other drugs, as well as in monotherapy.
1.3.3. Cucurbitacins Anti-proliferative Activities
The anticancer activity of cucs have been investigated in many cancer cell lines, including
lung, leukemia, hepatocellular carcinoma, breast, ovarian, colon, brain, and pancreatic
cancers.23 Generally, cucs as antiproliferative activity can be divided into four mechanisms:
proapoptosis, induction of autophagy, cell cycle arrest, and inhibition of cancer invasion
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and migration.24 Cucs have been demonstrated to interfere with important signaling
pathways involved in tumor growth, such as EGFR, PI3K/Akt, mTOR, STAT3 and ERK
signaling.25 Epidermal growth factor receptor (EGFR) is a transmembrane protein that has
extracellular and intracellular domains.26 Two mechanisms are used to inhibit EFGR
activity. One mechanism competitively inhibits the extracellular binding site of EGF,
prevents the dimerization of two EGFR monomers and inhibits the initiation of the
downstream cascade. The second mechanism involves the inhibition of kinase activity by
which EGFR can phosphorylate the downstream proteins. EGFR is found to be
overexpressed in many cancer types, such as breast, lung, pancreatic and liver cancers.27
The inhibition of EGFR can restrain the pathways of (Ras/Raf/MEK/ERK) that are
significant in many cancer types. Another important target for cucs is signal transducer and
activator of transcription 3 (STAT3), which is phosphorylated by receptor-associated Janus
Kinases (JAK).28 Moreover, cuc B was reported to inhibit the PI3K/Akt/mTOR pathway.
Through inducing p53, p21, and caspase-3, cucs inhibit the growth of tumors through
apoptosis29 and interact with the microtubules and cycloskeleton of the cell, which leads to
cell cycle arrest at the G2/M phase.30
Upon investigation of the structure activity relationship (SAR) of cucs, studies proofed that
the α-β-unsaturated C22-C24 enone side chain is the main pharmacophore for cuc anticancer
activity. This was demonstrated by decreasing the antiproliferative activity of dihydro-cucs
B and D. Moreover, the glycosylated cucs showed less cytotoxic activity than the nonglycosylated cucs. Also, the acetylation of C25 of cuc B increased its antiproliferative
activity by 1000 fold, compared to cuc D.31
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Cuc D also demonstrated antiproliferative activity against the PrCa prostate cancer cell
line, with an IC50 of 0.1 μM to 1μM. This was accomplished by decreasing the GLUT1
expression, which led to a decrease in glucose uptake and lactate secretion. Cuc D affect
cell cycle arrest in the G2/M phase, and upon treatment using a PrCa xenograft mouse
model, it inhibited tumor growth.32
Upon investigation against the gemcitabine-resistant AsPC-I pancreatic cell line, cuc D
displayed antiproliferative activity by inhibiting the Muc13 expression, EGFR, and AKT
activation, along with enhancing miR-145 expression. Compared to a control group, cuc
D reduced tumor size in SCID mice injected with pancreatic cells.
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Figure 1.4. Anticancer activity mechanism of cucurbitacin on different pathways.

1.3.4. Mechanism of Antiproliferative Activity of Cucurbitacins
1.3.4.1. Inhibition of MAPK/ERK pathway
The MAPK/ERK (or Ras/B-Raf/MEK/ERK) (Figure 1.5.) pathway is a group of proteins
that act as a chain when the receptor, which is the transmembrane protein (EGFR), is
activated. This initiates and activate a cascade that ends in the nuclear DNA and regulates
vital biological functions such as cell division, differentiation, survival and cell death. This
pathway has been considered as one of the successful strategies to treat cancer, although
resistance is created by mutation, mainly in the proteins of this pathway.33
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Figure 1.5. The major downstream targets of ERK1/2 in the MAPK pathway.
1.3.4.2. Epidermal Growth Factor Receptors (EGFR) and Cancer
EGFR (ERB1) is one of the four types of the ErbB receptor family. This tyrosine receptor
kinase consists of an extracellular binding domain, a hydrophobic transmembrane domain,
and a cytosolic domain that causes kinase (phosphorylation) activity for the downstream
proteins.34 When the growth factors, such as transforming growth factor α (TGF- α), binds
to the extracellular domain of EGFR, the dimerization or activation of the receptor occurs,
resulting in phosphorylation of specific tyrosine residues in the intracellular cytosolic
domain of EGFR. This leads to a subsequent activation of the downstream proteins.34, 35
Liovet et al. showed that the deactivation of EGFR increased the survival rate of patients
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in the late stages of hepatocellular carcinoma.36 This occurs through the inhibition of EGFR
phosphorylation in pancreatic cancer cells.25
1.3.4.3. Rat Sarcoma (RAS) Protein Family and Cancer
Ras gene was discovered in the 1960’s in a study that was focused on Harvey sarcoma and
Kristen sarcoma viruses originally found in rats, thus named Rat sarcoma. 37 Ras proteins
consist of six beta strands and five α-helices, which form GTP, a GDP-binding domain and
a C-terminal region. Ras proteins are activated when GTP is bound to it, and deactivated
after phosphorylation of the downstream proteins with GDP bound to it.38 Mutations of
RAS proteins, mainly K-RAS mutation, have recently been identified in many cancer cells,
such as small intestine, colon, pancreatic, and biliary tract cancers.39 Due to the ability of
phosphorylated RAS to rewire and activate different pathways, it is challenging to inhibit
its downstream activity.40 For example, one of these important pathways is the
posttranslational modification of C-MYC, which results in the increased activity of MYC,
which is one of the critical pathways of RAS-driven activity.40 Shukla et al. reported that
cuc B downregulated C-MYC/K-RAS at the protein level.41
1.3.4.4 Rapidly Accelerated Fibrosarcoma (RAF) and Cancer
RAF proteins are activated by RAS-GTPases and consist of three family members. This
family of receptors are characterized by the presence of serine/threonine-specific kinases.
After phosphorylation by RAS proteins, the A-C proteins phosphorylate the downstream
MEK1/2 proteins.42

14
1.3.4.5. Mitogen-Activated Protein Kinase and Cancer (MEK1/2)
Currently, seven types of MAP kinases have been identified; however, MEK1 and 2 are
the only known substrates of RAF kinases. These consist of C- and N- terminal domains
and an ERK-binding region. RAF phosphorylates MEK/2 at tandem serine residues at a
site called an activation loop. Phosphorylated MEK1/2 regulates different cell functions,
such as the ERK activation.43
1.3.4.6. Extracellular Signal–Regulated Kinases (ERKs)
ERK proteins are involved in the regulation of many cellular functions, such as cell
division. The mechanism of activating ERK1/2 by RAF kinases involves phosphorylation.
Evidence has been found to show that the phosphorylated ERK2 activated by MEK1 is
transferred to the nucleus where it activates the proliferation process, while ERK2 activated
by MEK2 is transferred to the cytosol and promotes cell survival.44 The inhibition of ERK
proteins is an important mechanism by which anti-cancer agents act.
1.3.4.7. Cucurbitacins Effect on Filamentous-Actin
Actins are protein components found in all eukaryotic cells and have many important
functions. These structures are either globular (G-actin) or filamentous (F-actin). F-actin
type maintain many functions in eukaryotic cells, such as maintaining the cytoskeleton and
facilitating cell migration.45 It has been reported that cuc E selectively inhibits F-actin
depolymerization (without inhibiting the monomeric globular G-actin) by covalently
binding with CYS 257 amino acid residue.46 Another study proved that cuc E stimulates
the actin cytoskeleton disturbance in the prostate cancer cell line.47
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1.3.4.8. Cucurbitacins' Effect on STAT3 Signaling Pathway
Signal transducers and activators of transcription are a family of cytosolic transcription
activators that stimulate the biosynthesis of cell surface receptors and transmit the signal
into the nucleus. Several reports indicate that this pathway is key to tumor growth. The
most important of the seven member family is STAT3, which promotes the initiation and
progression of cancer by several mechanisms, including inhibiting apoptosis and inducing
cell proliferation.48 Activation of STAT3 is carried out by IL-6 and EGF proteins using
several mechanisms.49 After the activation of STAT3, dimerization occurs in the
cytoplasm, and subsequently activates the Janus-kinase (JAK) phosphorylation, which
leads to phosphorylation of other STAT3 monomers. Phosphorylated STAT3 also induces
transcription by binding to DNA.50
The activity of cucs in inhibiting the STAT3/JAK pathway has been studied and the
structure activity relationship has been demonstrated according to the different
functionalities of cucs compounds. For example, cuc I acts by inhibiting the
phosphorylation of STAT3 in lung cancer,51 while cuc A inhibits the activation of JAK2,
and cucs B and E act by inhibiting both STAT3 and JAK2.52
1.3.4.9. Cucurbitacins' Effect on mammalian target of rapamycin (mTOR) Pathway
mTOR is one of the downstream proteins in PI3K/AKT/mTOR that affects the cell
proliferation cycle.53 The up regulation of this pathway has been observed in cancer cells
such as osteosarcoma. Cuc B has been shown to inhibit mTOR directly as a single agent,
as well as in combination with methotrexate, although the authors suggest that the exact
mechanism by which cuc B inhibits mTOR needs further investigation.54
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1.3.4.10. Hepatoprotective activity of cucurbitacins
Interestingly, cuc D and dihydrocuc D at lower than the antiproliferative dose indicate a
hepatoprotective effect against carbon tetrachloride-induced toxicity on HepG2 cell line.
An investigation of the underlying mechanism indicates that cuc D and its dihydro form
decrease the production of tumor necrosis factor-alpha and interleukin-6 in hepatocellular
carcinoma cell line HSC-T6.55
1.4. Pancreatic Cancer
1.4.1 Background
Cancer is a disease that is characterized by abnormal growth of cells. These uncontrolled
cells have the ability to invade surrounding tissues when the disease reaches the metastasis
stage.56 Pancreatic ductal adenocarcinoma (PDAC) is the most malignant tumor among
pancreatic cancer types and represents about 85% of the diagnosed pancreatic cancer
cases.57 Anatomically, the pancreas, which is about 6 inches long in a normal adult, is
characterized by three main parts. The first part is the head, which is located on the right
side of the abdomen in front of the small intestine where the duodenum and stomach meet.
The larger part of the pancreas, the body, is behind the stomach, while the tail lies on the
left site of the abdomen beside the spleen.58 Histologically, the pancreas contains two types
of cells: endocrine and exocrine cells. Exocrine cells excrete digestive enzymes into ducts
that merge with bile ducts, then secrete fluid into the duodenum. The endocrine ducts,
which secrete less than the exocrine ducts, biosynthesize important hormones such as
insulin and glucagon.58 The tumors that occur with exocrine cells, acinar cells, is called
pancreatic ductal adenocarcinoma, which represent the majority of pancreatic cancer types.
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The mortality statistics on pancreatic ductal carcinoma (pancreatic cancer) cases indicate
it has the fourth highest mortality among cancer types in United States.59

Figure 1.6. Anatomy and histology of the pancreas.60
Pancreatic cancer mortality data indicates an increasing number of deaths,61 and it is
expected to be ranked as the second cause of death among cancer types in the near future.62
The estimate for the number of patients with pancreatic cancer in 2016 is 53,070, and
according to the current mortality rate, most of them will have a survival period of 5 years
or less.63 Of the previous cases, 75% of the pancreatic ductal adenocarcinoma patients were
between the ages of 55 and 84 years and the majority of them were men. This indicates that
the age of 55 is one of the risk factors.64 Other risk factors are related to lifestyle, including
smoking, alcohol usage, and a high cholesterol diet.65 Based on its pathology, PDAC can
be divided into three main stages. The initiation stage begins when the mutation occurs due
to the environment effect or a failure in DNA repair after cell division. It is estimated that

18
the first cell that has the mutation of the drive gene for PDAC occurs 20 years before the
disease can be diagnosed.66 In the second stage, the mutated cell begins to divide and
proliferate until it reaches the third stage, where the mutated population of cells spread to
the surrounding cells and break the basement membrane.67
Molecular biology and genetic sequencing indicate that four common types of mutations
occur in PDAC. Mostly KRAS mutation, which encodes the RAS family of GTP-binding
proteins, are responsible for cell proliferation and cell survival.68 Of the analyzed PDAC
cases, the KRAS mutation is found in about 95% of the cases.69 Other mutations include
the tumor gene suppressor CDKN2A, the transcription factor TP53, and the cotranscription factor SMAD4.69
The symptoms of PDAC include jaundice, dark urine, greasy stool, itchy skin and back
pain. The reason for the high mortality rate with pancreatic cancer is the absence of
biomarkers that can be detected in the early stages.70 Moreover, the progress in developing
pancreatic anticancer agents is very slow.71
The treatment of PDAC differs according to the stage of the disease and the health of the
patient. The surgical option is the first choice of treatment if the patient is diagnosed to
have stage I, II, or III PDAC. In stage I, the tumor is restricted to the pancreas, while in
stage II, the tumor is 2-4 cm in size. By stage III, the tumor has spread to the major blood
vessels or nerves close to the pancreas.59 However, if the patient is diagnosed to have stage
IV PDAC, where the cancer has spread to other organs, chemotherapy is the best option.
The current standard treatment for pancreatic cancer is gemcitabine; it has an 18% 1-year
survival rate, which is much better than the former standard treatment, 5-fluorouracil (5-
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FU), that had only a 2% 1-year survival rate. The six-month survival rates for gemcitabine
and 5-FU are 23.8% and 4.8%, respectively, which indicates that there is an urgent need to
find novel agents for pancreatic cancer treatment.

1.4.2. Current Treatment of Pancreatic Ductal Adenocarcinoma
1) Surgical Resection
Because PDAC is usually diagnosed in the late stages in more than 95% of the patients,
the surgical option is only used in 10-15% of the patients. However, several cases have
been found in which the surgical resection cannot be performed. These cases include the
presence of metastasis on the liver, distant metastasis or lymph node enlargement.
Moreover, the mortality rate is approximately 3-5% in the cases in which surgery was
performed.72 Also, the statistical studies indicate that the survival rate after surgery is 316% of patients for 5 or more years.73
2) Radiotherapy
Applied radiotherapy has been used alone or in combination with surgery or chemotherapy.
A Gastrointestinal Tumor Study Group (GITSG) indicated that the survival rate increased
to 19% after 10 years of radio chemotherapy.74
3) Chemotherapy:
Since the majority of pancreatic cancer patients are diagnosed in the late stage of the
disease, chemotherapy is the first option used. Administration of gemcitabine
chemotherapy as a single agent is tried first.75 Gemcitabine has an 18% one-year survival
rate compared to the former standard 5-fluorouracil (5-FU) that has only a 2% 1-year
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survival rate. The six-month survival rates for gemcitabine and 5-FU are 23.8% and 4.8%,
respectively.76 Several studies have been conducted in which gemcitabine is combined with
other drugs, such as cisplatin. In this combination, cisplatin induced DNA lesions, while
gemcitabine enhanced this effect by inhibiting DNA repair, resulting in apoptosis of the
cells.77 Colucci et al. conducted a clinical study in which two groups of pancreatic ductal
adenocarcinoma

patients

were

administered

either

gemcitabine

or

the

gemcitabine/cisplatin combination weekly for 7 weeks, followed by 1 week rest, then
interrupted doses for a period of 4 weeks at days 1, 8, and 15. In this study, no improvement
was seen in the combination treatment group. Rather, hematologic toxicity cases were
observed in the group administered combination therapy.75
After its uptake by human nucleoside transporters (hNTs), gemcitabine is metabolized to
2՛, 2՛-difluoro-2՛-deoxycytidine triphosphate before it is phosphorylated by deoxycytidine
kinase and pyrimidine nucleoside monophosphate kinase to produce gemcitabine
diphosphate (dFdCDP). At this point, it is incorporated into DNA chain biosynthesis by
the DNA polymerase, which results in its termination.78 However, due to the steps needed
for gemcitabine to reach its target, several mechanisms of resistance are adopted by cancer
cells to avoid DNA termination. These mechanisms include lack of transporters and
phosphorylation enzymes, along with overexpression of gemcitabine deactivating
enzymes, such as cytidine deaminase, that convert gemcitabine into its inactive metabolite
dFdU.79 The low survival rate of PDAC patients compared to other cancer types has
inspired researchers to investigate novel, more effective anti-pancreatic cancer drugs.
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1.5. Cucurbitacin-Inspired Estrone (CIE) Analogs
Chemically, cucurbitacins are characterized by the presence of a cucurbitane nucleus and
an α,β-unsaturated ketone side chain that is responsible for the anticancer activity of
cucurbitacin.80 Cuc B was the first cuc that was made biosynthetically. From a biosynthetic
point of view, cucs E and B are considered the precursors of all cucs compounds, based on
the studies of their biosynthetic gene cluster. For instance, cucurbitacins A, D, C, F, G and
H can be synthesized via biotransformation of cuc B, whereas cucs I, K, J and L can be
biosynthesized from cuc E.81 However, due to the low yield of cucs from their natural
sources and the challenge of total chemical synthesis, cucs could not be advanced to clinical
studies. However, the core of the cucurbitacins was synthesized via a highly regio- and
stereoselective Diels-Alder Reaction. 82 Moreover, chemical modifications of cuc B were
carried out to study the anticancer activity of cuc B derivatives.83
In order to overcome this obstacle, we developed a molecular-modeling dependent novel
strategy with cucs pharmacophores, using the triterpenoid four-membered rings estrone as
a scaffold. One important pharmacophore of cucs is 23, 24 α, β- unsaturated ketone side
chain that is responsible for the anticancer activity of cucs. Interestingly, when we installed
this side chain on estrone, it showed comparable anticancer activity to that of
cucurbitacin.84 These cucurbitacin-inspired estrone analogues (CIEA’s) opened the door to
more investigations regarding the functionalization of this compound at different positions.
We searched for more potent anticancer compounds through in-silico molecular modeling
of these analogs against known cucurbitacin molecular targets. Currently, we have proven
that the functionalization of rings A, C and D of CIE analogs can lead to more potent
anticancer agents than the currently available standard treatments. Previously, we reported
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that the dehydrogenation of C9-C11 and C16-C17 generally increased the potency of this
group of compounds.85 Moreover, methylation and sulfamoylation of C3 increased the
potency relative to the originally found phenol.86 One of the recent modification strategies
for the anticancer drugs which currently induce resistance from cancer cells is the
introduction of a nitric oxide releasing group, such as NCX-1000, that shows effective
hepatoprotective activity. Recently, our investigation shows promising anticancer activity
for NO-CIE analogs containing nitric oxide releasing functional groups, such as the
furoxan moiety. In this instance, a furoxan moiety was installed at ring C3 through an ether
linker. The IC50 of the hybrid with phenyl para-trifluoromethyl side chain against HepG2
cell line was 4.69µM. 87 Another modification included the introduction of many functional
groups instead of a cucurbitacin side chain through aldol condensation; one such group was
phenyl para-trifluoromethyl, which showed potent anticancer activity.
One of the arguments regarding CIE analogs is the presence of an aromatic ring instead of
ring A in the cucurbitacins. However, the aromatic ring at this position did not decrease
the anticancer activity, as previous studies mentioned. Moreover, fevicordin A is an anticancer agent that has an aromatic ring as an estrone scaffold and the cucs general structure
as well, indicating that the presence of an aromatic ring is not a drawback for CIE analogs.88
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1.6. Project Objectives
Based on the previous studies that were conducted in our lab and the molecular docking
studies, this project focuses on the modification of cucurbitacin-inspired estrone analogs
(CIEA’s) that target pancreatic cancer. Based on molecular docking data a library of virtual
compounds will be designed and the candidates with high binding affinity to the molecular
targets will be chemically synthesized and their inhibitory effects will be investigated on
EGFR and downstream signaling pathways, including Mitogen Activated Protein Kinase
(MAPK) pathway comprised of RAS/ RAF/ MEK/ ERK proteins and PI3K/Akt/mTOR
pathway. Moreover, a structure activity relationship study will be conducted in order to
sum up the data obtained over 5 years of work on the development and optimization of
CIEA’s as promising anticancer agents for the treatment of different cancer types.
The main objectives of this project are:


Molecular modeling study of different CIE analogs modified in rings A, C and D

on potential molecular targets of pancreatic cancer cells.


Synthesis of CIE analogs that have a promising calculated binding affinity to the

used molecular targets, according to the molecular modeling study.


Biological evaluation of the synthesized CIE analogs against three pancreatic

cancer cell lines using 2D and 3D cell viability assay using 2D and 3D models.


Study the cell cycle arrest of CIE analogs that have promising IC50 value compared

to the currently available drug of choice for pancreatic cancer (gemcitabine).


Study the effect of these compounds in caspas-3 activity and inducing cell
apoptosis.
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Study the inhibitory effect of the promising analogs

using the potential molecular targets that were used in the first objective to the rank the
virtually designed CIE analogs using In-Cell Western (ICW) assay.

25
1.7. References
1.

Drews, J. J. s., Drug discovery: a historical perspective. 2000, 287 (5460), 1960-

1964.
2.

Dickson, M.; Gagnon, J. P. J. N. r. D. d., Key factors in the rising cost of new

drug discovery and development. 2004, 3 (5), 417.
3.

U.S. Department of Health & Human Services, About New Therapeutic Uses. 10-

30-2018
4.

U.S. Department of Health and Human Services The Drug Development Process.

(accessed Jan-23).
5.

Advances in Biological Sciences, Guided Tool for Virtual Drug Discovery. 2017.

6.

Gibbs, J. B. J. S., Mechanism-based target identification and drug discovery in

cancer research. 2000, 287 (5460), 1969-1973.
7.

Ferreira, L.; dos Santos, R.; Oliva, G.; Andricopulo, A. J. M., Molecular docking

and structure-based drug design strategies. 2015, 20 (7), 13384-13421.
8.

Acharya, C.; Coop, A.; E Polli, J.; D MacKerell, A. J. C. c.-a. d. d., Recent

advances in ligand-based drug design: relevance and utility of the conformationally
sampled pharmacophore approach. 2011, 7 (1), 10-22.
9.

Halgren, T. A. J. J. o. c. c., Merck molecular force field. I. Basis, form, scope,

parameterization, and performance of MMFF94. 1996, 17 (5‐6), 490-519.
10.

López-Vallejo, F.; Caulfield, T.; Martínez-Mayorga, K.; A Giulianotti, M.;

Nefzi, A.; A Houghten, R.; L Medina-Franco, J. J. C. C.; Screening, H. T., Integrating
virtual screening and combinatorial chemistry for accelerated drug discovery. 2011, 14
(6), 475-487.

26
11.

Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. J. A. d. d. r.,

Experimental and computational approaches to estimate solubility and permeability in
drug discovery and development settings. 1997, 23 (1-3), 3-25.
12.

Brown, N. J. B. i. M. C., Bioisosterism in medicinal chemistry. 2012, 1-14.

13.

Faivre, S.; Kroemer, G.; Raymond, E. J. N. r. D. d., Current development of

mTOR inhibitors as anticancer agents. 2006, 5 (8), 671.
14.

Samedan LTD Pharmaceutical Publisher, The Roots of Innovation. 2011.

15.

Miro, M. J. P. r., Cucurbitacins and their pharmacological effects. 1995, 9 (3),

159-168.
16.

Fuller, R. W.; Cardellina, J. H.; Cragg, G. M.; Boyd, M. R. J. J. o. n. P.,

Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus
keithii. 1994, 57 (10), 1442-1445.
17.

Gry, J.; Søborg, I.; Andersson, H. C., Cucurbitacins in plant food. Nordic

Council of Ministers: 2006.
18.

Alghasham, A. A., Cucurbitacins–a promising target for cancer therapy.

International journal of health sciences 2013, 7 (1).
19.

Molavi, O.; Ma, Z.; Mahmud, A.; Alshamsan, A.; Samuel, J.; Lai, R.; Kwon,

G. S.; Lavasanifar, A., Polymeric micelles for the solubilization and delivery of STAT3
inhibitor cucurbitacins in solid tumors. International journal of pharmaceutics 2008, 347
(1), 118-127.
20.

Doskotch, R. W.; Hufford, C. D. J. C. J. o. C., Hexanor–cucurbitacin D, a

degraded cucurbitacin from Begonia tuberhybrida var. alba. 1970, 48 (11), 1787-1788.

27
21.

Chawech, R.; Jarraya, R.; Girardi, C.; Vansteelandt, M.; Marti, G.; Nasri, I.;

Racaud-Sultan, C.; Fabre, N. J. M., Cucurbitacins from the leaves of Citrullus
colocynthis (L.) Schrad. 2015, 20 (10), 18001-18015.
22.

Bernard, S. A.; Olayinka, O. A., Search for a novel antioxidant, anti-

inflammatory/analgesic or anti-proliferative drug: Cucurbitacins hold the ace. Journal of
Medicinal Plants Research 2010, 4 (25), 2821-2826.
23.

Alghasham, A. A. J. I. j. o. h. s., Cucurbitacins–a promising target for cancer

therapy. 2013, 7 (1), 77.
24.

Zhou, Y.; Ma, Y.; Zeng, J.; Duan, L.; Xue, X.; Wang, H.; Lin, T.; Liu, Z.;

Zeng, K.; Zhong, Y. J. N. p., Convergence and divergence of bitterness biosynthesis and
regulation in Cucurbitaceae. 2016, 2 (12), 16183.
25.

Kaushik, U.; Aeri, V.; Mir, S. R. J. P. r., Cucurbitacins–an insight into medicinal

leads from nature. 2015, 9 (17), 12.
26.

Alsayari, A. S., Anticancer and Antiviral Activities of Cucurbitacins Isolated

From Cucumis Prophetarum var. Prophetarum Growing in the Southwestern Region of
Saudi Arabia. 2014.
27.

Willoughby, D. A.; Moore, A. R.; Colville-Nash, P. R. J. T. L., COX-1, COX-2,

and COX-3 and the future treatment of chronic inflammatory disease. 2000, 355 (9204),
646-648.
28.

Recio, M. C.; Prieto, M.; Bonucelli, M.; Orsi, C.; Máñez, S.; Giner, R. M.;

Cerda-Nicolas, M.; Ríos, J.-L., Anti-inflammatory activity of two cucurbitacins isolated
from Cayaponia tayuya roots. Planta medica 2004, 70 (05), 414-420.

28
29.

Wang, Y.; Zhao, G.-X.; Xu, L.-H.; Liu, K.-P.; Pan, H.; He, J.; Cai, J.-Y.;

Ouyang, D.-Y.; He, X.-H. J. P. o., Cucurbitacin IIb exhibits anti-inflammatory activity
through modulating multiple cellular behaviors of mouse lymphocytes. 2014, 9 (2),
e89751.
30.

Hassan, S.; Berchová-Bímová, K.; Petráš, J.; Hassan, K. J. S. A. J. o. B.,

Cucurbitacin B interacts synergistically with antibiotics against Staphylococcus aureus
clinical isolates and exhibits antiviral activity against HSV-1. 2017, 108, 90-94.
31.

Cai, Y.; Fang, X.; He, C.; Li, P.; Xiao, F.; Wang, Y.; Chen, M. J. T. A. j. o. C.

m., Cucurbitacins: A systematic review of the phytochemistry and anticancer activity.
2015, 43 (07), 1331-1350.
32.

Zhou, J.; Zhao, T.; Ma, L.; Liang, M.; Guo, Y.-J.; Zhao, L.-M. J. O.,

Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by
suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling. 2017, 8 (61), 103167.
33.

Herbst, R. S. J. I. J. o. R. O. B. P., Review of epidermal growth factor receptor

biology. 2004, 59 (2), S21-S26.
34.

Seshacharyulu, P.; Ponnusamy, M. P.; Haridas, D.; Jain, M.; Ganti, A. K.;

Batra, S. K. J. E. o. o. t. t., Targeting the EGFR signaling pathway in cancer therapy.
2012, 16 (1), 15-31.
35.

Yuan, Z.-l.; Guan, Y.-j.; Wang, L.; Wei, W.; Kane, A. B.; Chin, Y. E. J. M.;

biology, c., Central role of the threonine residue within the p+ 1 loop of receptor tyrosine
kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. 2004, 24 (21),
9390-9400.

29
36.

Alsayari, A.; Halaweish, F. T.; Gurusamy, N. J. P. R., The role of cucurbitacins

in combating cancers: A mechanistic review. 2018, 12 (24), 157.
37.

Wang, X.; Tanaka, M.; Peixoto, H. S.; Wink, M. J. P., Cucurbitacins:

Elucidation of their interactions with the cytoskeleton. 2017, 5, e3357.
38.

Matsuda, H.; Nakashima, S.; Abdel-Halim, O. B.; Morikawa, T.; Yoshikawa,

M., Cucurbitane-type triterpenes with anti-proliferative effects on U937 cells from an
egyptian natural medicine, Bryonia cretica: structures of new triterpene glycosides,
bryoniaosides A and B. Chemical and Pharmaceutical Bulletin 2010, 58 (5), 747-751.
39.

Liu, F.; Yang, X.; Geng, M.; Huang, M. J. A. p. s. B., Targeting ERK, an

Achilles' Heel of the MAPK pathway, in cancer therapy. 2018.
40.

Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. J. T. E. j., The ErbB

signaling network: receptor heterodimerization in development and cancer. 2000, 19 (13),
3159-3167.
41.

Gullick, W. J. J. E.-R. C., The Type 1 growth factor receptors and their ligands

considered as a complex system. 2001, 8 (2), 75-82.
42.

Llovet, J. M.; Bruix, J., Molecular targeted therapies in hepatocellular carcinoma.

Hepatology 2008, 48 (4), 1312-1327.
43.

Malumbres, M.; Barbacid, M. J. N. R. C., RAS oncogenes: the first 30 years.

2003, 3 (6), 459.
44.

Vetter, I. R.; Wittinghofer, A. J. S., The guanine nucleotide-binding switch in

three dimensions. 2001, 294 (5545), 1299-1304.
45.

Prior, I. A.; Lewis, P. D.; Mattos, C. J. C. r., A comprehensive survey of Ras

mutations in cancer. 2012, 72 (10), 2457-2467.

30
46.

National Cancer Institute, N., RAS and MYC: Co-conspirators in Cancer. 2017,

https://www.cancer.gov/research/key-initiatives/ras/ras-central/blog/2017/myc-ras.
47.

Shukla, S.; Khan, S.; Kumar, S.; Sinha, S.; Farhan, M.; Bora, H. K.; Maurya,

R.; Meeran, S. M. J. C. p. r., Cucurbitacin B alters the expression of tumor-related genes
by epigenetic modifications in NSCLC and inhibits NNK-induced lung tumorigenesis.
2015, canprevres. 0286.2014.
48.

Roskoski Jr, R. J. B.; communications, b. r., RAF protein-serine/threonine

kinases: structure and regulation. 2010, 399 (3), 313-317.
49.

Johnson, G. L.; Lapadat, R. J. S., Mitogen-activated protein kinase pathways

mediated by ERK, JNK, and p38 protein kinases. 2002, 298 (5600), 1911-1912.
50.

Gentry, L.; Samatar, A. A.; Der, C. J., Inhibitors of the ERK mitogen-activated

protein kinase cascade for targeting RAS mutant cancers. In The Enzymes, Elsevier:
2013; Vol. 34, pp 67-106.
51.

Stricker, J.; Falzone, T.; Gardel, M. L. J. J. o. b., Mechanics of the F-actin

cytoskeleton. 2010, 43 (1), 9-14.
52.
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Chapter two

Molecular Modeling of Novel Cucurbitacin-Inspired Estrone Analogs Against
Molecular Targets of Pancreatic Adenocarcinoma

2.1. Introduction
Computer-based drug design is one of the fundamental tools in modern drug discovery due
to the time, effort and cost minimization facilitated by computational drug design
programs.1 The main purpose of the docking study is to predict the binding of a ligand
towards an active site of a molecular target based on the most stable conformer of a
designed ligand and a 3-D structure of a crystalized molecular target using a computational
docking tool.2
There are many approaches in drug discovery focusing in investigation for novel potent
drugs. Among these approaches is pharmacophore approach which include linking the
active pharmacophores in small molecules to result in one entity that have most or similar
potency to that of the parent molecule.3 Based on the kind of the modification, two
strategies are adopted in pharmacophore approach.4 The first approach where the
modification of the ligand is hypothesized based on the active compound and is called
ligand-based approach. On the other hand, the receptor-based modification utilize the
binding pocket for the agonist and the antagonist in order to modify novel ligands.4
However, each strategy has its challenges and drawbacks. For example, ligand flexibility
represents a challenge in ligand-based drug discovery because based on the predicted
conformation the molecular docking against the target pocket will be conducted. In order
to minimize the error caused by the variations exist in 3D conformation prediction, two
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strategies have been used. The first strategy is creating different conformers of each ligand
and screen them against the target pocket or conducting an extensive modeling process to
each ligand to calculate the most stable conformer against specific pocket which is time
consuming.5 One of the challenges that limit the use of receptor-based drug discovery
approach is availability of 3D structure of the macromolecule crystallized with its ligand
which is fundamental to build the modified ligands based on the features of the original
ligand and the arrangement of the amino acids in the binding pocket.5
An example of a drug developed using computational drug design is the development of
carbonic anhydrase II inhibitor, dozolamide that is used for treatment of glaucoma. Based
on cone-shape pocket of X-ray crystallography of carbonic anhydrase II, dorzolamide was
developed by introducing sulfamoyl moiety that show a significant coordination with
zinc.6
Another example of rational drug design is neuraminidase (NA) enzymes inhibitors used
as antiviral agents. NA enzymes are essential macromolecules of influenza virus envelops
that catalyze the breakdown of glycosidic linkage between the virus sialic acid and
hemagglutinin residues and the host cell wall followed by spreading the virus all around
the body. Inhibition of this enzyme will restrict the virus and force it to remain connected
to the cells and prevent its spread.95 After reporting the crystal structure of neuraminidase
II, antiviral agents were developed based on the conservative sites in NA II enzyme using
GRID software and utilizing NA II inhibitor 2-deoxy-2, 3-dehydro-N-acetylneuraminic
acid (DANA). Subsituting 4-hydroxy group in DANA with amine led to a potent inhibitor
for NA which was called zanamivir.8

38
Nolatrexed dihydrochloride is a phase I anticancer agent showed anticancer activity against
hepatocellular carcinoma was developed based on the crystal structure of E.coli
thymidylate synthase that catalyze the conversion of deoxyuridine monophosphate to
deoxy thymidylate by methylation and reduction of thymidyl ring which is an essential in
DNA synthesis.8, 9
Molecular modeling programs are used in many aspects to improve drug design including
pharmacodynamics data such as potency, affinity, and efficacy along with pharmacokinetic
properties, which are absorption, distribution, metabolism, and excretion which lead
eventually to structure activity relationship (SAR) for different groups of compounds.1
Generally, there are three main approaches of conducting molecular dockings including
flexible ligand docking where the molecular target is rigid and a library of different
conformers of ligands are docked against that rigid target. In rigid docking, both the target
and ligands are rigid molecules which is opposite to the flexible docking where both the
screened ligands and the target molecules are flexible.10 The molecular modeling that we
utilized in our investigation is a semiflexible modeling, meaning that the pocket of the
molecule is fixed while different conformers of the designed compound that were designed
using ChemBio3D Ultra 12.0

11

are screened against the pocket of the protein that was

downloaded from protein data bank12 and processed using Make Receptor® software. This
approach led to decrease the cost and effort of the medicinal chemists in drug discovery
and result in increasing discovery of huge number of small molecules to be used
pharmacologically in treatment of different diseases.2
OpenEye® Scientific Software is one of the molecular docking software that uses FRED
software which docks multi-conformers database of molecules against a putative binding
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pocket of a rigid receptor using exhaustive search algorithm.13 Our molecular modeling
studies was carried out using two OpenEye Softwares, (Omega) that generates the
conformers of the compounds and rigid exhaustive docking (FRED). The targets for the
previously mentioned proteins were processed and generated using Make Receptor®
software.
ChemBio3D Ultra 12.0 utilizes two force fields to predict the bond angles, MM2 and
MMFF94, where the later uses different equations to estimate the intramolecular Van der
Waals interactions and contain more parameters.14 Calculating the most minimized form
of the compound based on its total energy is conducted following the equation:
Esteric energy = Estr + Ebend + Estr-bend + Eoop + Etor + EVdW + Eqq
Where Estr is the energy needed to stretch or compress the bond between two atoms and
Ebend is the energy required to bend a bond from its equilibrium angle, θ o. Estr is the
energy needed to stretch or compress the bond when the bond is bent because the energy
required at this case is affected by that bent. Eoop estimates the energy required for an
atom to move of that angle of planar plane. While Eoop is used with the atoms that form
planar geometry such as in sp2 hybridized carbons and is called improper torsion, Etor is
used to calculate the energy required to torsion rotate bonds, which means that this
calculation is used in single bonds but not the double or the triple rigid bonds. EVdW and
Eqq are the two interactions that exists between the non-bonded atoms and are important
in the formation of the molecule geometry. Eqq are the electrostatic energy which exists
when there are polar or partial electrostatic charges bonds in the molecule.14 The main
difference between MM2 (2nd generation Molecular Mechanics) and MMFF94 (Merck
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Molecular Force Field) is that the constants used to predict EVdW in MM2 are derived
from hydrocarbons and is not reliable in calculating the field force for the compounds that
contain oxygen or in compounds containing nitrogen or sulfur.14
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Figure 2.1. The promising C11 functionalized CIE analogs.

Previously, utilizing OpenEye® Scientific Software we developed a molecular-modeling
strategy to design hybrid antiproliferative compounds consists of estrone as a carrier and
cucurbitacin main pharmacophore 23, 24 α, β- unsaturated ketone side chain that is
responsible for its anticancer activity. Based on cell viability assays, Cucurbitacin-Inspired
Estrone compounds were found to have anticancer activity comparable to that of
cucurbitacins.15 Following that, several modifications have been conducted on these
compounds led to increase the antiproliferative potency dramatically against many cancer
cell lines. These modifications include dehydrogenation of C9-C11 in ring C, and C16-C17
in ring D,

16

and modifications in ring A including methylation, sulfamoylation and the

nitric oxide releasing moiety furoxan at C3 which was proofed to have promising
antiproliferative activity against hepatocellular carcinoma.17,18 The other modifications
include introducing of many 23, 24 α, β- unsaturated ketone side chains other that of
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cucurbitacin side chain through aldol condensation such as para-trifluoromethyl, which
dramatically increased the anticancer potency.
These results inspired us to investigate more for novel cucurbitacin-inspired estrone (CIE)
analogs modified at C11 on ring C of CIE analogs in order to develop more potent
antiproliferative compounds. In this study different functional groups were introduced
virtually to C11 of CIE analogs including halogens, hydroxyl, ketone, amine, amide, ethers,
hydrazine, and methyl ketone functional groups. Our molecular-docking study
demonstrates that there are three promising functional groups have high calculated affinity
to pancreatic ductal adenocarcinoma targets such as EGFR, Erk, STAT3, and JAKI. These
modifications include dehydrogenation of C9-C11 in ring C that showed cucurbitacin-like
conformation upon docking in Erk active pocket. Another modifications include
introducing hydroxyl and ketone groups at C11 which show low consensus scores upon
docking to EGFR ATP binding site.
2.2. Results and Discussions
More than 400 analogs were generated using Chem3D with different functional groups at
rings A, D, and ring C at C11 in order to investigate for the effect of functionalization of
ring C in binding affinity calculations. Previously, our molecular modeling studies and the
biological evaluation of CIE analogs indicated that the functionalization of ring C can lead
to increase in the anticancer activity on melanoma cancer cells.7
In order to conduct the molecular modeling study, each designed virtual compound was
energy minimized using MMFF94 application to calculate the most stable conformer. The
target proteins were downloaded from protein data bank using the following codes from
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the protein data bank (PDB) database (EGFR PDB ID # 1M17, STAT3 PDB ID # 4ZIA,
3LJ2, RAF PDB ID # 3OMV, MAPK PDB ID # 2YO8, RAS PDB ID # 4DTS, ERK PDB
ID # 2OJJ, Akt PDB ID # 3MV5, PI3K PDB ID # 3L54)
The processing of the proteins was achieved by selecting the required pockets with the
crystalized original ligand followed by removing of the water molecules and determining
the margins of the box where it contains the pocket where the designed compounds will be
screened against. In order to conduct the docking experiment, the designed compounds
must be compiled onto one file which is achieved by the required command according to
OPENEYE® instruction manual.101 The file after that was converted into the required
OEB format using OMEGA® software (one of included softwares). FRED® software
conduct the exhaustive molecular docking using the required command and VIDA is used
to analyze the final results where the tested ligands are arranged from the ligand that has
the highest affinity or the lower consensus score followed by the lower affinity, while the
compounds that cannot be fitted in the pocket are excluded. The scoring function that are
mathematical calculations used to predict the binding affinity of the pocket toward certain
molecule are different from software to another. Generally, the binding affinity are
calculated by different functions which calculate the difference the total energy of the
protein-ligand complex and the free energy of each of the compound and the protein
separately. The scoring functions initially was optimized based on the known ligand
erlotinib that was crystalized with EGFR ATP binding pocket. Using the following scoring
functions shapegauss, chemgauss3, oechemscore, screenscore and PLP optimization of the
docking for erlotinib in its binding pocket was conducted and compared to the published
data. These scoring functions differ from each other in certain functions while they are
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similar in some. Table 2.1 indicates the various intermolecular interactions that the scoring
functions available in FRED® use to rank the compounds during the docking experiment.
The used scoring functions differ in the used parameters to rank the compounds. For
example, screenscore and PLP scoring functions show similar parameters which indicate
that their results are close to each other, while Chemgauss3 is assumed to calculate different
results due to the presence of the algorithm of desolvation calculation.

16

Based on these

values, VIDA rank the compounds using the consensus score which represents the total
energy difference of the complex compared to the binding free energy of the protein and
ligand before binding. The negative free energy is preferable because it means that the
protein has a good affinity to the binding pocket of the protein.
After conducting the molecular docking against EGFR, we used the reported data for
erlotinib on its crystallization with EGFR that is available in protein data bank to confirm
the validity of the docking study where it has a hydrogen bonding with methionine
MET:769: A as it has been reported (figure 2.2).
Molecular modeling results against EGFR, JAK, STAT3, Raf, Ras, Erk, Akt and PI3K
proteins, indicate that the dehydrogenation of C9 and C11 and introducing of hydroxyl,
carbonyl functional groups at C11 with methylation of ring A at C3 lead to high consensus
scores compared to erlotinib cucurbitacin B, and D which were used as standards for the
molecular docking. introducing of hydroxyl, carbonyl functional groups at C11 with
methylation of ring A at C3 Show promising virtual binding affinity towards molecular
targets such as EGFR and STAT3, while dehydrogenation of C9 and C11 showed a better
binding affinity to ERK binding pocket compared to the C-11 functionalized analogs
(Figure 2.1).
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A. A diagram indicates the amino acid binding to erlotinib through hydrogen bonding.

B. Docking of erlotinib to ATP binding site of EGFR mimic the crystallization reported data.
Figure 2.2. Comparison between the reported crystallization data and the molecular
modeling results for erlotinib in EGFR validate the conducted molecular docking
experiment and the used docking scores.
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Table 2.1. The interactions that scoring functions of FRED® calculate.16
Scoring Function

Shape

H Bonds

Metal

Aromatic

Desolvation

Shapegauss

Yes

No

No

No

No

Chemgauss3

Yes

Yes

Yes

No

Yes

Chemscore

Yes

Yes

Yes

No

No

Screenscore

Yes

Yes

Yes

No

No

PLP

Yes

Yes

Yes

No

No

The molecular modeling study shows that most of these compounds are ranked high in
other molecular targets that are inhibited by previously synthesized CIE analogs such as
ERK.
The molecular docking experiment indicate that there are 3 set of compounds
functionalized at C11 CIE. The first group of compounds which include KA20, KA22,
KA19, KA23, and KA21 are dehydrogenated at C9 and C11, where the other analogs with
hydroxyl group and ketone groups which show good binding affinities in ATP binding site
of EGFR, while the desaturated compounds show a better binding affinity to ERK biding
pocket.
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A.

The docking of KA2 in ATP binding site of EGFR.

B.
The binding of KA9 in ATP Binding pocket of EGFR.
Figure 2.3. The binding of KA2 and KA9 in ATP binding site of EGFR.
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An example of C11-hydroxyl compounds are KA1 and KA2, containing paratrifluoromethyl and cucurbitacin side chains, respectively, which show high binding
affinities toward ATP binding site of EGFR binding pocket (Figure 2.3A and 2.4). KA2
shows a hydrogen bonding with proline 770 in chain A of EGFR which occurs with the
hydroxyl group of the side chain.
Generally, para-trifluoro side chain indicate a good binding affinity such as KA1 and KA9
with C11 hydroxyl and ketone, respectively as it is indicated in Figure 2.3.
From the indicated results, the docking profiles of the two compounds are close to each
other; however, KA9 show a better fitting in the pocket compared KA1 which show a space
between the compound and the amino acids.
One the other hand the third modification that show constant pattern is the desaturated C9C11 compounds where they score better than the other compounds including C11
oxygenated-CIE analogs in Erk and RAS proteins which indicate the importance of this
modification to be investigated more by modifying it with different side chains. In terms
of functional groups,

hydroxyl group containing compounds score more higher than

the compounds desaturated at C9 and C11 and C11-ketone containing analogs.
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Figure 2.4. The hydrogen bonding of hydroxyl group of isopropyl alcohol side chain
of KA2 to proline 770: A in ATP binding site of EGFR.

The docking results of the same library against ERK binding pocket indicate the
importance of the double bond introduced in C9 and C11 which lead to change the
conformation of the whole molecule to adopt the structure of cucurbitacin D as indicated
from figure 2.5 (A and B). For example, phenyl para-nitro side chain adopts the similar
binding conformation of cuc D in ERK binding pocket as it was indicated previously. This
conformation is one of the modifications that led to increase the calculated binding affinity
of CIE analogs in Erk binding pocket.
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A.

The curve-like structure of KA19 in ERK binding pocket.

B.

Similarity of KA19 with cuc D structure in fitting into ERK binding pocket.

Figure 2.5. The similarity of KA19 and cuc D binding in ERK pocket.
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Table 2.2. The consensus scores obtained from VIDA software for the virtually
designed CIE analogs docked in different potential molecular targets.
VIDA
Name

EGFR

STAT3

RAF

RAS

ERK

PI3K

KA9_57

18

0

183

59

84

41

KA13_53

25

31

97

49

82

84

KA11_43

26

19

93

28

60

KA8_153

31

13

56

54

55

KA3_126

32

60

35

47

87

KA6_73

35

111

150

47

50

111

KA1_72

36

79

62

77

37

72

KA7_143

37

1

162

33

37

68

KA4_156

42

61

99

82

31

53

KA14_3

51

78

53

45

98

49

KA5_62

52

23

78

74

63

84

KA12_127

54

52

50

58

72

88

KA20_31

57

75

37

14

44

123

KA22_55

59

42

15

17

17

126

KA19_112

60

42

37

9

9

17

CucD_197

67

100

99

98

106

59

Iso B_113

73

303

116

80

94

135

KA10_64

74

62

55

26

75

67

KA23_55

76

50

70

36

36

32

IsoCucD

82

100

99

108

82

96

KA21_29

83

54

252

83

7

104

Erl_38

126

63

30

100

162

89

22
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2.3. Methods of Molecular Modeling
All computer works were conducted on Gateway Computer with Windows XP and
OpenEye.6
2.3.1. Preparation of the virtual ligands
A virtual library of 400 CIE analogs containing 23, 24 α, β- unsaturated ketone side chain
assembled in C17 of estrone and different functional groups at C11 with hydroxy-, methoxy, at C3 skeleton with cucurbiracins B and D and the inhibitors of the used receptors as
standards were generated and energy minimized utilizing Chem3D office 2012, using
MMFF94 force field function for energy minimization process in order to acquire similar
structural confirmation mimic that of the existed 3-D structure adopted by the designed
molecules.
The energy minimized compounds were compiled in one folder and through OMEGA
software were converted from .pdb format to .oeb format which is compatible with FRED
software. Omega produce different conformers of each single compound in the virtual
library. Some of Omega settings were modified from the default settings such as highest
number of output conformers 400 (GP-NUM-OUT-CONFS), rejecting conformers that has
energy differences compare to standards minimum ˃ 0.5 Kcal/mole (GP-ENERGYWINDO) and choosing the conformers with lowest energy from the final calculations (GPSELECT-RANDOM false). Furthermore, increase the number of free rotatable bonds in
each ligand to be 30 (GP-MAX-ROTORS) to create different conformers for all molecules
in our library.
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2.3.2. Preparation of the molecular targets
Receptor preparation started by choosing the receptor of interest and processing it using
make receptor application which convert the .pdb file into 3-D view of the receptor chains
including its binding ligands and co-factors. Then the next step is pointing to the binding
pocket that the co-crystalized ligand binds to. Then mode selection window of the
application will allow the generation of the grid box which should be in specific size of
60,000 Ao or lower. However, if a large grid box needed to be form (larger than 60.000
Ao), the box can be divided to two sites, otherwise the docking process will not be
conducted smoothly. Final step is specifying the pocket shape so the docking program can
recognize the inner and outer contour. After conducting all the previous steps, the protein
will be ready for executive molecular docking.
2.3. 3. Conducting Molecular Docking Process Using FRED
FRED program locates the 3D area where the algorithmic search conducted and recognize
the possible shape for docking calculations that is called shape fitting step. The shape fitting
step determines the 3D area for the ligand best binding pocket avoiding unnecessary
binding with other components of the protein and at the same time reserving the area for
optimal interactions. In the last step, both files of the combined ligands and the files of the
prepared receptor are put into FRED to conduct the molecular docking simulations. Scoring
functions perspective can be optimized by different available optimization steps including
torsion optimization, rigid skeleton optimization and hydroxyl group rotamers
optimization. Consensus scores of the docking study can be acquired by various scoring
functions at the final stage such as shapegauss, chemgauss3, oechemscore, screenscore and
PLP. All the functional commands for OpenEye® FRED can be found in electronic manual
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(link www.eyesopen.com/products). 3D structure of the docked ligands with protein can
be visualized utilizing OpenEye® VIDA application where 3D picture of the ligand-protein
complex can be taken.

2.4. Conclusion
Theoretical modification conducted in C11 indicates the importance of investigation of this
position experimentally. Different groups show different affinities to the MAPK signaling
pathway. For instance, C9-C11 unsaturated CIE analogs score better in Erk and RAS
proteins compared to the other modifications. One of the important challenges in treatment
of pancreatic ductal adenocarcinoma is KRAS mutation which is responsible about 90% of
the resistance against gemcitabine. Moreover, Ketone containing compound KA9 is the
highest scoring compound among CIE analogs in EGFR. However, the hydroxyl
containing compounds generally score in all the used proteins better than any other C11
functionalized compounds except Erk and RAS.

54

2.5. References
1.

Gibbs, J. B. J. S., Mechanism-based target identification and drug discovery in

cancer research. 2000, 287 (5460), 1969-1973.
2.

Dar, A.; Mir, S. J. J. A. B. T., Molecular docking: approaches, types, applications

and basic challenges. 2017, 8, 2.
3.

Cui, F.; Yang, K.; Li, Y. J. P. O., Investigate the binding of catechins to trypsin

using docking and molecular dynamics simulation. 2015, 10 (5), e0125848.
4.

Mills, N., ChemDraw Ultra 10.0 CambridgeSoft, 100 CambridgePark Drive,

Cambridge, MA 02140. www. cambridgesoft. com. Commercial Price:
1910fordownload, 2150 for CD-ROM; Academic Price: 710fordownload, 800 for CDROM. ACS Publications: 2006.
5.

Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig,

H.; Shindyalov, I. N.; Bourne, P. E. J. N. a. r., The protein data bank. 2000, 28 (1), 235242.
6.

SCINTIFIC, O., 2018, https://www.eyesopen.com/.

7.

Ahmed, M. S.; Halaweish, F. T. J. J. o. e. i.; chemistry, m., Cucurbitacins:

potential candidates targeting mitogen-activated protein kinase pathway for treatment of
melanoma. 2014, 29 (2), 162-167.
8.

Alsayari, A.; Kopel, L.; Ahmed, M. S.; Pay, A.; Carlson, T.; Halaweish, F. T. J.

S., Design, synthesis, and biological evaluation of steroidal analogs as estrogenic/antiestrogenic agents. 2017, 118, 32-40.

55
9.

Ahmed, M. S.; Kopel, L. C.; Halaweish, F. T. J. C., Structural optimization and

biological screening of a steroidal scaffold possessing cucurbitacin‐like functionalities as
B‐raf inhibitors. 2014, 9 (7), 1361-1367.
10.

Cousins, K. R., Computer review of ChemDraw Ultra 12.0. ACS Publications:

2011.
11.

Stéphan, E.; Zen, R.; Authier, L.; Jaouen, G. J. S., Improved synthesis of a

protected 11-oxoestrone. 1995, 60 (12), 809-811.
12.

Shattuck, T. W. J. D. o. C., Colby College, Waterville, Maine, Colby College

Molecular Mechanics Tutorial. 2008, 4901.
13.

Lensink, M. F.; Méndez, R.; Wodak, S. J. J. P. S., Function,; Bioinformatics,

Docking and scoring protein complexes: CAPRI 3rd Edition. 2007, 69 (4), 704-718.
14.

Du, X.; Li, Y.; Xia, Y.-L.; Ai, S.-M.; Liang, J.; Sang, P.; Ji, X.-L.; Liu, S.-Q.

J. I. j. o. m. s., Insights into protein–ligand interactions: mechanisms, models, and
methods. 2016, 17 (2), 144.
15.

Ahmed, M. S.; Kopel, L. C.; Halaweish, F. T. J. C., Structural Optimization and

Biological Screening of a Steroidal Scaffold Possessing Cucurbitacin‐Like
Functionalities as B‐Raf Inhibitors. 2014, 9 (7), 1361-1367.
16. OpenEye Scientiﬁc Software, I., FRED Fast Rigid Exhaustive Docking OpenEye
Scientiﬁc Software, Inc. : 9 Bisbee Ct, Suite D Santa Fe, NM 87508 2008
17.

Ahmed, M. S.; Kopel, L. C.; Halaweish, F. T. J. C., Structural Optimization and

Biological Screening of a Steroidal Scaffold Possessing Cucurbitacin‐Like
Functionalities as B‐Raf Inhibitors. 2014, 9 (7), 1361-1367.

56
18.

Mahnashi, M. H., Design, Synthesis and Biological Screening of Novel

Cucsinspired Estrone Analogues Towards Treatment of Hepatocellular Carcinoma. 2017.

57
CHAPTER THREE
Synthesis and Biological Activity of 9, 11 dehydrogenated Cucurbitacin Inspired
Estrone Analogs Targeting Pancreatic Cancer

Abstract
Pancreatic cancer is expected to be the second leading cause of death in Untied States by
2030. The standard treatment is Gemcitabine as a mono-chemotherapy; this is currently
used in combination with other anticancer drugs. However, the survival rate range after
treatment is low compared to other cancer types, which suggests an urgent need to search
for new treatment agents. Recently, the triterpenoid natural product, cucurbitacin B,
showed promising antiproliferative activity against human pancreatic cancer cells. This
activity involved decreasing the expression levels of pSTAT3 and pEGFR in a dose- and
time-dependent manner by inducing cell apoptosis via inhibition of STAT3
phosphorylation. Additionally, in an in vivo study, it decreased the pancreatic tumor size
in combination with gemcitabine. Due to the low yield of cucurbitacin from its natural
sources and the challenging chemical synthesis of its highly stereochemical complexity,
we developed a novel strategy that facilitates the use of cucurbitacin pharmacophores with
estrone as a scaffold. We virtually installed the cucurbitacin pharmacophores on estrone,
then used molecular modeling software to identify the best candidates for chemical
synthesis and in-vivo study. The molecular docking study showed promising binding
affinity for the cucurbitacin-inspired estrone analogues (CIEAs) unsaturated in C9 and C11;
this group of compounds show better calculated affinity than the saturated analogs, due to
cis conformation at the juncture of rings B and C. Moreover, the molecular docking study
displayed similar conformation for all the analogs upon docking in the EGFR and Erk
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binding sites. Based on that result, 8 analogs were synthesized and biologically screened
against PANC-I and AsPC-I pancreatic cancer cell lines. Two analogs showed promising
IC50 values compared to cucurbitacin B, so they were further studied through in-cell
western analysis to confirm the inhibition of pErk overexpression as the mechanism of
action. KA19 and KA20 inhibited the phosphorylation of Erk and the inhibition increase
up on increasing the treatment concentration, which confirmed the theoretical result
obtained from the previously conducted molecular modeling study.
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3.1. Introduction
Pancreatic adenocarcinoma (PDAC) is one of the leading causes of death in both men and
women. The understanding of its pathology is advancing, since more cases are now found
in Europe, North America and Australia. In the United States PDAC is expected to be the
second leading cause of death by 2030.1,2 Pancreatic cancer is the only cancer type that has
a stable rate of mortality in both men and women, reported to be 3.5% for women in 2017.3
The reason for the high mortality rate for pancreatic cancer is the absence of biomarkers
with to detect the disease in its earlier stages.4 The risk factors for pancreatic cancer include
type II diabetes mellitus, smoking, and obesity.5,6 Studies have reported that an increase in
the waist to hip ratio increases the risk of PDAC by 70%. Inversely, a decrease in weight
and exercise can reduce the PDAC risk.7 In addition to the late diagnosis for pancreatic
cancer, the anti-pancreatic cancer drug discovery process has been slow compared to other
cancer types.8 The nucleoside analog gemcitabine is the drug of choice for the treatment of
PDAC, either as a monotherapy or in combination with other anticancer drugs such as
cisplatin. The one-year survival rate is 18% for patients treated with gemcitabine,
compared with 2% for the previously used anti-pancreatic cancer drug 5-fluorouracil (5FU).9 Recently, it was reported that a combination of gemcitabine and capecitabine
increased the 25-month survival rate from 22.7-27.9 to 95% in terms of 28 months.10 After
its uptake by human nucleoside transporters (hNTs), gemcitabine is metabolized to 2՛,2՛difluoro-2՛-deoxycytidine triphosphate before it is phosphorylated by deoxycytidine kinase
and pyrimidine nucleoside monophosphate kinase to produce gemcitabine diphosphate
(dFdCDP). At this point, it is incorporated into the DNA chain biosynthesis by DNA
polymerase and results in its termination.11 However, due to the numerous steps that
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gemcitabine has to pass through to reach its target, several mechanisms of resistance have
been adopted by cancer cells to avoid DNA termination. These mechanisms include lack
of transporters and phosphorylation enzymes, along with overexpression of gemcitabine
deactivating enzymes, such as cytidine deaminase, that converts gemcitabine into its
inactive metabolite, dFdU.12
The low patient survival rate compared to other cancer types has inspired researchers to
search for novel, more effective anti-pancreatic cancer drugs. Overexpressed proteins such
as pEGFR and pERK, which leads to effects such as tumor growth, overexpression of fatty
acid synthase enzyme and a disturbance in lipid metabolism and cell migration have been
reported in pancreatic cancer patients.13
The natural anticancer triterpenoid, cucurbitacin B, in combination with gemcitabine at
low doses, led to the inhibition of pancreatic tumor growth.14 Recent studies have indicated
that cucurbitacin works mainly by inhibiting the JAK-STAT and MAPK pathways, which
play an important role in tumor growth and survival.14
Among the promising, new compounds that demonstrate significant inhibition of cancer
growth and the MAPK pathway are the semisynthetic estrone analogs that mimic
cucurbitacin compounds. Cucurbitacin-inspired estrone (CIE) analogs were initially
designed based on molecular modeling against cucurbitacin's potential targets, such as
EGFR and ERK proteins.15One of the reported targets for CIE analogs is epidermal growth
factor receptor (EGFR), where CIE analogs inhibit its phosphorylation, along with that of
extracellular signal-regulated kinase (ERK).16
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A recent target-based drug discovery has developed more potent CIE analogs targeting
different cancer types. Molecular modeling studies have been utilized to synthesize three
major groups of compounds so far. The first group contain a 23, 24 α, β- unsaturated ketone
side chain that mimics cuc compounds.17 Additional compounds were designed based on
molecular modeling results and verified biologically by replacing the cuc side chain with
different side chains that improved the activity of these compounds against hepatocellular
carcinomas, both resistant and non-resistant HepG2.18,19 The second group included the
dehydrogenation of C16 and C17, which dramatically increased its activity compared to the
previously synthesized analogs. The third modification to this group was the synthesis of
CIE analogs that contain a sulfamoyl moiety instead of methyl at C3; that modification
showed promising anticancer activity.20 The dramatically increased activity of this group
was attributed to the ability of sulfamoyl-modified compounds to bypass the first phase
metabolism, as noted in a study that showed anticancer activity on a 3-sulfamoyl estrone.21

3.2. Molecular Modeling Design Strategy
A molecular modeling study using the biological screening data of the first group of
compounds indicated that the dehydrogenation of C9 and C11 cucurbitacin-inspired estrone
analogs (CIEA’s) increased the anticancer activity of MSA-8 to 12.2 µM, compared to that
of MSA-7, which is saturated at the previously mentioned positions22 (Figure 3.1). Thus,
this modification shows great promise for improving the activity of CIE analogs. This
increase in anticancer activity is attributed to the configuration of the compound, changing
ring B from the chair to half-chair configuration. Moreover, the substitution of a 23, 24 α,
β- unsaturated ketone side chain was reported to increase anticancer activity; however, the
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effect of substituting this side chain with a different side chain is yet to be investigated in
depth. The modification of ring A resulted in blocking the estrogenic activity of the CIE
analogs.22
Considering the findings from the biological studies, as well as the molecular docking
studies, different CIE analogs were virtually designed with various substituted side chains
and modeled against CIE potential analogs using OpenEye® scientific software. The study
used novel designed CIE analogs with an alkene group at C9 and C11 and various 23, 24 α,
β- unsaturated ketone side chains with lower consensus scores and show promising binding
calculations against potential molecular targets of pancreatic cancer, including EGFR,
ERK, STAT3, JAK2, P53, B-RAF.

Figure 3.1. The dehydrogenation of MSA-8 at C9 and C11 increased the anticancer
activity of MSA-7 due to a change in the configuration of the molecule.20
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3.3. Results and Discussions
3.3.1. In-silico molecular modeling
A virtual library of CIE analogs was designed to mimic cucurbitacin compounds with
different functional groups in positions 9 and 11, and different enon side chains at position
17. Cucurbitacins B and D, with erlotinib and NCX-1000 were used as standards and
designed through in ChemDraw software, followed by energy minimization by Chem3D
using the force field MMFF94. The catalytic domains for EGFR and ERK proteins were
downloaded from the protein data bank using their PDB codes, 1M17 and 2OJJ,
respectively.23 Various OpenEye® software applications were used to perform the
molecular modeling experiment. OMEGA application generated different conformers,
while the docking was conducted using FRED software. The output of the molecular
modeling process was visualized using VIDA application, which ranked the compounds
based on their consensus scores, where the lower score indicates a better binding affinity
of the compound toward an active site of the protein that was processed and determined
using MAKE RECEPTOR®. Based on this process, 8 compounds were selected to be
synthesized and biologically tested against PANC-I and AsPC-I pancreatic cancer cell
lines. All the selected ligands (Figure 3.3) showed better binding than the previously
mentioned standards, based on consensus score calculations, (Table 3.1). The molecular
modeling process was validated by using the binding profile of the standard erlotinib to
EGFR. Among the high scoring ligands, KA19 showed promising binding affinity to ERK
binding site where it adopts the same profile as cuc D binding to the same pocket. This
explains the increased anticancer potency of this group compared to the previously
synthesized CIE analogs (Figure 2.3 A, B).
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A.

KA19 docking profile in ERK binding pocket.

B.
KA19 shows a cuc-like docking profile in the Erk binding pocket.
Figure 2.3. The docking profile of the highest scoring CIE analog in Erk docking.
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Figure 3.3. The structures of the promising C9-C11 dehydrogenated cucurbitacininspired analogs.
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Table 3.1. The consensus scores of the docked C9-C11 dehydrogenated CIE analogs on
Erk binding pocket.
Consensus
Chemgauss3 OEChemscore Screenscore Score

VIDA Name

PLP

KA19_59

57.9087 -64.6093

-46.7819

-140.123

9

KA17_117

61.5173 -60.1572

-44.8431

-143.464

14

KA22_64

53.9205 -62.8396

-44.9295

-126.344

17

KA23_66

52.4111 -57.3973

-44.7099

-117.968

36

KA20_37

55.5477 -51.1163

-41.5947

-125.192

44

KA18_182

45.3341 -59.6018

-45.5775

-104.68

47

ISo D_68

38.3577 -61.9525

-42.9418

-87.7898

70

Cucurbitacin I_22 35.6603 -58.9337

-41.6845

-99.3021

76

KA21_37

41.3433 -37.2141

-42.7684

-105.011

76

Iso B_88

39.4889 -28.2737

-43.2004

-104.984

80

KA26_9

38.9837 -39.097

-33.543

-114.729

90

KA25_28

29.1705 -42.2166

-35.7163

-101.308

97

CucD_53

36.6245 -36.1404

-39.0127

-97.0475

98

CucurbitacinE_21 25.1026 -42.2368

-33.4445

-83.312

108
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3.3.2. Chemical synthesis
As described in Scheme 1, the key intermediate C9-C11 desaturated α-hydroxy methyl
ketone (KI9) was synthesized from estrone in 10 steps. Intermediate KI9 was used to
synthesize the target compounds by installing the required side chains at C 21. The key
intermediate synthesis began by protecting the estrone phenolic ring A at C3 with tertbutyldimethylsilyl chloride (TBSCl). Wittig reaction was carried out on the estrone TBS
ether (KI1) on ring D to produce alkene intermediate (KI2). Hydroboration oxidation was
used to obtain KI3 using 9-borabicyclo [3.3.1] nonane (9-BBN) at 60 ℃, followed by
oxidation using PCC to produce intermediate KI4.
The reaction of (KI4) with TMSCN in DCM, in the presence of a catalytic amount of zinc
iodide, resulted in nitrile intermediate KI5 at an 84% yield. Intermediate KI5 was moved
to the next reaction where the nucleophilic addition of MeLi was carried out in ether at 0
℃ to generate imine, which was converted into α-hydroxy methyl ketones by the addition
of glacial acetic acid. After the separation of intermediate KI6, it was deprotected using
TBAF to yield (KI7). The desaturation of C9 and C11 was carried out at 45℃ in the presence
of DDQ in methanol. This was followed by the methylation of crude extract KI8 by MeI
in acetonitrile in the presence of CsCO3 to produce the key intermediate (KI9).
In order to synthesize the required product at C21, the key intermediate was reacted with a
suitable aldehyde, as indicated in Scheme 1, by conducting aldol condensation in THF in
the presence of NaOH. The synthesized analogs include aromatic aldehydes with different
substituents at the para position of the benzene ring. Moreover, the CIE analogs, KA23
and KA24, contained the heterocyclic rings 4-chloro-furan and 4-methylthiophen.
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Although the yield of the DDQ reaction with intermediate KI8 was 53%, which is lower
than that of estrone (80%), Reaction DDQ with KI8 was preferred to avoid the side reaction
that occurred upon the reaction of C9-C11 dehydrogenated estrone with 9-BBN after Wittig
product. One of the challenges is the separation of the final products, as they have an Rf
value close to key intermediate KI9.
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Scheme 1. The synthetic route for KA17-KA24.
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3.3.3. Biological evaluation
In order to evaluate the antiproliferative activity against pancreatic ductal adenocarcinoma,
MTT assay was conducted against two pancreatic cancer cell lines PANC-I and AsPC-1.
Five concentrations ranging from 3.125 µM to 50 µM quadruplicate was treated from each
compounds in 10,000 cells/ well with –ve control wells that contain 0.05 % of DMSO.
Based on the absorbance, the percent of the viable cells was calculated after normalization
by the number of cells in the wells containing the –ve control. After treatment of each
compounds for 48 hrs., KA19 and KA20 containing phenyl para-nitro and para-trifluoro
side chains showed promising antiproliferative activities with IC50s of 11.23 and 7.674 μM,
respectively, upon treatment of PANC-I and with IC50 values of 11.68 and 9.67 μM upon
treatment against AsPC-I (Table 2.3).
Table 3.2. IC50 values of the synthesized CIE analogs on PANC-1 and AsPC-I cell
lines.
Compound

PANC-I (μM)

AsPC-I (μM)

KA17

NA

NA

KA18

NA

NA

KA19

11.22±0.38

11.68±1.1

KA20

7.674 ±1.34

9.674±0.68

KA21

NA

NA

KA23

NA

NA

KA24

NA

NA

>100

>100

Gemcitabine
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These promising results are correlated to some extent with the molecular docking data in
which Para-trifluoromethyl and para-nitro scored higher than various side chains, as well
as the cucurbitacin compounds previously mentioned in the docking experiments. In Erk
molecular modeling, KA19 showed a lower consensus score than KA20. However, when
focusing on molecular docking against multiple targets, such as EGFR, STAT3, RAF,
RAS, and PI3K, KA20 scored higher than KA19 (Table 2.2 in chapter 2), which can be
correlated with the results obtained by MTT cell viability assay.
Previous published results by our group indicate that Erk phosphorylation is inhibited by
CIE analogs. In order to confirm whether this is the same mechanism of action adopted by
KA19 and KA20 on pancreatic cancer cells, in-cell western analysis was conducted on
PANC-I cells. During this test, the cells were treated with four different concentrations of
each compound (¼, ½, 1, and 2 of IC50 values). In the case of KA19, significant inhibition
of Erk phosphorylation was noted, compared to the negative control and the lower
concentrations of the same compound. Similar results were obtained with KA20, although
less inhibition was noted than with KA19. The anticancer activity of KA19 and KA20 act
through inhibition of the pErk activation, as indicated in Figures 3.4 and 3.5, based on incell western analysis.
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Figure 3.4. In-Cell Western analysis of potential KA19 targets. (A) ICW plate image
(p-Erk intensity in 800 channels was normalized to total Erk intensity in
700channel) (B) Analysis of Erk phosphorylation in PANC-I cells.
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Figure 3.5. In-Cell Western analysis of potential KA20 targets. (A) ICW plate image
(p-Erk intensity in 800 channels was normalized to total Erk intensity in
700channel) (B) Analysis of Erk phosphorylation in PANC-I cells.
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3.4. MATERIAL AND METHODS

3.4.1 Chemistry experiment section
General
All chemicals and solvents (ACS grades) were purchased from Fisher Scientific or Sigma
Aldrich and used without any additional treatment. Before conducting the experiments, all
the glassware and tools were cleaned, washed and dried in a 120 °C oven, and before
conducting the reaction according to the mentioned conditions, closing and introducing
nitrogen gas to the reaction vessel for all the reaction period was performed, except when
mentioned during the experiment. TLC plates (Silica gel, 0.2-mm thick, polyester backed,
Sorbtech) were used to analyze the reaction conditions under UV254. All synthetic
intermediates and final compounds were purified using column chromatography packed
with silica gel 60A, 40-63 μm. 1H and 13C NMR spectra were carried out using Bruker
AVANCE-400 MHZ and 600 MHZ NMR spectrometers, while the solvents used for the
compounds are CDCl3. NMR chemical shifts were presented in 𝛿(PPM) using residual
solvent peaks as standards (CDCl3, 7.26 (1H), 77.16 (13C)). High resolution mass (HRMS)
was performed using a Thermofinnigan MAT 95XL mass spectrometer at the Buffalo mass
spectroscopy facility. X-ray crystallography was conducted at the University of South
Dakota on KI 9 using a Bruker APEXᴵᴵ diffractometer.
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H
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HO
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To a stirred solution of estrone (5 g, 18.5 mmol) in DMF (75 ml), imidazole (3.5 g, 50.85
mmol) and tert-butyldimethylsilyl chloride (TBSCl) (4.2 g, 27.75 mmol) were added. The
reaction was stirred overnight at room temperature. The result mixture were evaporated to
provide the crude extract that was purified using column chromatography and eluted using
80 % hexane: ethyl acetate produce the white solid estrone tert-butyldimethylsilyl ether
KI1 (6.75 g, 95%).18

1H

NMR (400 MHz, Chloroform-d) δ 6.91 (dd, J = 8.6, 1.0 Hz, 1H), 6.47 – 6.33 (m, 2H),

2.72 – 2.59 (m, 3H), 2.28 (dd, J = 18.7, 8.7 Hz, 1H), 2.16 (dt, J = 14.0, 3.7 Hz, 1H), 2.08
– 1.65 (m, 5H), 1.48 – 1.14 (m, 7H), 0.79 (s, 9H), 0.75 – 0.65 (m, 4H), 0.00 (s, 6H).
13C

NMR (101 MHz, Chloroform-d) δ 219.97, 153.47, 137.57, 132.47, 126.17, 120.02,

117.35, 50.44, 47.98, 44.04, 38.34, 35.87, 31.65, 29.54, 26.62, 25.85 21.63, 18.20, 13.90,
-4.30.
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KI 2

To prepare the ylide, (4 g, 35.9 mmol) of potassium tert-butoxide was added to a solution
of ethyl triphenylphosphonium bromide (18 g, 38.52 mmol) in THF (33.83 ml) at room
temperature to result in an orange mixture that was stirred for 1 hr. A solution of KI 1 (6.5g,
16.9 mmol) in THF (15 ml) was added to the prepared ylide and the orange mixture was
stirred for 6 hrs. at 70 0C. After that, the reaction mixture was allowed to cool to room
temperature and quenched with saturated ammonium chloride (NH4Cl) solution, followed
by extraction of the aqueous layer by ethyl acetate (3×100 ml), dried over sodium sulfate
anhydrous (Na2SO4), filtrated and concentrated. The crude extract was purified by silica
gel column chromatography 80 % hexane: ethyl acetate) to obtain KI 2 (4.8 g, 82%).18
1H NMR (400 MHz, CDCl3) δ 7.06 (d, J = 8.4 Hz, 1H), 6.56 (dd, J = 8.4, 2.5 Hz, 1H),
6.50 (d, J = 2.4 Hz, 1H), 5.10 (dtd, J = 7.1, 5.1, 2.1 Hz, 1H), 2.87 – 2.69 (m, 2H), 2.45 –
2.11 (m, 6H), 1.93 – 1.81 (m, 1H), 1.57 – 1.16 (m, 9H), 0.93 (s, 10H), 0.13 (d, J = 3.1 Hz,
6H).
13C

NMR (101 MHz, Chloroform-d) δ 153.33, 150.30, 137.87, 133.32, 126.11, 126.11,

119.99, 117.18, 113.45, 55.33, 44.63, 43.93, 38.40, 37.32, 31.51, 29.77, 27.66, 26.96,
25.80, 24.24, 18.24, 17.03, 13.23, -4.31.
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To the purified mixture of KI 2 (4.8 g, 12.184 mmol), 9-BBN (0.5 M in THF, 107.4 ml,
53.72 mmol) was added at room temperature. The reaction mixture was stirred for 18 hrs.,
then cooled down to 0 0C and 200 ml of 10%NaOH and 200 ml of 30% H2O2 were added
drop wisely. The reaction mixture was stirred for 1 hr. at 0 0C followed by extraction by
ethyl acetate (3×100 ml) and the mixture was washed with 100 ml of saturated sodium
thiosulfate, dried over sodium sulfate anhydrous (Na2SO4) and concentrated. Column
chromatography was used to purify the crude extract with 70 % hexane: ethyl acetate to
provide alcohol KI 3 (3.7 g, 75 %).18
1H NMR (400 MHz, CDCl3) δ 6.92 (t, J = 6.9 Hz, 1H), 6.41 (dd, J = 8.4, 2.5 Hz, 1H),
6.36 (d, J = 2.3 Hz, 1H), 3.63 (ddd, J = 12.0, 8.2, 3.8 Hz, 1H), 3.52 (tt, J = 12.3, 6.3 Hz,
1H), 2.73 – 2.54 (m, 2H), 2.25 – 1.93 (m, 5H), 1.79 (ddd, J = 15.0, 11.4, 7.7 Hz, 3H),
1.71 – 1.58 (m, 5H), 1.50 (dddd, J = 15.6, 11.1, 4.9, 2.0 Hz, 7H), 1.11 – 1.02 (m, 5H),
0.79 (s, 9H), 0.51 (s, 17H), -0.00 (s, 6H).
13C

NMR (101 MHz, Chloroform-d) δ 153.25, 137.82, 133.23, 126.03, 119.95, 117.12,

72.01, 58.59, 55.38, 43.79, 42.03, 38.41, 34.66, 27.47, 26.42, 25.75, 23.59, 22.76, 18.17,
12.60, -4.36.
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KI 4

KI 3 (3.7 g, 9 mmol) was dissolved in 50 ml of dried DCM, followed by addition of 40 A
powdered molecular sieves (3.5 g), and 2.9 g, 43 mmol of sodium acetate (NaOAc) and
pyridinium chlorochromate (PCC) (3.87 g, 17.8 mmol). The reaction mixture was stirred
at room temperature for 5 hrs. The crude extract was filtered over a silica gel pad using
ethyl acetate to elute the material and trap the pyridinium. The collected material was then
concentrated and the crude extract was purified by column chromatography (80 % hexane:
ethyl acetate) to yield ketone KI 4 (2.85 g, 76 %).18
1H NMR (400 MHz, CDCl3) δ 6.92 (t, J = 6.9 Hz, 8H), 6.41 (dd, J = 8.4, 2.5 Hz, 9H),
6.36 (d, J = 2.3 Hz, 8H), 3.63 (ddd, J = 12.0, 8.2, 3.8 Hz, 10H), 3.52 (tt, J = 12.3, 6.3 Hz,
9H), 2.62 (t, J = 7.9 Hz, 15H), 2.23 – 1.94 (m, 44H), 1.79 (ddd, J = 15.0, 11.4, 7.7 Hz,
21H), 1.71 – 1.59 (m, 38H), 1.55 – 1.42 (m, 62H), 1.06 (t, J = 4.9 Hz, 33H), 0.79 (s, 72H),
0.51 (s, 20H), -0.00 (s, 51H), -0.10 (d, J = 3.0 Hz, 6H)
13C

NMR (101 MHz, Chloroform-d) δ 209.31, 153.36, 137.72, 132.80, 126.05, 119.99,

117.20, 67.01, 63.81, 55.69, 44.38, 43.71, 39.01, 38.70, 31.49, 29.64, 27.74, 26.62, 25.75,
24.16, 22.88, 18.17, 13.45, -4.35.
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KI5

To a stirred solution of KI 4 (2.85 g, 6.8 mmol) in DCM (20 ml), zinc iodide (ZnI2) (0.07
g, 0.2 mmol) was added, followed by addition of (0.85 g, 8.8 mmole) of trimethylsilyl
cyanide (TMSCN) and the mixture was stirred at room temperature for 2 hrs. The reaction
was quenched with water and extracted with DCM (3 X 30 ml), dried over sodium sulfate
anhydrous (Na2SO4) and concentrated. Column chromatography was used to purify the
crude material (90 % hexane :ethyl acetate) to yield KI 5 (2.8 g, 84 %).18
1H NMR (400 MHz, CDCl3) δ 6.95 (d, J = 8.5 Hz, 8H), 6.45 (dd, J = 8.3, 2.3 Hz, 10H),
6.40 (s, 8H), 2.80 – 2.58 (m, 20H), 2.16 – 1.96 (m, 30H), 1.77 – 1.67 (m, 20H), 1.68 – 1.55
(m, 41H), 1.39 – 1.24 (m, 32H), 1.25 – 1.11 (m, 43H), 1.11 – 1.02 (m, 15H), 0.84 (s, 82H),
0.13 (s, 49H), 0.05 (s, 33H).
13C

NMR (101 MHz, Chloroform-d) δ 151.69, 136.09, 131.52, 124.45, 120.47, 120.47,

118.33, 115.57, 70.79, 58.92, 53.30, 42.25, 42.16, 38.41, 36.52, 29.21, 28.02, 26.13, 24.87,
24.16, 23.26, 22.26, 16.58, 11.23, 0.00, 0.23, -5.95.
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KI 6

A solution of KI 5 (5.6 g, 11.2 mmole) in ether (34 ml) was stirred at 00 C, and (1.6 M in
ether, 21 ml, 34 mmole) of methyl lithium (MeLi) was added in drop wisely and the
reaction mixture was stirred for 2 hrs. at 0 0C. After that, reaction was quenched by adding
glacial acetic acid (4.2 ml) at 0 0C and stirred for 30 min. Saturated sodium bicarbonate
solution was added to neutralize the acidic mixture. The mixture was extracted with ethyl
acetate (3X50ml) and dried with sodium sulfate anhydrous (Na2SO4) and concentrated.
The resulting mixture were purified by silica gel column chromatography using 95 %
hexane: ethyl acetate to result in α-hydroxyl ketone 6 (3.07 g, 59 %).18
1H NMR (400 MHz, CDCl3) δ 6.92 (d, J = 8.5 Hz, 1H), 6.42 (dd, J = 8.4, 2.6 Hz, 1H),
6.36 (d, J = 2.5 Hz, 1H), 3.79 (s, 1H), 2.69 – 2.54 (m, 2H), 2.12 – 2.05 (m, 2H), 2.02 (s,
3H), 1.71 – 1.59 (m, 2H), 1.53 (ddd, J = 14.6, 8.6, 4.6 Hz, 2H), 1.45 – 1.33 (m, 4H), 1.28
(s, 3H), 0.81 – 0.79 (m, 8H), 0.75 (s, 3H), 0.08 – -0.04 (m, 6H).
13C

NMR (101 MHz, Chloroform-d) δ 211.69, 153.32, 137.78, 133.10, 126.05, 119.99,

117.18, 80.10, 55.79, 55.15, 44.25, 43.88, 40.73, 38.08, 31.65 , 25.74, 24.62, 23.73, 23.24,
22.70, 18.18, 13.54, -4.38.
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KI7 and KI8

Tetra-butyl ammonium fluoride (TBAF) (14.3 ml, 14.13 mmol) was added to a stirred
solution of KI 6 (2.08 g, 4.56 mmol) in 70.7 THF and stirred for 48 hrs. before the
reaction was quenched by the addition of an NH4Cl solution. The aqueous layer was
extracted by ethyl acetate (3 X 50 ml). The organic layer was dried using Na2SO4,
concentrated in vacuo.
The crude extract was dissolved in 152 ml of methanol at a temperature of 45 0C,
followed by addition of 2, 3-Dichloro-5, 6-dicyano-1, 4-benzoquinone (DDQ) (1.6 g,
6.83 mmol). The reaction was stirred for 5 hrs. followed by evaporation of methanol
using vacuu. The crude extract was moved to the next reaction.
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The crude material was dissolved in acetonitrile (90 ml), followed by the addition of
crushed granulate potassium hydroxide (4.032 g, 86.46 mmole). Then, methyl iodide (2.24
g, 35.94 mmole) was added to the reaction mixture. The reaction was stirred at room
temperature for 2h and quenched by the addition of water (400 ml) and stirred for 15
minutes. Ethyl Acetate (3 ˣ100 ml) was used to extract the aqueous layer, and the organic
layer was dried over sodium sulfate anhydrous and concentrated in vacuo to obtain the dry
organic portion. Next, a silica gel column was used to purify the crude material using 9:1
(hexane: ethyl acetate) to provide KI 9 (4.3 g, 71.33 %) as a white material.
1H

NMR (400 MHz, CDCl3) δ 7.53 (d, J= 8.81 Hz, 1H, -CH (1)), 6.72 (dd, J= 8.8

Hz,

2.7,

1H),

1H),

3.79

(s,

1.94-1.15
13C

6.59
3H),

(d,

J=

2.95-2.75

(m,10H),

2.77
(m,
1.48

Hz,

2H),

1H),
2.36-2.11
(s,3H),

6.09
(m,

(m,

1H),

4

2H),

2.23

(s,2H),

0.94

(s,

(s,3H)

NMR (101 MHz, Chloroform-d) δ 211.8, 158.3, 137.5, 134.9, 127.3, 125.1, 117.5,

113.2,112.6,80.0, 55.2, 52.7, 43.06, 42.3, 38.1, 30.0, 28.6, 24.7, 24.3, 23.3, 22.2, 13.6.
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1H NMR (600 MHz, CDCl3) δ 7.84 (d, J = 15.5 Hz, 1H), 7.56 (dd, J = 12.5, 8.7 Hz, 3H),
7.28 (d, J = 8.4 Hz, 2H), 7.01 (d, J = 15.6 Hz, 1H), 6.76 (dd, J = 8.8, 2.7 Hz, 1H), 6.63 (d,
J = 2.4 Hz, 1H), 6.14 (s, 1H), 3.82 (s, 3H), 2.90 (d, J = 13.2 Hz, 1H), 2.84 (d, J = 17.2 Hz,
1H), 2.60 (d, J = 16.8 Hz, 1H), 2.55 (s, 3H), 2.48 (d, J = 17.8 Hz, 1H), 2.36 (s, 1H), 2.20
(s, 1H), 2.09 (s, 1H), 2.03 (s, 1H), 2.00 – 1.96 (m, 1H), 1.84 (s, 1H), 1.70 (s, 2H), 1.59 (s,
3H), 1.54 – 1.47 (m, 2H), 1.01 (s, 3H).
13C NMR (151 MHz, CDCl3) δ 201.88, 158.35, 145.30, 143.16, 137.56, 134.99, 130.67,
129.05, 127.41, 125.89, 125.13, 117.62, 117.12, 113.27, 112.68, 78.98, 55.26, 52.75,
43.11, 42.37, 38.21, 31.95, 30.09, 29.73, 29.39, 28.63, 24.75, 24.12, 22.72, 22.20, 15.08,
14.15, 13.78.
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1H NMR (600 MHz, CDCl3) δ 7.86 (d, J = 15.5 Hz, 1H), 7.60 (t, J = 5.8 Hz, 2H), 7.58
(d, J = 8.8 Hz, 1H), 6.97 (d, J = 1.9 Hz, 1H), 6.96 (d, J = 1.8 Hz, 1H), 6.95 – 6.92 (m,
1H), 6.76 (dd, J = 8.7, 2.7 Hz, 1H), 6.63 (d, J = 2.5 Hz, 1H), 6.16 – 6.13 (m, 1H), 4.32 (s,
1H), 3.89 (s, 3H), 3.82 (s, 3H), 2.95 – 2.81 (m, 2H), 2.61 (ddd, J = 17.4, 5.4, 1.7 Hz, 1H),
2.48 (d, J = 17.6 Hz, 1H), 2.13 – 1.96 (m, 3H), 1.84 (ddd, J = 19.4, 11.8, 5.2 Hz, 1H),
1.70 (ddd, J = 16.0, 12.9, 4.0 Hz, 1H), 1.63 (d, J = 8.4 Hz, 2H), 1.58 (d, J = 8.3 Hz, 3H),
1.54 – 1.48 (m, 1H), 1.37 (dddd, J = 19.7, 13.8, 11.8, 4.6 Hz, 4H), 1.01 (d, J = 6.8 Hz,
3H).
13C NMR (151 MHz, CDCl3) δ 201.88, 162.06, 158.34, 145.64, 137.56, 134.98, 130.55,
127.43, 126.99, 125.13, 117.67, 115.84, 114.48, 113.28, 112.67, 78.89, 55.48, 55.32,
55.26, 52.76, 43.12, 42.35, 38.22, 30.10, 28.63, 24.75, 24.17, 22.19, 13.77.
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1H NMR (600 MHz, Acetone) δ 8.32 – 8.29 (m, 20H), 8.11 – 8.07 (m, 21H), 7.85 (dd, J
= 15.7, 7.4 Hz, 11H), 7.81 – 7.77 (m, 10H), 7.56 (d, J = 8.8 Hz, 7H), 6.73 (dd, J = 8.6, 2.7
Hz, 10H), 6.64 (d, J = 2.7 Hz, 7H), 6.14 (td, J = 3.9, 1.7 Hz, 7H), 3.78 (s, 28H), 2.90 (s,
28H), 2.87 – 2.78 (m, 21H), 2.69 (dt, J = 20.0, 7.6 Hz, 6H), 2.55 – 2.52 (m, 16H), 2.43
(ddd, J = 19.2, 14.5, 6.5 Hz, 8H), 2.27 – 2.21 (m, 11H), 2.17 (dtd, J = 13.8, 7.1, 2.1 Hz,
5H), 2.07 (dt, J = 4.4, 2.2 Hz, 24H), 2.05 – 2.00 (m, 14H), 1.87 – 1.74 (m, 24H), 1.60 (d,
J = 4.1 Hz, 29H), 1.52 – 1.44 (m, 12H), 1.37 – 1.27 (m, 32H), 0.99 (s, 21H).
13C NMR (151 MHz, Acetone) δ 203.21, 159.46, 149.56, 142.26, 142.01, 138.25,
135.77, 130.56, 125.97, 125.69, 124.82, 124.68, 118.31, 114.18, 113.94, 113.48, 111.58,
80.34, 67.48, 55.60, 55.42, 53.45, 43.39, 42.95, 39.15, 30.68, 30.26, 30.13, 30.01, 29.88,
29.75, 29.62, 29.49, 25.45, 24.45, 22.95, 14.35.

85
KA20
HO

O
H

HO
CF3

O

H
H
O

O

NaOH
H

105 0C/THF

H

CF3

O
KA20

1H NMR (600 MHz, CDCl3) δ 8.29 (dd, J = 9.1, 2.0 Hz, 2H), 7.88 (d, J = 15.7 Hz, 1H),
7.78 (t, J = 5.5 Hz, 2H), 7.57 (d, J = 8.8 Hz, 1H), 7.22 – 7.18 (m, 1H), 6.76 (dd, J = 8.8,
2.7 Hz, 1H), 6.63 (d, J = 2.6 Hz, 1H), 6.14 – 6.12 (m, 1H), 3.82 (s, 3H), 2.95 – 2.88 (m,
1H), 2.86 – 2.81 (m, 1H), 2.61 (ddd, J = 17.3, 5.5, 1.7 Hz, 1H), 2.49 (d, J = 17.6 Hz, 1H),
2.09 (dd, J = 11.2, 9.5 Hz, 1H), 2.06 – 1.97 (m, 2H), 1.90 – 1.83 (m, 1H), 1.76 – 1.68 (m,
1H), 1.63 (d, J = 7.8 Hz, 3H), 1.55 – 1.48 (m, 1H), 1.36 (dddd, J = 11.6, 9.2, 6.4, 4.2 Hz,
3H), 1.01 (s, 3H).

13C NMR (151 MHz, CDCl3) δ 201.63, 158.39, 148.80, 142.55, 140.34, 137.54, 135.00,
129.25, 127.31, 125.14, 124.24, 122.25, 117.45, 113.27, 112.71, 79.42, 55.26, 55.12,
52.72, 43.05, 42.47, 38.18, 30.06, 28.61, 24.75, 23.97, 22.27, 13.82.
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1H NMR (600 MHz, CDCl3) δ 7.96 – 7.93 (m, 5H), 7.87 – 7.82 (m, 9H), 7.57 (dd, J = 8.7,
5.2 Hz, 8H), 7.27 – 7.23 (m, 5H), 7.01 (s, 6H), 6.76 (dd, J = 8.7, 2.7 Hz, 7H), 6.73 – 6.67
(m, 4H), 6.63 (d, J = 2.6 Hz, 6H), 6.15 – 6.13 (m, 6H), 4.23 (s, 6H), 3.82 (s, 19H), 2.90
(ddd, J = 15.7, 13.8, 5.0 Hz, 11H), 2.86 – 2.76 (m, 12H), 2.61 (ddd, J = 17.3, 5.5, 1.6 Hz,
7H), 2.48 (d, J = 17.6 Hz, 8H), 2.30 (s, 4H), 2.12 – 2.01 (m, 23H), 2.01 – 1.96 (m, 14H),
1.91 – 1.82 (m, 13H), 1.73 – 1.67 (m, 15H), 1.60 (s, 20H), 1.53 – 1.48 (m, 11H), 1.46 (s,
23H), 1.01 (s, 17H).
13C NMR (151 MHz, CDCl3) δ 201.82, 190.55, 158.36, 144.51, 137.55, 134.99, 132.31,
132.24, 130.71, 130.65, 127.38, 125.55, 125.13, 118.01, 117.57, 116.47, 116.31, 116.17,
113.28, 112.69, 79.06, 55.25, 55.22, 52.75, 43.10, 42.39, 38.20, 34.25, 30.34, 30.08,
29.73, 28.63, 24.74, 24.06, 22.21, 13.78.
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1H NMR (600 MHz, CDCl3) δ 7.39 (d, J = 8.7 Hz, 1H), 7.31 (dd, J = 10.9, 5.8 Hz, 1H),
6.72 – 6.69 (m, 1H), 6.57 (dt, J = 9.3, 3.2 Hz, 2H), 6.54 (d, J = 3.5 Hz, 1H), 6.44 (d, J =
2.7 Hz, 1H), 6.16 (d, J = 3.5 Hz, 1H), 3.63 (s, 4H), 2.76 – 2.68 (m, 2H), 2.67 – 2.65 (m,
1H), 2.39 (dddd, J = 19.6, 17.5, 5.6, 1.9 Hz, 2H), 2.32 (d, J = 17.6 Hz, 1H), 2.23 (dd, J =
15.4, 5.9 Hz, 1H), 2.08 (s, 1H), 1.89 – 1.83 (m, 4H), 1.53 – 1.45 (m, 3H), 1.39 (d, J = 2.5
Hz, 3H), 1.33 (s, 1H), 1.28 (s, 3H).
13C NMR (151 MHz, CDCl3) δ 201.67, 158.33, 150.67, 140.18, 137.53, 134.92, 130.25,
127.45, 125.15, 118.98, 117.69, 116.09, 113.28, 112.66, 109.76, 79.04, 55.25, 55.06,
52.70, 43.03, 42.38, 38.21, 30.33, 30.09, 29.72, 28.62, 24.76, 24.02, 22.19, 13.78.
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3.4.2. Biological evaluations
Cytotoxicity assay
Two cell lines were used to carry out the cytotoxicity assay against pancreatic
cancer, PANC-I and AsPC-1. In a 96-well plate, a total of 10x105 cells were seeded. After
24 hrs, a serial dilution of the synthesized compounds (from 50 μM down to 3.125 μM as
Quadruplicate for each concentration) was added to make the total volume 200 μL /well.
0.05% DMSO (Acros Organics) was used as a negative control and cuc B as a positive
control. This was followed by incubation at 37 °C and 5% CO2 for 48 hrs. After 48 hrs, 20
μL of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) (Sigma
Aldrich) (5 mg/mL PBS) was added to each well and the plate was incubated in the same
conditions for 2hrs. The solutions were discarded from each well and 200 μL DMSO was
added to each well and mixed. The absorbance was measured directly at 570 nm with a
Hidex Sense Microplate reader.
In-cell western assay (ICW)
PANC-I cell line was seeded in clear-bottomed, black walled 96-well plates with a density
of 1 × 105 cells/well and allowed to grow till conﬂuency. Next, the cells were treated with
different concentrations of KA19 or KA20 starting from ¼ to twice IC50 for 24 hrs. and
DMSO was used as a -ve control. The cells were then fixed with 3.7% formaldehyde in 1X
PBS for 30 min, then washed and permeabilized with 0.1% TritonX-100 in 1X PBS. Cells
were then blocked with 1X PBS fish gel solution and incubated with an antibody to Erk
(cell signaling technology), Phospho-Erk (Santa Cruz Biotechnology), and GAPDH (Santa
Cruz Biotechnology) for 2 h with gentle shaking. They were then incubated overnight at 4
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°C without shaking (i.e.: stationary). The cells were then washed with 0.1% Tween-20 in
1X PBS four times and incubated with secondary antibodies conjugated to IR dye for 1h
with gentle shaking (protected from light). Cells were next washed with 0.1% Tween-20
in 1X PBS four times. After the last wash, any residual liquid was gently pipetted out and
the plate was blotted dry using the In-cell Western protocol on an Odyssey® imager (LICOR®), according to manufacturer's directions. Phospho-proteins were normalized for
total protein signals. To correct for well-to-well variation in cell numbers, percentinhibition was determined relative to control wells. Data are expressed as mean values of
at least two runs ± the standard deviation (SD).
3.5. Conclusion
Molecular modeling study against known molecular targets of pancreatic ductal
adenocarcinoma has been conducted to filter out the best candidates to be synthesized. The
current structure-based drug design approach enabled us to synthesize 9 promising
cucurbitacin-inspired analogs modified desaturated at C9 and C11, followed by cell viability
MTT assay against two pancreatic ductal adenocarcinoma cell lines, among which two
promising candidates KA19 and KA20 show promising IC50 values against pancreatic
cancer cell lines PANC-I, 11.2 and 7.7 µM, and ASPC-I , 11.7 and 9.7 µM, compared to
the current standard treatment gemcitabine. Furthermore, both compounds show promising
inhibition of Erk phosphorylation at the double concentration of IC50’s ,which support the
obtained results from the molecular docking study that this group score higher than the
other CIE analogs modified at C11. Our results indicate that the modification of C11 can
increase the antiproliferative activity compared to the non-modified CIE analogs.
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Chapter Four

Synthesis and Biological Activity of C-11 Hydroxy Cucurbitacin-Inspired Estrone
Analogs Targeting Pancreatic Ductal Adenocarcinoma

Abstract
Pancreatic cancer was the fourth leading cause of cancer-related deaths in 2016. However,
the long-term survival rate is low, compared to other cancer types, due to poor prognosis
and low survival after treatment with the standard drug, gemcitabine. This suggests an
urgent need to investigate for new treatment agents. Recently, the triterpenoid natural
product, cucurbitacin B, showed promising antiproliferative activity against human
pancreatic cancer cells in a dose- and time-dependent manner. However, the low yield of
cucurbitacin from its natural sources and the challenging chemical total synthesis due its
highly stereochemical complexity hindered its usage in clinical trials. In order to overcome
this obstacle, molecular modeling studies were performed against known molecular targets
of pancreatic cancer, using a novel strategy that uses estrone as a scaffold with cucurbitacin
pharmacophores. More than 400 virtual compounds were designed by installing the
cucurbitacin pharmacophores, such as various 23, 24 α, β- unsaturated ketone side chains,
on estrone with different functionalizations at C11. This was followed by molecular docking
against known pancreatic cancer molecular targets, such as the proteins EGFR, JAK,
STAT3, Raf, Ras, Erk, Akt and PI3K. The molecular docking study showed a promising
binding affinity for the cucurbitacin-estrone hybrid analogues, substituted with a hydroxy
group at C11. Using this approach, 8 analogs were synthesized through 12 steps, followed
by an MTT cell viability assay against PANC-I, AsPC-I, and BXPC-3 pancreatic cell lines.
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Three C11 hydroxyl analogs KA1, KA2, and KA11 containing phenyl para-trifluoro,
cucurbitacin, and phenyl para-methtylthio side chains, showed promising IC50 values. The
first two were further studied in cell cycle arrest. Also, the cell cycle arrest for KA1 and
KA2 was studied at different time points. In order to further investigate the effectiveness
of these two analogs, they were evaluated against 2D and 3D pancreatic cancer cell line
PANC-I using cell Titer assay. KA1 and KA2 were proven to increase caspase-3 activity
and induce cell death. Our results indicate that KA1 and KA2 are promising
antiproliferative agents and are possible candidates for clinical study. Moreover, our results
indicate that additional modifications to the cucurbitacin-inspired estrone analogs may lead
to more potent antiproliferative agents.
4.1. Introduction
Among cancer types, pancreatic cancer is the only type that has demonstrated a stable rate
of mortality.1 Pancreatic cancer is currently the fourth leading cause of death among cancer
types2, and is expected to be the second in the next twenty years.3 The reason for the high
mortality of pancreatic cancer is the absence of biomarkers that can be detected in its early
stages.4 Moreover, the development of pancreatic anticancer agents is still slow.5
The current treatments for pancreatic cancer are correlated with the stage of the disease.
Only 20% of pancreatic ductal adenocarcinoma patients can be treated with surgery, while
the remaining patients are diagnosed after the disease reaches its late stages.6 The current
standard chemotherapy treatment for pancreatic cancer is gemcitabine; however, it has an
18% one-year survival rate, which is significantly better than the former standard, 5fluorouracil (5-FU) that has only a 2% 1-year survival rate.7 The six-month survival rates
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for gemcitabine and 5-FU are 23.8% and 4.8%, respectively. These data highlights the
urgent need to investigate for novel agents for pancreatic cancer treatments.
Epidermal transmembrane factor receptor (EGFR) is a 170 kd glycoprotein and one of
tyrosine kinase that is overexpressed in many cancer types, including pancreatic cancer.
EGFR overexpression was found to be related to the advancement of the disease, its low
survival rate, and metastasis.8, 9
Natural products have been the main source for drug discovery until recent times. From
1981 to 2010, statistics indicate that almost two-thirds of the approved drugs were related
to natural products, either directly by using the natural products or indirectly through
chemical modification and structure replication of the useful compounds.10 Approximately
47% of the approved anticancer drugs were derived from natural products, which indicates
the importance of these products in the discovery of novel anticancer agents.11 One of these
natural products is cucurbitacins (Figure 4.1), a group of triterpenoid compounds that
contain cucurbitane ring and are characterized by bitterness and toxicity.12, 13 Currently,
more than 18 types of cucurbitacins have been found, among which 9 compounds have
been reported to have anticancer activity against lung, breast, colon, and pancreatic
cancers.14,15,

16

Moreover, cucurbitacins also have other biological effects, such anti-

inflammatory and antiviral activities.17
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Figure 4.1. General structures of cucurbitacin and steroid

In 2010, Lwanski et al. reported that a relatively low dose of cucurbitacin B, in combination
with gemcitabine (0.5 mg/Kg and 25 mg/Kg, respectively), resulted in a significant
decrease in tumor size.10 The mechanism of action for cucurbitacin B included inhibition
of STAT3 phosphorylation, activation of caspase 3, and upregulation of p53 and p21
expression.18 Cucurbitacin E showed antiproliverative activity against pancreatic cancer
through inhibition of STAT3 phosphorylation and upregulation of the tumor suppressor
p53.19,20 However, one of the challenges that prevents the use of cucurbitacins as anticancer
remedies is the difficulty of separating the natural sources due to their polarity and the
minute amounts that are obtained after separation. Moreover, the oxygenated A, C, and D
and the stereochemistry of cucurbitacin represent a challenge in attempting the total
synthesis of cucurbitacins, although successful trials have synthesized rings C and D of
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cucurbitacin I.21 One of the important pharmacophores is the 23, 24 α, β- unsaturated
ketone side chain that is responsible for the anticancer activity of cucurbitacin.22
Interestingly, this side chain was installed in the four membered-rings estrone, and it shows
a comparable anticancer activity to that of cucurbitacin.23 These cucurbitacin-inspired
estrone analogues (CIEA’s) opened the door for further functionalization of these family
of compound in different positions. Molecular modeling was employed to search for more
potent anticancer compounds through the modeling of these novel analogs against known
cucurbitacin molecular targets.
Up to date, we have proved that the functionalization of rings B and C leads to potent
anticancer agents which are more active than the currently available standard treatments.
Previously, we reported that the dehydrogenation of C9-C11 and C16-C17 generally increased
the potency of this group of compounds.24, 25 Moreover, the methylation of C3 increased
the potency relative to the originally found phenol. The other modifications include the
introduction of many functional groups at the cucurbitacin side chain, such as paratrifluoromethyl through aldol condensation, which showed potent anticancer activity.26
Here, we report molecular modeling of more than 400 virtual CIEA’s analogs with
synthesis of a 8 CIE analogs functionalized at C11, and screening them using MTT cell
viability assay against 3 pancreatic cancer cell lines PANC-I, AsPC-I, and BXPC-I
followed by flowcytometric analysis of the most potent CIEA’s at different time points.
4.2. Results and Discussions
4.2.1. Molecular Modeling Design Strategy
Based on the previously obtained results regarding CIE analogs, it was found that
transferring the C3 OH group into ether can increase the anticancer activity of these
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compounds. Also, through molecular modeling studies, we found that the introduction of
various side chains, such as phenyl para-trifluoromethyl and phenyl para-thiomethyl at
C17 on ring D of estrone can result in high scoring analogs against many molecular targets,
such as EGFR. Therefore, to investigate further, we designed additional analogs with a
hydroxy group at C11 and carried out the molecular modeling analysis on molecular targets
reported to be expressed in pancreatic ductal adenocarcinoma.
A virtual library of 400 CIEA compounds were designed to mimic cucurbitacin compounds
with various functional groups in positions C3 and C11, as well as several methyl hydroxy
enon side chains at position C17. Also, cucurbitacins B and D were used as standards for
the molecular targets. Molecular modeling results indicate that 8 compounds (Figure 4.2)
show a better binding affinity to EGFR and other molecular targets such as STAT3, Akt,
PI3K, than the standards, erlotinib, cucurbitacin B and D. One of the high scoring
compounds is KA1, a CIE analog with C11 hydroxy and a phenyl para-trifluoro enone side
chain. This demonstrated hydrogen bonding with Pro: 770: A at EGFR binding site (Figure
4.3 A), close to the erlotinib hydrogen binding site with Met: 769: A (Figure 4.3B). In
addition, KA2 and KA11, containing a cucurbitacin and a phenyl para-thiomethyl side
chains, respectively, showed promising binding affinity to EGFR compared to the
previously mentioned standards. This indicates that the hydroxyl group modification may
increase the binding affinity to known pancreatic cancer molecular targets.
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Table 4.1. The consensus scores of hydroxylated C11 CIE analogs on the EGFR
binding pocket.

Chemgauss3 OEChemscore Screenscore

Consensus
Score

VIDA Name

PLP

KA11_43

-51.7283 -66.5209

-39.2823

-116.575

26

KA8_153

-48.7798 -68.3666

-40.7735

-103.059

31

KA3_126

-51.8626 -51.2126

-41.1819

-109.046

32

KA6_73

-55.8415 -47.2346

-42.2838

-104.658

35

KA1_72

-47.2135 -80.9063

-35.1766

-118.451

36

KA7_143

-48.619

-70.2779

-39.9259

-97.2335

37

KA4_156

-45.7753 -68.0197

-40.0748

-99.0202

42

KA5_62

-48.1965 -66.2347

-35.877

-102.4478

52

CucD_197

-40.4721 -54.3241

-38.0069

-92.221

67

Iso B_113

-39.2614 -50.7752

-38.6223

-89.5715

73

KA10_64

-39.3671 -67.012

-33.2958

-89.5334

74

Iso D_37

-35.4754 -44.8475

-41.7118

-80.8827

82

KA15_1

-37.2535 -61.1314

-31.4152

-81.4897

88

Cucurbitacin
I

-33.1051 -41.8658

-41.5028

-78.295

89

Cucurbitacin
E

-35.7174 -48.0769

-38.0201

-73.3811

90

Erl_38

-39.3291 -53.9956

-33.5598

-84.2492

90
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Molecular docking was also carried out against the previously reported targets for
cucurbitacin, including the MAPK signaling pathway proteins (EGFR, RAS, RAF, MEK,
and ERK proteins. (Figure 4.4)
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Figure 4.2. The structures of the synthesized oxygenated cucurbitacin-inspired
analogs.
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A.

B.
Figure 4.3. A) Binding of KA1 into EGFR ATP binding pocket. B) Overlay with
erlotinib binding in the same pocket.

103

Figure 4.4. The major targets of MAPK signaling pathway.27

Generally, up on the docking against EGFR, the best-scoring compounds contained ketone,
followed by analogs containing hydroxyl functional groups at C11, which scored better than
the analogs desaturated at C9 and C11.
4.2.2. Chemical Synthesis

Scheme 1 shows the general route for the synthesis of the best scoring compounds. The
chemical challenge that prevented the convergent synthesis for the CIEA analogs using
Grignard reaction was the stereochemistry product of at C20, where the major product was
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S instead of R, as in a cucurbitacin side chain. So, the first step was oxidation of C9-C11 of
estrone using DDQ. The best yield for this step was obtained upon its reaction with estrone,
rather than with methylated estrone; however, the next step was run on the crude extract
due to the poor solubility of the product and, therefore, its purification. Following this, was
the formation of a ketal at C17 to avoid side reactions upon the hydroboration hydroxylation
reaction. One of the chemical challenges for the synthesis of the target analogs was the
hindrance of position C11, as will be indicated below. Three reagents were used to carry
out the hydroboration. With 9-BBN, no hydroboration was obtained, while hydroboration
with BH3 yielded 28% of the hydroxylated product. However, the highest yield in this
reaction was obtained with (CH3)2SBH3 at 60%. After the purification of KI3 and its
deprotection was carried out using 10% HCl/ acetone mixture to obtain KI4. The protection
of the C11 hydroxyl group was initially carried out by TBSCl in DMF in presence of
imidazole. However, no product was obtained, although it was previously found that this
reaction worked with C3 phenolic OH using the same conditions, which further indicates
that this position is hindered by the stereochemistry of the compound. TMS-protection was
performed and worked successfully, but it was not stable after Wittig reaction to produce
KI6; some of the product was deprotected. This indicates that TBS protection was the only
choice to proceed through the synthetic route. A convenience method for protection of the
hindered hydroxyl groups, such as tertiary alcohols or secondary alcohols adjacent to a
tertiary alcohol was reported, using Mg turnings as a catalyst in DMF with TBSCl. Upon
using this condition to protect the C11 hydroxyl group, a 90% yield of KI5 was obtained.
The installation of the cucurbitacin side chain was gained through the Wittig reaction,
followed by hydroboration oxidation using 9-BBN as a hydroboration reagent. The
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oxidation of the hydroxyl group and the cyanohydrin formation was performed as indicated
in the experimental section. KI10 was obtained after methylation and the formation of a
hydroxy-methyl ketone from the imine. In order to indicate the stereochemistry of the
hydroxy group in C11

at

the key intermediate hydroxy-methyl ketone KI10, X-ray

crystallography for KI10a was carried out (Figure 4.5). The aldol condensation reaction
was performed using LDA at -78 °C due to the low boiling point of the TBS protected isopropyl aldehyde compared to the other indicated aldehydes. This boiling point is much
lower than the other used aldehydes that were reacted using NaOH at 105 °C.

O

O
Si

OH
O

Figure 4.5. X-ray crystal structure of KI10 indicates that the stereochemistry of C11
is an R configuration.

The products KI11-KI18 were used to synthesize the target final compounds. The general
procedure to deprotect the hydroxylated C11 was using 12 equivalence of TBAF and
running the reaction for 72 hrs. in order to obtain the products KA1-KA8. The high
equivalence of TBAF and the long period of time needed is also proof for the hindrance of
this position (Scheme 2).
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4.2.3. Biological Evaluation

All the synthesized compounds were screened against three pancreatic cell lines: BXPC3,
PANC-I, and AsPC-I, as noted in Table 4.2. The results indicate that the compounds KA1
and KA2, containing a phenyl para-trifluoro side chain and cuc side chain, respectively,
are the most potent analogs. Generally, based on MTT results, the presence of a hydroxyl
group increases the antiproliferative activity of the synthesized compounds.
Table 4.2. IC50 results of the synthesized CIE analogs after treatment with 3
pancreatic cancer cell lines
Compound

PANC-I IC50 (µM) AsPC-I IC50 (µM)

BXPC-3 IC50 (µM)

KA1

5.52

11.2

4.7

KA2

12.81

16.28

10.89

KA3

>100

NA

85.9

KA4

44.71

49.04

49.04

KA5

NA

NA

NA

KA6

NA

NA

NA

KA11

NA

NA

NA

KA15

NA

NA

NA

>100

>100

>100

Gemcitabine

To further investigate the mechanism of action of KA1 and KA2, cell cycle analysis was
carried out in 24, 48, and 72 hrs. periods to investigate the inhibition at different time
points. The results confirm that both CIE analogs accumulate cells during the G1 phase in
24 hrs; however, inhibition decreased after this point.
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Control

KA1

KA2

Figure 4.6.A. Cell cycle analysis for KA1 and KA2 after 24
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Control

KA1

KA2

Figure 4.6.B. Cell cycle analysis for KA1 and KA2 after 48.
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Control

KA1

KA2

Figure 4.6.C. Cell cycle analysis for KA1 and KA2 after 72.
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4.3.

Material and methods

4.3.1. Molecular Modeling
The molecular modeling studies were carried using two OpenEye software programs, 28
Omega to generate the conformers of the compounds and FRED to allow rigid exhaustive
docking.29 The targets for the previously mentioned proteins were processed and generated
using MakeReceptor®. After the molecular docking was carried out, the consensus scores
were visualized using VIDA software.
4.3.2. Chemical Synthesis
General:
All chemicals and solvents (ACS grades) were purchased from Fisher Scientific or Sigma
Aldrich and used without any additional treatment. Before conducting the experiments, all
the glassware and tools were cleaned, washed and dried in a 120 °C oven. Before the
reaction the flasks were closed and flushed with nitrogen gas for all of the reaction period,
except when mentioned during the experiment. TLC plates (Silica gel, 0.2-mm thick,
polyester backed, Sorbtech) were used to analyze the reaction conditions under UV254.
All synthetic intermediates and final compounds were purified using column
chromatography packed with silica gel 60A, 40-63 μm.

1

H and

13

C NMR spectra were

carried out using Bruker AVANCE-400 MHZ and 600 MHZ NMR spectrometers. The
solvents used for the compounds were CDCl3, as will be indicated later. NMR chemical
shifts were presented in 𝛿(PPM) using residual solvent peaks as standards (CDCl3, 7.26
(1H), 77.16 (13C)). High resolution mass (HRMS) was performed using Thermofinnigan
MAT 95XL mass spectrometer at the Buffalo mass spectroscopy facility. X-ray
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crystallography was conducted on KI9 at the University of South Dakota using a Bruker
APEXᴵᴵ diffractometer.
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To a stirred solution of estrone (5g, 18.49 mmole) in 600 ml of methanol at a temperature
of 47 0C, 2, 3-Dichloro-5, 6-dicyano-1,4-benzoquinone (DDQ) (6.3 g, 27.74 mmole) was
added. The reaction was stirred for 5 hrs. and the reaction progress was tested by TLC
using 6:4 (hexane: ethyl acetate mixture) followed by the evaporation of methanol using a
vacuum. The crude extract was dissolved in 308 ml of toluene to proceed to the next
reaction. The solution was heated to 205 0C. Ethylene glycol (4.53 ml, 81.49 mmole) was
poured into one portion, and then para-toluene sulfonic acid (0.212 g, 11.19 mmole) was
added. The reaction mixture was stirred and refluxed for 8 hours using a Dean-Stark
apparatus to eliminate the condensed water; this prevented it from returning to the reaction
mixture and reversing the reaction. The reaction was cooled to room temperature, then a
saturated NaHCO3 solution was added to quench the reaction. Ethyl acetate (3 ˣ 100 ml)
was used to extract the aqueous layer, then the organic layer was dried over anhydrous
NaSO4 and evaporated. The crude material was dissolved in DMSO (90 ml), followed by
the addition of crushed granulate potassium hydroxide (4.032 g, 86.46 mmole); next,
methyl iodide (2.24 g, 35.94 mmole) was added to the reaction mixture. The reaction was
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stirred at room temperature for 2 hours, quenched by the addition of water (400 ml) and
stirred for 15 minutes. Ethyl Acetate (3 ˣ100 ml) was used to extract the aqueous layer,
while the organic layer was dried over sodium sulfate anhydrous and concentrated in vacuo
to obtain the dry organic portion. Then, the silica gel column was used to purify the crude
material using 9:1 (hexane: ethyl acetate) to provide KI 2 (4.3 g, 71.33 %) as a white
material.

1H NMR (400 MHz, Chloroform-d) δ 7.52 (d, J = 8.8 Hz, 1H), 6.70 (dd, J = 8.8, 2.8 Hz,
1H), 6.58 (d, J = 2.8 Hz, 1H), 6.12 (dt, J = 5.2, 2.3 Hz, 1H), 3.98 – 3.84 (m, 4H), 3.76 (s,
3H), 2.84 (qdd, J = 14.8, 8.5, 3.8 Hz, 2H), 2.58 (dt, J = 17.6, 3.1 Hz, 1H), 2.15 – 1.97 (m,
3H), 1.94 – 1.66 (m, 5H), 1.38 (dtd, J = 17.0, 12.4, 6.5 Hz, 2H), 0.89 (s, 3H).
13C

NMR (101 MHz, CDCl3) δ 158.29, 137.48, 134.50, 127.60, 125.15, 119.06, 117.90,

113.27, 112.66, 65.27, 64.60, 55.23, 46.83, 44.33, 39.19, 33.87, 32.81, 30.17, 28.21 23.25,
14.72.
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The KI2 compound (4.3 g, 13.19 mmole) was dissolved in 30 mL anhydrous THF. Then
10 mL (~ 1.5 equivalence) of borane dimethyl sulfide complex solution in THF (2 M) was
added portion-wise, stirring under argon, and the reaction was stirred at room temperature
for 15 hrs. Next, 3.25 ml NaOH solution (3M) and 3.25 ml H2O2 were added portion-wise
and the reaction was stirred for 1 hr. under air (Note: the stopper must be removed after the
addition of NaOH and H2O2 .30 The aqueous layer was extracted using ethyl acetate (3 ˣ 50
ml) and the organic layer was dried over sodium sulfate anhydrous and concentrated in
vacuo. The crude extract was purified using a 7:3 hexane ethyl acetate mixture to obtain
KI3 as a white material (3.13 g, 69%).

1H NMR (400 MHz, Chloroform-d) δ 7.88 (dd, J = 8.7, 1.0 Hz, 1H), 6.69 (dd, J = 8.7,
2.9 Hz, 1H), 6.62 (d, J = 2.8 Hz, 1H), 4.10 (d, J = 7.1 Hz, 1H), 3.95 – 3.84 (m, 5H), 3.75
(s, 3H), 2.78 (dd, J = 8.0, 6.1 Hz, 2H), 2.13 (t, J = 10.1 Hz, 2H), 2.02 – 1.97 (m, 1H), 1.91
– 1.83 (m, 3H), 1.72 – 1.65 (m, 2H), 1.25 (dd, J = 9.5, 4.8 Hz, 2H), 0.84 (s, 3H).
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13C NMR (151 MHz, CDCl3) δ 157.69, 139.05, 132.56, 127.49, 118.88, 113.69, 111.06,
70.95, 65.30, 64.58, 55.11, 50.36, 48.99, 46.96 , 41.47, 37.58, 34.28, 28.79, 26.83, 22.45,
14.97.

KI4

O
HO

O
O

H
H

H

O

HO
H

10%HCl
Acetone

H

H

O

KI4
The 3.13 g (9.10 mmole) of KI3 that was obtained from the previous step was then
dissolved in 130 ml (1:1, 10% HCl: Acetone) and stirred at room temperature overnight.
The next day, the reaction was quenched by the addition of NaHCO3 to neutralize the
excess acid. The reaction mixture was extracted with ethyl acetate (3 X 100 ml) and dried
over Na2SO3 anhydrous, followed by evaporation in vacuo. The purification process used
a 6:4 hexane ethyl acetate mixture to yield 3-methoxy-1, 3, 5(10)-trien-11-ol-17-one (2.5
g, 91%) as a purple solid material.
1H NMR (400 MHz, Chloroform-d) δ 7.90 (dd, J = 8.7, 1.0 Hz, 1H), 6.74 (dd, J = 8.7,
2.9 Hz, 1H), 6.67 (d, J = 2.9 Hz, 1H), 4.21 (ddd, J = 10.8, 9.7, 5.3 Hz, 1H), 3.79 (s, 3H),
3.46 (s, 1H), 2.85 (t, J = 6.8 Hz, 2H), 2.54 (d, J = 3.7 Hz, 0H), 2.55 – 2.43 (m, 3H), 2.28
(dd, J = 12.5, 5.3 Hz, 1H), 2.21 (q, J = 5.7 Hz, 1H), 2.21 – 2.12 (m, 1H), 2.09 – 1.96 (m,
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1H), 1.98 (s, 1H), 1.54 (ddd, J = 10.4, 8.5, 5.9 Hz, 2H), 1.40 (dd, J = 12.5, 10.9 Hz, 1H),
1.29 (s, 2H), 1.28 (s, 1H), 0.95 – 0.80 (m, 1H), 0.87 (s, 3H).

13C NMR (101 MHz, CDCl3) δ 219.88, 157.73, 138.81, 132.11, 127.62, 113.68, 111.13,
77.48, 77.17, 76.85, 70.28, 55.18, 50.27, 49.78, 48.70, 41.71, 36.68, 35.95, 28.61, 26.27,
21.65, 14.28.
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H
H

O

H

H

TBSCl, Mg turnings
DMF

H

H

O

KI5
The purified compound KI4 (2.5 g, 8.28 mmol) was dissolved in 40 ml DMF, followed
by the addition of 0.6 g of magnesium turning. With regard to magnesium turnings, the
reaction must be facilitated, since the reaction does not work in the absence of a catalyst.
Next, 3.75 g of TBSCl was added and the color turned from purple to red. The reaction
was run at room temperature for 14 hrs. before it was quenched with water. The reaction
mixture was extracted with ethyl acetate (3 X 100 ml) and dried with Na2SO3 anhydrous.
The TBS-protected compound KI5 was purified using hexane: ethyl acetate (8:2) mixture
to obtain 3.3 g (95%).
1H NMR (600 MHz, CDCl3) δ 7.56 (d, J = 8.7 Hz, 1H), 6.49 (dd, J = 8.7, 2.8 Hz, 1H),
6.46 (d, J = 2.7 Hz, 1H), 4.12 (ddd, J = 10.6, 9.5, 5.1 Hz, 1H), 3.59 (d, J = 2.0 Hz, 2H),
2.67 – 2.63 (m, 1H), 2.31 (ddd, J = 13.8, 10.7, 3.0 Hz, 1H), 2.13 (t, J = 9.7 Hz, 1H), 2.07
(dd, J = 12.6, 5.1 Hz, 1H), 2.02 – 1.94 (m, 1H), 1.87 – 1.76 (m, 2H), 1.08 – 1.05 (m, 1H),
0.72 (d, J = 3.2 Hz, 6H), 0.69 (s, 2H), -0.00 (s, 2H), -0.04 (d, J = 2.9 Hz, 2H).
13C NMR (151 MHz, CDCl3) δ 159.94, 141.60, 134.92, 130.94, 115.91, 112.92, 74.61,
57.56, 52.91, 52.34, 51.09, 44.33, 39.46, 38.48, 31.23, 28.77, 28.59, 24.17, 20.70, 16.82,
-0.00, -1.55.
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O
TBSO

TBSO

tert-BuOK

H
H
O

H

Ph3P
THF, 70°C

H
H

H

O
KI6

To a solution of ethyltriphenylphosphonium bromide (8.76 g, 23.58 mm) in 22 ml of
THF, potassium tert-butoxide (2.47 g, 22 mmole) was added, resulting in an orange
mixture that was stirred at room temperature for 1 hr. A solution of (3.3 g, 7.86mmole)
KI5 in 15 ml THF was added and the mixture was stirred at 70 °C for 5 hrs. The reaction
was allowed to cool to room temperature and NH4Cl solution was added to quench the
reaction, followed by extraction with ethyl acetate (3 X 50 ml) and drying using
anhydrous sodium sulfate. The compound KI6 (2.6 g, 80%) was purified using hexane:
ethyl acetate (9:1).

13C NMR (101 MHz, CDCl3) δ 160.05 (C3), 152.06 (C17), 141.37 (C5), 135.37 (C10),
130.98 (C1), 116.24 (C20), 115.91 (C4), 113.04 (C2), 75.50 (C11), 57.52 (C3), 57.15
(C13), 52.77 (C9), 50.50, 47.51(C14), 39.36(C8), 33.97(C16), 31.70 (C6), 30.01(C7),
28.79(C12), 26.86(C15), 20.67(C24), 20.18 (C24), 15.66 (C18), -0.00(C22), -1.26(C23).
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HO
TBSO

TBSO
i. 9-BBN,THF

H
H
O

H

H

ii. NaoH,H2O2

H

H

O
KI7

In a 1 L flask of 9-Borabicyclo [3.3.1] nonane, 9-BBN (0.5 M in THF,49 ml, 24.4 mmol)
was added portion-wise to KI 5 (2.68 g, 6.288 mmole) at 0 °C and stirred for 30 min. at
room temperature. The reaction mixture was run at 60 °C for 18 hr., then run at 0 °C for
10 min., followed by the slow addition of 48 mL of 10% NaOH and 92 mL of 30% H2O.
The reaction was then allowed to run at room temperature without closing the system. The
mixture was extracted with ethyl acetate (3 X 100 ml) and the organic layers were washed
with saturated sodium thiosulfate to reduce any extra H2O2. The organic layer was dried
with (Na2SO4), and concentrated in vacuo. The crude extract was moved to the next
reaction.
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KI8

HO

O

TBSO

TBSO
PCC,NaOAc/4A MS

H
H

H

H

CH2Cl2

O

H

H

O

80 %
2.65 g (5.97 mmole) of KI7 was dissolved in 28 ml CH2Cl2 containing 2.35 g of 4 A°
molecular sieves, followed by the addition of (2.34 g, 28.6 mmol) of NaOAc. Next, (2.5
g, 11.92 mmole) of pyridinium chlorochromate (PCC) was added and the reaction was
run at room temperature for 5 hrs. The reaction mixture was filtered using normal phase
silica to remove PCC and the resulting crude mixture was purified using hexane: ethyl
acetate (8:2) to produce KI7 (2.3 g, 80%).

13C

NMR (101 MHz, Chloroform-d) δ 201.04, 158.22, 152.43, 140.38, 137.69, 132.75,

113.87, 111.41, 72.56, 55.61, 55.20, 46.52, 44.26, 37.04, 34.84, 32.03, 29.67, 27.81,
27.19, 26.50, 20.70, 25.89, 24.22, 22.71, 14.84, -4.31.
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90 %
2.11 g (4.77 mmol) of KI8 was dissolved in 10 ml of CH2Cl2, while ZnI2 (0.045 g, 0.14
mmole) was added as a catalyst. Next, (0.83 ml, 6.142 mmole) of TMSCN was added to
the reaction mixture and stirred at room temperature for 3 hrs. After completion of the
reaction, H2O was added to quench the reaction and extraction was carried out using
CH2Cl2 (3 X 50 ml). The crude extract was dried with Na2SO2 and concentrated, purified
using hexane: ethyl acetate (9:1) to yield 2.9 g (90%) of KI9.
Note. Due to the toxicity of TMSCN, it should be handled under the fume hood.
1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 8.6 Hz, 1H), 6.52 (dd, J = 8.6, 2.8 Hz, 1H),
6.49 (d, J = 2.7 Hz, 1H), 4.15 (td, J = 10.4, 5.1 Hz, 1H), 3.98 (q, J = 7.1 Hz, 1H), 3.63 (s,
2H), 2.67 (t, J = 6.8 Hz, 2H), 2.41 (dd, J = 12.5, 5.1 Hz, 1H), 2.11 (t, J = 9.3 Hz, 1H),
1.95 – 1.87 (m, 2H), 1.48 (s, 2H), 1.14 – 1.11 (m, 3H), 0.84 (s, 2H), 0.78 (s, 4H), 0.18 (d,
J = 3.2 Hz, 6H), 0.04 (s, 2H), -0.00 (s, 2H).
13C NMR (101 MHz, CDCl3) δ 155.90, 137.27, 131.00, 126.60, 120.14, 111.58, 108.78,
70.74, 58.63, 58.29, 53.34, 52.67, 48.66, 48.32, 42.87, 35.20, 29.02, 27.19, 24.45, 19.34,
16.60, 12.57, 11.95, 0.04, -3.88, -5.71.
KI10

123
To synthesize the main intermediate KI10, (2.9 g, 5.37 mmol) of KI9 was dissolved in 13
ml of Et2O and stirred for 15 min at 0 °C, followed by the drop-wise addition of MeLi (13
ml). The reaction was run at 0 °C for 2 hrs. Next, 2 ml of glacial acetic acid was added to
the reaction and the mixture was stirred for 30 min. before the addition of NaHCO3 to
neutralize the acidic environment. The aqueous mixture was extracted with (3 X 50 ml)
CH2Cl2, dried with Na2SO4, concentrated, and purified using gradient mobile phase
hexane: ethyl acetate (9:1) then (8:2) to yield KI9 (e.e. 47 %).

O

TMSO CN

HO

TBSO

TBSO

H

TBSO

MeLi/Et2O, 0°C
CH3COOH
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H
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O

H

+
H

H

H

O
7%

47 %

1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.7 Hz, 4H), 6.50 (dd, J = 8.7, 2.7 Hz, 4H),
6.46 (d, J = 2.5 Hz, 3H), 4.15 (td, J = 10.2, 5.0 Hz, 4H), 3.84 (s, 4H), 3.60 (s, 13H), 2.64
(t, J = 6.3 Hz, 8H), 2.43 (dd, J = 12.0, 4.9 Hz, 4H), 2.15 – 2.09 (m, 5H), 2.07 (s, 11H), 1.96
– 0.99 (m, 75H), 0.78 (s, 34H), 0.75 (s, 12H), 0.70 (ddd, J = 6.4, 5.3, 2.3 Hz, 5H), 0.04 (s,
11H), -0.00 (s, 11H).
13C NMR (101 MHz, CDCl3) δ 211.39, 157.55, 139.07, 132.88, 128.40, 113.55, 110.43,
79.93, 72.48, 55.13, 54.87, 51.33, 50.14, 44.88, 36.72, 29.11, 27.55, 26.26, 24.65, 23.75,
23.19, 22.19, 18.46, 14.49, -2.47, -3.90.
TBS – protected aldehyde was prepared as synthesized in our lab previously.
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LDA/THF, -78 °C
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At 78 °C, 0.76 ml (1.85 mm) of n-BuLi dissolved in hexane (2.5 M) was added to 1.85
mmole (0.93 ml of 2 M) of diisopropylamine dissolved in THF, and the mixture was stirred
for 1 hr. A solution of KI9 0.514 mmole dissolved in THF (1 mL) was then added to
produce the enolate and the mixture was stirred for 1 hr. at -78 °C. Next came the addition
of 0.085 g (0.44 mmole) TBS protected aldehyde (KI10) that was dissolved in 1.32 ml THF
(0.15 M). The reaction was allowed to warm to room temperature and stirred for 24 hrs.
After that, the reaction was quenched with the addition of saturated NH4Cl. The aqueous
layer was extracted by ethyl acetate (3 X 50 mL), dried with Na2SO4, concentrated, and
purified using hexane: ethyl acetate (8:2) to yield (0.470 g, 55%) as a white powder.
1H

NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 14.9 Hz, 1H), 6.63 –

6.56 (m, 1H), 6.52 (dd, J = 8.7, 2.7 Hz, 1H), 6.48 (d, J = 2.5 Hz, 1H), 4.18 (td, J = 10.2,
5.0 Hz, 1H), 4.02 (s, 1H), 3.63 (s, 3H), 2.66 (t, J = 6.6 Hz, 2H), 2.47 (dd, J = 12.0, 5.0
Hz, 1H), 2.13 (dd, J = 12.4, 6.9 Hz, 1H), 1.69 (dd, J = 12.0, 6.8 Hz, 2H), 1.35 (s, 3H),
1.26 – 1.21 (m, 8H), 1.18 (dd, J = 12.5, 6.6 Hz, 3H), 1.12 (s, 2H), 0.82 (s, 8H), 0.80 (s,
8H), 0.78 (s, 3H), 0.06 (s, 3H), 0.02 (s, 3H), -0.00 (s, 3H), -0.01 (s, 3H).
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13C NMR (101 MHz, CDCl3) δ 204.24, 159.53, 159.52, 140.97, 134.76, 130.38, 120.10,
115.40, 112.47, 80.87, 75.65, 74.47, 57.26, 57.12, 56.57, 53.50, 52.16, 46.86, 38.79,
32.00, 31.87, 31.12, 29.48, 28.25, 27.93, 26.07, 25.76, 24.72, 23.97, 20.36, 20.32, 16.46,
16.17, -0.00, -0.03, -0.70, -1.75.
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Tetra-butyl ammonium fluoride (TBAF) (8.5 ml, 8.5 mmol) was added to a stirred solution
of 11 ml THF containing KI11 (0.470 g, 0.71 mmol) and stirred for 48 hrs. The reaction
was then quenched by the addition of NH4Cl solution. The aqueous layer was extracted by
ethyl acetate (3 X 50 ml). The organic layer was dried using Na2SO4, concentrated in vacuo,
and purified using hexane: ethyl acetate (6:4) to yield (0.18 g, 59 %) as a white solid
powder.
1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.6 Hz, 1H), 7.08 (d, J = 15.2 Hz, 1H), 6.65
(dd, J = 8.8, 2.7 Hz, 1H), 6.61 (d, J = 15.2 Hz, 1H), 6.57 (d, J = 2.4 Hz, 1H), 4.23 – 4.12
(m, 1H), 3.70 (d, J = 2.2 Hz, 3H), 2.82 – 2.69 (m, 2H), 2.55 (dd, J = 11.9, 5.0 Hz, 1H),
2.36 – 2.17 (m, 1H), 2.14 – 2.03 (m, 2H), 1.85 – 1.73 (m, 2H), 1.72 – 1.62 (m, 1H), 1.58
(dd, J = 8.8, 5.2 Hz, 1H), 1.42 (d, J = 7.7 Hz, 3H), 1.39 – 1.29 (m, 9H), 1.18 (s, 3H), 1.15
– 1.03 (m, 2H), 0.90 – 0.82 (m, 3H).
13C NMR (101 MHz, CDCl3) δ 202.14, 157.66, 156.40, 139.03, 132.41, 127.31, 117.94,
113.68, 111.12, 79.02, 71.30, 70.83, 55.20, 54.28, 50.95, 50.29, 45.41, 45.01, 36.52,
29.72, 29.53, 29.46, 28.78, 27.37, 24.15, 23.66, 22.00, 14.50.
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General synthesis procedure for (KI12-KI24):
KI10 (0.3 mmol) was dissolved in 1 ml THF, then grounded in NaOH powder (0.87 mm)
and 0.36 mmol aldehyde. The reaction mixture was heated in a 20 mL vial for 15 min under
105 °C. After that, the reaction was quenched by water and extracted with 3 X 20 mL ethyl
acetate, dried over NaSO4 and purified using 9:1 hexane: ethyl acetate.
KI12
HO

O

HO
F3C

TBSO
H
H

H

O

O
TBSO

H

H

NaOH/THF, 105°C

O

H

CF3
H

O

1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.7 Hz, 4H), 7.33 – 7.24 (m, 5H), 6.66 (d, J =
15.2 Hz, 5H), 6.51 (d, J = 3.5 Hz, 5H), 6.49 (d, J = 2.8 Hz, 3H), 6.47 (d, J = 2.8 Hz, 3H),
6.43 (d, J = 2.7 Hz, 5H), 6.13 (d, J = 3.5 Hz, 4H), 4.13 (td, J = 10.2, 5.0 Hz, 5H), 4.00 (s,
3H), 3.58 (s, 12H), 2.59 (dd, J = 14.6, 7.2 Hz, 11H), 2.43 (dd, J = 12.0, 4.9 Hz, 5H), 2.11
(t, J = 9.3 Hz, 5H), 1.71 (dd, J = 17.2, 7.8 Hz, 7H), 1.67 – 1.61 (m, 6H), 1.49 – 1.39 (m,
17H), 1.35 (s, 13H), 1.19 (t, J = 7.9 Hz, 15H), 1.09 – 1.05 (m, 11H), 0.77 (d, J = 2.9 Hz,
36H), 0.75 (s, 14H), 0.04 – -0.01 (m, 27H).
13C NMR (101 MHz, CDCl3) δ 201.44, 158.31, 145.00, 140.91, 134.97, 134.59, 129.92,
128.51, 126.00, 125.14, 122.44, 120.62, 113.45, 110.52, 79.21, 72.51, 55.14, 55.11,
54.78, 51.38, 50.14, 45.02, 36.81, 29.18, 27.44, 26.26, 24.26, 23.68, 22.19, 18.38, 14.66,
-2.58, -3.91.
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1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 15.1 Hz, 7H), 7.62 (d, J = 8.7 Hz, 7H), 6.99
(d, J = 3.6 Hz, 6H), 6.57 (dd, J = 3.6, 1.0 Hz, 7H), 6.49 (d, J = 2.7 Hz, 5H), 6.47 (d, J =
3.7 Hz, 6H), 6.44 (s, 10H), 4.13 (td, J = 10.1, 4.9 Hz, 8H), 4.05 (s, 6H), 3.59 (s, 21H),
2.60 (d, J = 7.4 Hz, 15H), 2.47 – 2.40 (m, 9H), 2.35 (s, 20H), 2.11 (t, J = 9.1 Hz, 7H),
1.67 (dd, J = 11.7, 7.7 Hz, 17H), 1.50 – 1.37 (m, 30H), 1.34 (s, 22H), 1.26 – 0.91 (m,
54H), 0.77 (s, 41H), 0.75 (s, 18H), 0.02 (d, J = 12.4 Hz, 40H).
13C NMR (101 MHz, CDCl3) δ 201.28, 157.50, 145.51, 139.04, 138.73, 137.74, 133.79,
132.70, 128.50, 127.06, 115.61, 113.41, 110.48, 78.74, 77.39, 77.07, 76.76, 72.54, 55.16,
55.07, 54.95, 51.35, 50.12, 44.91, 36.82, 29.20, 27.43, 26.27, 24.44, 23.67, 22.12, 18.38,
16.01, 14.60, -2.58, -3.92.
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1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 2.3 Hz, 3H), 7.85 (s, 2H), 7.62 (t, J = 5.7 Hz,
4H), 7.03 (t, J = 2.2 Hz, 1H), 7.01 (d, J = 2.1 Hz, 2H), 6.98 – 6.97 (m, 3H), 6.96 (s, 2H),
6.73 (dd, J = 8.7, 2.8 Hz, 2H), 6.67 (d, J = 2.7 Hz, 2H), 4.39 (dd, J = 10.0, 4.8 Hz, 2H),
4.36 (s, 2H), 3.90 (s, 3H), 3.88 (s, 6H), 3.81 (s, 6H), 2.82 (d, J = 7.0 Hz, 4H), 2.70 (dd, J =
12.0, 4.9 Hz, 2H), 2.34 (t, J = 8.9 Hz, 2H), 1.98 (t, J = 9.6 Hz, 3H), 1.91 – 1.82 (m, 3H),
1.70 – 1.65 (m, 5H), 1.62 (s, 7H), 1.41 (d, J = 4.0 Hz, 8H), 1.30 (d, J = 5.4 Hz, 5H), 1.25 –
1.14 (m, 5H), 1.01 (d, J = 2.7 Hz, 18H), 1.00 (d, J = 2.0 Hz, 6H), 0.97 – 0.86 (m, 9H), 0.28
(s, 6H), 0.25 (s, 6H).
13C NMR (101 MHz, CDCl3) δ 201.50, 162.13, 157.56, 145.83, 138.99, 132.69, 131.99,
130.62, 128.49, 126.98, 115.77, 114.50, 114.33, 113.43, 110.52, 78.83, 77.54, 77.22,
76.90, 72.58, 55.40, 55.08, 54.97, 51.42, 50.04, 44.94, 37.00, 31.65, 29.21, 27.48, 26.30,
24.49, 22.72, 22.18, 18.55, 18.39, 14.65, 14.22, -2.54, -3.89.
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1H NMR (400 MHz, CDCl3) δ 7.63 (s, 1H), 7.60 (d, J = 6.5 Hz, 1H), 7.36 (d, J = 8.5 Hz,
2H), 7.24 – 7.17 (m, 2H), 6.81 (t, J = 10.4 Hz, 1H), 6.49 (dt, J = 8.7, 4.4 Hz, 1H), 6.43 (d,
J = 2.5 Hz, 1H), 4.13 (td, J = 10.1, 4.9 Hz, 1H), 3.98 (s, 1H), 3.58 (s, 3H), 2.60 (d, J = 6.8
Hz, 2H), 2.44 (dd, J = 12.0, 4.9 Hz, 1H), 2.15 – 2.05 (m, 1H), 1.75 – 1.61 (m, 3H), 1.38
(s, 3H), 0.77 (s, 8H), 0.02 (d, J = 13.0 Hz, 6H).
13C NMR (101 MHz, CDCl3) δ 201.45, 157.54, 144.52, 138.99, 137.03, 132.72, 132.61,
129.90, 129.34, 128.50, 118.66, 113.45, 110.51, 79.05, 77.42, 77.10, 76.79, 72.52, 55.14,
54.82, 51.40, 50.15, 44.99, 36.81, 29.76, 29.20, 27.45, 26.27, 24.32, 23.69, 22.75, 22.17,
18.38, 14.66, -2.57, -3.90.
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1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.7 Hz, 1H), 7.32 – 7.24 (m, 1H), 6.65 (t, J =
12.5 Hz, 1H), 6.51 (d, J = 3.5 Hz, 1H), 6.48 (dd, J = 8.7, 2.8 Hz, 1H), 6.43 (d, J = 2.7 Hz,
1H), 6.13 (d, J = 3.5 Hz, 1H), 4.13 (td, J = 10.2, 5.0 Hz, 1H), 4.02 (d, J = 19.6 Hz, 1H),
3.59 (d, J = 2.9 Hz, 3H), 2.60 (t, J = 6.3 Hz, 2H), 2.43 (dd, J = 12.0, 4.9 Hz, 1H), 2.11 (t,
J = 9.3 Hz, 1H), 1.72 (t, J = 9.6 Hz, 1H), 1.67 – 1.61 (m, 1H), 1.47 – 1.40 (m, 3H), 1.35
(s, 3H), 1.19 (t, J = 7.9 Hz, 3H), 1.07 (dd, J = 11.7, 6.3 Hz, 3H), 0.77 (d, J = 2.8 Hz, 8H),
0.75 (s, 3H), 0.71 (t, J = 2.4 Hz, 1H), 0.02 (d, J = 3.0 Hz, 3H), 0.01 (d, J = 4.5 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 201.38, 157.47, 150.75, 140.37, 139.11, 132.91, 130.36,
128.56, 119.10, 116.18, 113.42, 110.54, 109.79, 78.91, 72.52, 55.22, 54.74, 51.27, 50.11,
44.96, 36.86, 29.23, 27.51, 26.27, 24.33, 23.75, 22.15, 18.37, 14.67, -2.56, -3.88.
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KI17
HO

O
S

TBSO

HO

O
H

NaOH/THF, 105°C
H

H

H

O

S

TBSO

H

H

O

H

O

1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 4.7 Hz, 1H), 7.60 (d, J = 0.9 Hz, 1H), 7.33 (d,
J = 8.4 Hz, 2H), 7.04 (d, J = 8.4 Hz, 2H), 6.80 (d, J = 15.5 Hz, 1H), 6.48 (dd, J = 8.7, 2.6
Hz, 1H), 6.43 (d, J = 2.4 Hz, 1H), 4.13 (td, J = 10.1, 4.8 Hz, 1H), 4.05 (s, 1H), 3.57 (s, 3H),
2.58 (d, J = 6.8 Hz, 2H), 2.45 (dd, J = 12.0, 4.8 Hz, 1H), 2.30 (s, 3H), 2.10 (t, J = 8.8 Hz,
1H), 1.72 (t, J = 9.5 Hz, 1H), 1.67 – 1.59 (m, 1H), 1.43 (d, J = 11.1 Hz, 3H), 1.37 (s, 3H),
1.19 (d, J = 14.8 Hz, 3H), 1.11 – 0.90 (m, 3H), 0.77 (d, J = 3.7 Hz, 9H), 0.76 (s, 2H), 0.03
(s, 3H), -0.00 (s, 3H).
13C NMR (101 MHz, CDCl3) δ 201.54, 157.54, 156.34, 145.52, 143.29, 142.06, 139.03,
132.68, 130.62, 129.13, 128.51, 125.87, 117.03, 113.45, 110.52, 78.95, 72.56, 55.17,
55.11, 54.91, 51.42, 50.18, 44.97, 36.79, 29.30, 27.47, 26.24, 24.48, 24.45, 23.69, 22.23,
18.46, 15.06, 14.68, -2.52, -3.85.
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KA1
HO

O

HO

TBSO

O

HO
H
H

H

CF3 TBAF, THF
H

O

H

CF3
H

O

1H NMR (600 MHz, CDCl3) δ 7.74 (d, J = 15.6 Hz, 35H), 7.61 (d, J = 8.3 Hz, 74H), 7.58
(d, J = 8.4 Hz, 75H), 6.88 (s, 32H), 6.73 (d, J = 8.6 Hz, 36H), 6.68 (dd, J = 8.6, 2.6 Hz,
37H), 6.63 (d, J = 2.5 Hz, 37H), 4.38 (s, 33H), 4.02 (s, 34H), 3.79 (d, J = 4.1 Hz, 7H), 3.72
(s, 118H), 2.88 (t, J = 10.2 Hz, 37H), 2.81 – 2.68 (m, 82H), 2.48 – 2.43 (m, 43H), 2.22
(tdd, J = 10.3, 9.6, 6.2 Hz, 60H), 2.04 (dt, J = 12.4, 3.2 Hz, 46H), 1.96 (t, J = 12.8 Hz, 39H),
1.84 (ddd, J = 12.4, 8.6, 5.1 Hz, 96H), 1.73 – 1.57 (m, 237H), 1.56 – 1.50 (m, 73H), 1.44
– 1.25 (m, 403H), 0.91 (s, 111H).
13C NMR (151 MHz, CDCl3) δ 212.87, 159.21, 144.22, 142.23, 138.01, 132.39, 128.86,
128.72, 127.49, 125.97, 125.95, 120.26, 114.43, 113.32, 78.62, 55.27, 53.71, 52.85, 47.85,
47.60, 41.10, 30.02, 29.68, 24.73, 24.07, 23.56, 22.69, 22.27, 20.24, 14.77.
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KA11
HO

O

HO

TBSO

HO
H
H

O

O

S

H

TBAF, THF

H

H

S
H

O

1H NMR (600 MHz, CDCl3) δ 7.90 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 15.5 Hz, 1H), 7.60
(d, J = 8.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 6.94 (d, J = 15.5 Hz, 1H), 6.76 (dd, J = 8.7,
2.6 Hz, 1H), 6.68 (d, J = 2.4 Hz, 1H), 4.33 – 4.27 (m, 2H), 3.89 (s, 3H), 3.81 (s, 3H), 2.84
(t, J = 6.6 Hz, 2H), 2.71 (dd, J = 11.9, 5.1 Hz, 1H), 2.19 (t, J = 9.2 Hz, 1H), 1.96 (t, J = 9.7
Hz, 1H), 1.92 – 1.86 (m, 1H), 1.81 (s, 1H), 1.72 – 1.63 (m, 2H), 1.59 (d, J = 16.7 Hz, 4H),
1.47 – 1.27 (m, 5H), 1.22 (td, J = 11.7, 6.4 Hz, 1H), 0.98 (d, J = 10.7 Hz, 3H)
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KA5
HO

O

HO

TBSO

HO
H
H

O

O

Cl

H

TBAF, THF

H

H

Cl
H

O

1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.7 Hz, 1H), 7.69 (d, J = 15.6 Hz, 1H), 7.45
(d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 6.91 (d, J = 15.6 Hz, 1H), 6.64 (dd, J = 8.6,
2.7 Hz, 1H), 6.55 (d, J = 2.6 Hz, 1H), 4.18 (td, J = 10.3, 5.1 Hz, 1H), 4.06 (s, 1H), 3.68 (s,
3H), 2.71 (d, J = 7.4 Hz, 2H), 2.58 (dd, J = 11.9, 5.1 Hz, 1H), 2.38 – 2.32 (m, 3H), 2.07 (t,
J = 9.3 Hz, 2H), 1.85 – 1.78 (m, 2H), 1.76 (dd, J = 5.9, 3.0 Hz, 1H).
13C NMR (101 MHz, CDCl3) δ 201.52, 144.46, 139.08, 137.04, 132.68, 132.35, 129.84,
129.34, 127.26, 118.66, 113.71, 111.12, 79.04, 70.79, 55.30, 55.19, 54.73, 53.67, 51.05,
50.32, 45.07, 36.53, 28.77, 27.36, 24.29, 23.65, 22.74, 22.07, 20.80, 14.50, 14.16.
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KA6
HO

O

HO
O

TBSO
H
H

Cl

1H

O

HO

Cl

H

TBAF, THF
H

O

O

H

H

O

NMR (600 MHz, CDCl3) δ 7.36 (d, J = 15.2 Hz, 1H), 6.73 (d, J = 8.6 Hz, 1H), 6.68

(dd, J = 8.6, 2.7 Hz, 1H), 6.64 (s, 1H), 6.62 (s, 1H), 6.62 (d, J = 2.2 Hz, 1H), 6.24 (d, J =
3.5 Hz, 1H), 3.72 (s, 2H), 2.89 (d, J = 12.5 Hz, 1H), 2.79 (s, 1H), 2.73 (d, J = 5.7 Hz, 1H),
2.47 (d, J = 12.6 Hz, 1H), 2.21 (tdd, J = 13.5, 6.1, 3.3 Hz, 1H), 2.03 (dd, J = 9.5, 6.2 Hz,
1H), 1.89 – 1.82 (m, 2H), 1.73 – 1.54 (m, 4H), 1.34 (s, 3H), 1.32 – 1.16 (m, 4H), 0.90 (s,
3H).

13C

NMR (151 MHz, CDCl3) 200.78, 159.32, 150.49, 140.38, 137.94, 130.64, 128.62,

127.39, 119.36, 115.55, 114.51, 113.35, 109.85, 78.40, 70.79, 55.23, 53.66, 52.89, 47.84,
47.55, 41.15, 24.73, 24.05, 23.60, 22.27, 20.30, 14.65.
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KA3

HO

O

HO
S

TBSO

S

HO
H
H

H

TBAF, THF
H

O

O

H

H

O

1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.6 Hz, 1H), 7.08 (d, J = 15.2 Hz, 1H), 6.65
(dd, J = 8.8, 2.7 Hz, 1H), 6.61 (d, J = 15.2 Hz, 1H), 6.57 (d, J = 2.4 Hz, 1H), 4.23 – 4.12
(m, 1H), 3.70 (d, J = 2.2 Hz, 3H), 2.82 – 2.69 (m, 2H), 2.55 (dd, J = 11.9, 5.0 Hz, 1H), 2.36
– 2.17 (m, 1H), 2.14 – 2.03 (m, 2H), 1.85 – 1.73 (m, 2H), 1.72 – 1.62 (m, 1H), 1.58 (dd, J
= 8.8, 5.2 Hz, 1H), 1.42 (d, J = 7.7 Hz, 3H), 1.39 – 1.29 (m, 9H), 1.18 (s, 3H), 1.15 – 1.03
(m, 2H), 0.90 – 0.82 (m, 3H).
13C NMR (101 MHz, CDCl3) δ 202.14, 157.66, 156.40, 139.03, 132.41, 127.31, 117.94,
113.68, 111.12, 79.02, 71.30, 70.83, 55.20, 54.28, 50.95, 50.29, 45.41, 45.01, 36.52, 29.72,
29.53, 29.46, 28.78, 27.37, 24.15, 23.66, 22.79, 22.71, 22.00, 14.50.
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KA4

HO

O

HO

TBSO

HO
H
H

O

O

O

H

TBAF, THF

H

H

O
H

O

13C NMR (151 MHz, CDCl3) δ 201.61, 162.12, 157.72, 145.80, 139.08, 132.45, 130.58,
127.28, 126.94, 115.77, 114.52, 113.72, 111.12, 78.84, 70.85, 55.50, 55.32, 55.20, 54.90,
51.10, 50.34, 45.04, 36.56, 28.80, 27.38, 24.45, 23.66, 22.07, 14.50.
1H NMR (600 MHz, CDCl3) δ 7.90 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 15.5 Hz, 1H), 7.60
(d, J = 8.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 6.94 (d, J = 15.5 Hz, 1H), 6.76 (dd, J = 8.7,
2.6 Hz, 1H), 6.68 (d, J = 2.4 Hz, 1H), 4.31 (d, J = 8.2 Hz, 2H), 3.89 (s, 3H), 3.81 (s, 3H),
2.84 (t, J = 6.6 Hz, 2H), 2.71 (dd, J = 11.9, 5.1 Hz, 1H), 2.19 (t, J = 9.2 Hz, 1H), 1.96 (t, J
= 9.7 Hz, 1H), 1.92 – 1.86 (m, 1H), 1.81 (s, 1H), 1.60 (s, 3H), 1.47 – 1.16 (m, 6H), 0.98
(s, 3H).
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KA15
HO

O

HO

TBSO

HO
H
H

O

1H

O

H

TBAF, THF
H

H

H

O

NMR (600 MHz, CDCl3) δ 7.73 (d, J = 8.4 Hz, 4H), 6.60 (dd, J = 8.7, 2.8 Hz, 4H),

6.54 (d, J = 2.8 Hz, 4H), 4.03 (q, J = 7.2 Hz, 7H), 3.68 (s, 12H), 3.29 – 3.24 (m, 15H), 2.90
– 2.86 (m, 33H), 2.74 – 2.70 (m, 9H), 2.25 (s, 11H), 2.04 (s, 10H), 1.95 (s, 7H), 1.90 – 1.76
(m, 21H), 1.72 – 1.65 (m, 39H), 1.58 (d, J = 7.4 Hz, 23H), 1.39 – 1.33 (m, 24H), 1.23 (s,
11H), 1.13 (d, J = 3.1 Hz, 5H), 1.10 – 1.05 (m, 9H), 0.87 (s, 10H).

13C

NMR (151 MHz, CDCl3) δ 212.87, 157.68, 138.98, 132.51, 127.32, 113.56, 111.02,

79.67, 77.33, 77.11, 76.90, 75.00, 70.35, 58.99, 55.80, 55.14, 52.12, 49.96, 48.88, 43.70,
36.56, 29.68, 28.74, 27.36, 26.33, 25.14, 24.14, 22.85, 22.58, 20.17, 19.76, 14.11, 13.69,
13.56.
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4.3.3. Biological evaluations
Cytotoxicity assay
Three cell lines were used to carry out the cytotoxicity assay: PANC-I, PCBX-3
and AsPC-1. In a 96-well plate, a total of 5x105 cells were seeded. After 24 hrs. A serial
dilution of the synthesized compounds (from 50 μM down to 3.125 μM as quadruplicate
for each concentration) were added to make a total volume of 200 μL/well. Next,
incubation was performed at 37 °C and 5% CO2 for 48 hrs. using 0.05% DMSO (Acros
Organics) as a negative control and cuc B as a positive control. After 48 hrs, 20 μL of 3(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) (Sigma Aldrich) and
(5 mg/mL PBS) were added to each well and the plate was incubated in the same conditions
for 2 hrs. In each well, the solutions were discarded and 200 μL DMSO was added and
mixed well. The absorbance was measured directly at 570 nm by Hidex Sense Microplate
readers.
Cell Cycle Analysis
PANC-I cells were seeded (3×105 cells/well) in a 6-well plate (3mL/ well) and incubated
overnight at 37 °C, 5% CO2. Next, the media were removed and replaced by 3 mL media
containing 11.23 μM or 7.674 μM from KA19 and KA20, respectively, as a duplicate in
each plate, along with cuc B and DMSO as duplicates. After incubating for 24 hrs, the cells
were washed twice with ice cold 1X PBS buffer (Hyclone™ Laboratories, Inc) and
collected after trypsinization. Then, deactivation with media was completed, by spinning
down at 1200 rpm/5 min/4 °C, discarding the supernatant and fixating by cold 70% ethanol:
1X PBS buffer overnight at −20 °C. Next, the cells were spinned down under the same
conditions and the supernatant was discarded. Lastly, 500 μL propidium iodide (PI)/ RNase
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staining solution (BD Biosciences) and 0.1%tritonx 100 were added and incubated in the
dark at room temperature for 30min, then analyzed within 1h by a flow cytometer (BD
Accuri C6, Becton-Dickinson, Mountain View, CA). Data was analyzed using MFLT32
software and 10,000 events with slow flowrate were recorded for each sample.

4.4. Conclusion
Design and synthesis of 8 cucurbitacin-inspired estrone analogs functionalized hydroxy
group at C11 have been achieved based on ligand-based drug discovery approach. 12
synthetic steps was conducted in order to produce each final compound. The
stereochemistry of the key intermediate KI10 was determined using crystallography.
Molecular modeling data indicate that the calculated binding affinity for the hydroxylated
analogs score higher than the dehydrogenated analogs in most of the used molecular targets
such EGFR, RAS, RAF, and PI3K. Moreover, in- vitro cell viability assay indicate that 3
hydroxylated CIE analogs show promising IC50 values. KA1, KA2, and KA4 containing
phenyl para-trifluoromethyl, cuc, and phenyl para-thiomethyl side chains show promising
IC50 values against 3 pancreatic cancer cell lines PANC-I, AsPC-I, and BXPC-3 with IC50,s
lower than the dehydrogenated analogs for KA1 and KA2. However, KA4 show higher
IC50 compared to the previously synthesized analogs. Results of cell cycle arrest analysis
show that KA1 and KA2 arrest the cell cycle at G0/G1 phase in a time dependent matter.
Our results indicate that hydroxylation of C11 increase the antiproliferative activity against
three pancreatic cancer cell lines.
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Chapter Five

Synthesis and Biological Activity of C-11 Ketone Cucurbitacin-Inspired Estrone
Analogs Targeting Pancreatic Ductal Adenocarcinoma

Abstract
The treatment of pancreatic cancer is one of the major unsolved health problems today.
The high mortality rate of pancreatic cancer patients, among other cancer types, is due to
the lack of early diagnosis and of effective treatments. Recently, cucurbitacin B has shown
promising antiproliferative activity against human pancreatic cancer cells via decreasing
the expression levels of pSTAT3 and pEGFR in a dose- and time-dependent manner. In
order to overcome the low yield of cucurbitacin B that prevented its clinical use, a
molecular-modeling based drug discovery process was undertaken to install cucurbitacin
pharmacophores in the four-membered ring estrone as a carrier scaffold. This resulted in
the discovery of Cucurbitacin-Inspired Estrone Analogs (CIEA’s).
Previously, we confirmed bioinformatically and biologically that the functionalization of
C11 of the CIE analogs can increase the anticancer effects of this group. Furthermore, the
inhibition of pEGFR and pErk expression was demonstrated on pancreatic cancer cell lines.
So far, two types of analogs have been synthesized to study the effects of the
functionalization of this group. The desaturation of C9 and C11led to increased activity
compared to the saturated analogs. Upon broader investigation, it was confirmed that the
hydroxylation of C11can further increase the activity. In order to increase the potency, both
a molecular modeling study and biological data were used to synthesize 8 CIE analogs with
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a ketone group at C11. Although only the KA9 analog showed promising activity, it has a
greater anticancer effect than previously discovered analogs. Moreover, the results of a
Cell Titer assay showed that KA9 had greater anticancer activity on 2D and 3D models of
pancreatic cancer cell lines than KA1 and KA2 that were synthesized previously. The
anticancer activity was also greater than gemcitabine, since it decreased the micro tumor
size after several days of treatment. KA9 demonstrates the inhibition of pEGFR and pErk
overexpression, compared to the phosphorylation of mTOR and STAT3. The cell cycle
arrest experiment indicated that KA9 inhibited the G1 phase in a time- and dose-dependent
manner. KA9 was proven to induce cell death through increased caspase-3 activity on
PANC-I cell lines. This result suggests that KA9 is a potential candidate for animal study
as a promising pancreatic anticancer agent.
5.1. Introduction
Based on the current incidence, the availability of the treatment and the developing
resistance of different cancer types, it is expected that pancreatic ductal adenocarcinoma
with liver cancer will be the second and third leading causes of deaths by 2030.1 Currently,
pancreatic cancer is the fourth leading cause of death among cancer types for both men and
women.2 This high mortality rate is attributed to the absence of diagnostic markers in the
early stages of pancreatic cancer.3 The slow progress in finding novel anticancer agents
contributes to this expectation of high mortality in the future.4 Since the disease is generally
detected in its late stages, the only option for treatment is chemotherapy, where
gemcitabine is the first line of treatment, either alone or in combination therapy. However,
its one-year survival rate is 18%, while the 6-month survival rate is 23.8%. The body's
resistance to gemcitabine uses many mechanisms, such as a decreased number of
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transporters and an overexpression of cytidine deaminase that converts gemcitabine into
its inactive metabolite 2',2'-difluorodeoxyuridine (dFdU).5 This indicates the importance of
finding new anticancer drugs with various mechanisms of action.
Epidermal transmembrane factor receptor (EGFR) is a tyrosine kinase that is overexpressed
in many cancer types, including pancreatic cancer. EGFR overexpression was found to be
related to the advancement of the disease, its low survival rate, and metastasis.6 One of the
important EGFR targeting compounds is Cucurbitacin-Inspired Estrone Analogs
(CIEA’s), which were initially synthesized by installing a 23, 24 α, β- unsaturated ketone
side chain in the four membered-rings of triterpene estrone. This compound shows
comparable anticancer activity to that of cucurbitacin.7 CIE analogs have been through
several modifications that increase their anticancer activities against different cancer cell
lines, including erlotinib resistant HepG2 and multidrug resistance protein (MRP1).8
Currently, we have shown that the functionalization of rings B and C leads to more potent
anticancer agents than the currently available standard treatments.
Previously, we found that the dehydrogenation of C9-C11, with the installation phenyl paratrifluoro and para-nitro side chains, can increase their anticancer activity against pancreatic
cancer cell lines. Moreover, the α-hydroxylation of C11 led to an increase in the anticancer
activity with a cuc side chain and phenyl para-trifluoro.9, 10 However, upon testing these
compounds in a 3-D model of PANC-I pancreatic cancer, these CIE analogs showed poor
penetration and weak anticancer activity, which suggests that further modifications and
optimization are needed before moving to an in vivo study.
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In this study, we report on the molecular modeling of CIEA analogs with ketone C11 CIE
analogs, a synthesis of the best scoring analogs. We include their bioavailability assay
results on PANC-I, AsPC-I, and BXPC-3 pancreatic cell lines, the flowcytometric analysis
of KA9, and their inhibition of pEGFR, pER activation using In-Cell Western Analysis.
Furthermore, the anticancer activity of KA9 was demonstrated on a 3D model of the
PANC-I pancreatic cell line, which indicates a promising potential for KA9 compared to
the previously synthesized CIE analogs.

5.2. Results and Discussion
5.2.1. Molecular Modeling Design Strategy
Based on the MTT screening results of CIE analogs, transferring an OH group in C-3 into
ether can increase the anticancer activity of MSA7 compared to the same analog with
phenolic OH. Also, the molecular modeling studies introduced different side chains, such
as para-trifluoromethyl phenyl, at C-17 on ring D of estrone, dramatically increasing the
antiproliferative activity against hepatocellular carcinoma, breast cancer, colon cancer and
others.10 Upon molecular modeling against an ATP binding site of pEGFR, the KA9 analog
was the best scoring analog, which indicates its high affinity upon docking against a
pEGFR binding pocket using hydrogen bonding with Ala:18: A (Figure 5.1).
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Figure 5.1. Docking profile of the highest scoring CIE analog KA9 on EGFR
pocket indicate insertion of the molecule in the pocket by hydrophobic interaction.
Moreover, KA9 demonstrated a promising binding affinity to an RAS binding pocket with
a hydrogen bond formation between C11 ketone and Ala: 18: A (Figure 5.2). The RAS
protein is one of the most investigated proteins in pancreatic ductal adenocarcinoma, due
to its importance in the resistance mechanism that exists in pancreatic ductal
adenocarcinoma patients. It has been reported that nearly 95% of PDAC patients have
mutations in KRAS, which is one of the key signaling proteins that leads to an increase in
tumor growth, even while inhibiting upstream proteins (KRAS: feeding pancreatic cancer
proliferation).
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Figure 5.2. KA9 binding in RAS binding pocket show a hydrogen bonding with Ala:
18: A.

5.2.2. Chemical Synthesis
This group of compounds is characterized by the carbonyl group at C11, which contrasts
with the previously synthesized compounds that have dehydrogenated C 9 and C11 or a
hydroxyl group. To obtain the final compounds KA9-KA16, the oxidation of the hydroxyl
group is first carried out using the same conditions which oxidize the hydroxylated C20.
However, this produced a very small yield of the oxidized product compared to using AlCl3
as a catalyst with a yield of 80%.11 This confirms that the stereochemistry of the compound
hinders the position of C11 and requires a catalyst, as in the case of hydroboration
hydroxylation and TBS protection.
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5.2.3. Biological evaluations:
Two cell lines were used to conduct the cell viability assay against 3 pancreatic
cancer cell lines, PANC-I, AsPC-1, and PCBX-3. Most of the synthesized compounds did
not show anticancer activity, including KA12, which contains a cuc side chain. This
contrasts with the previously synthesized analogs that showed activity from the cuc side
chain containing compounds with different modifications. KA9, which contains a phenyl
para-trifluoro unsaturated side chain, shows greater anticancer potency than any
previously synthesized C11 functionalized CIE analog. The IC50’s were 4.30, 4.17 and 5.7
μM upon treatment of PANC-I, AsPC-1, and PCBX-3, respectively (Table 5.1).
In order to further investigate the effects of KA1 and KA2, an MTT assay was conducted
with the addition of HPaSteC cells, which are the main fibroblastic cells of the pancreas.
The HPaSteC cells stimulate pancreatic cancer proliferation, inhibit apoptosis, and enhance
angiogenesis.12 Upon co-culturing PANC-I with HPaSteC cells, no main difference was
observed between the two results, which indicates the effectiveness of these analogs.
Clearly, they are not affected by the inducers of pancreatic cell proliferation (Figure 5.4),
unlike the standard treatment, gemcitabine.
MTT assay is one of the best known experiments to study the effects of small molecules in
terms of cell viability.13 It measures the concentration of ATP based on the luminescence
produced by oxyluciferine after it is formed from luciferine. This assay also has a lower
sensitivity than a CellTiter assay. Upon treating the cells with CIE analogs KA1, KA2, and
KA9 to PANC-I and PANC-I/ HpaSteC, no noticeable difference was found in IC50 results
(less than 3 µM), as indicated in Figure 5B and Table 5.3.
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In order to the study the mechanism by which CEI analogs lead to the inhibition of cancer
growth, two mechanism can occur— either inducing cell death or inhibiting cell division.
Along with the analysis of cytotoxicity, we measured caspase 3/7 activation in cancer cells
using different concentrations of the tested compounds. We revealed that KA1, KA2 and
KA9 could cause a 1.5-2-fold increase in caspase activity at sub-toxic concentrations; at
toxic concentrations, caspase activity dropped due to a drastic decrease in the cell numbers
(Figure 5.5 B). At the same time, we observed as much as a 20% increase in caspase
activity by GEM and no drop in the considered concentration range (up to 50 µM).
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Figure 5.3. The structures of the synthesized oxygenated cucurbitacin-inspired
analogs.
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Table 5.1. IC50’s in μM of the synthesized CIE analogs upon treatment of PANC-I,
AsPC-1, and PCBX-3.
Compound

PANC-I

AsPC-I

BXPC-3

KA9

4.9± 0.3

4.17± 0.9

5.7± 0.65

KA10

NA

NA

NA

KA11

NA

NA

NA

KA12

NA

NA

NA

KA13

NA

NA

NA

KA14

NA

NA

NA

Figure 5.4. MTT assays of PANC-1 and PANC-1/HPaSteC co-culture cell viability
after 48 h exposure to cucurbitacin derivatives (KA1, KA2, and KA9) and
gemcitabine (GEM). Data are given as means±SD.
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Figure 5.5. Cytotoxic efficacy of cucurbitacin derivatives in monolayers. (A) CellTiter
assays of PANC-1 and PANC-1/HPaSteC co-culture cell viability after 48 h exposure
to cucurbitacin derivatives (KA1, KA2, and KA9) and gemcitabine (GEM). (B)
Caspase 3/7 activity in PANC-1 and PANC-1/HPaSteC 2D co-cultures after 48 h
exposure to cucurbitacin derivatives (KA1, KA2, and KA9) and gemcitabine (GEM).
Data are given as means±SD.

We then studied the changes that the compounds caused in DNA during different phases
of cell growth. According to the mechanism of action of the anticancer agent, a specific
growth phase will be affected. If G1 was affected that means the mechanism that is likely
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to be is DNA damage or affecting the growth factors; however, if the growth was affected
in the S phase, that means the affect was in DNA synthesis.
To further investigate for the effects of active CIE analogs, cell cycle analysis was
conducted with these compounds against the PANC-I cell line. The results demonstrated
that they accumulate cells at the G1 phase, which indicates that the mechanism of action is
similar in these compounds. Moreover, KA9 induced cell cycle arrest in a time- and
concentration-dependent manner, as indicated in Figures 5.6 and 5.7 and Tables 5.4 and
5.5.
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Control

KA9 (2.45 µM)

KA9 (9.8 µM)

KA9 (4.9 µM)

Figure 5.6. Effects of different concentrations of KA9 upon cell cycle indicates G1
phase accumulation after 48 hrs.

Table 5.2. Effects of KA9 treatment on cell cycle upon treatment with different
concentrations
Groups
Control
KA9 (2.45 µM)

G0 – G1
22.1
20.8

S
6.82
8.18

G2 - M
69.7
69.3

KA9 (4.9 µM)
KA9 (9.8 µM)

27.9
30.5

11
13.7

59.1
55
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KA9 (24 hrs.)

Control (24 hrs.)

KA9 (48 hrs.)

KA9 (72 hrs.)

Figure 5.7. Effects of KA9 upon cell cycle indicates inhibition in a time-dependent
manner.
Table 5.3. Effect of KA9 upon cell cycle indicates inhibition in a time-dependent
manner.
Groups
Control (24 hrs.)
KA9 (24 hrs.)

G0 – G1
21.8
26.9

S
7.10
12.1

G2 - M
69.6
60

KA9 (48 hrs.)
KA9 (72 hrs.)

27.9
33.8

11
10.0

59.1
54
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The PANC-I cell line was treated with different concentrations of KA9 in order to study
the inhibition of various protein activations. Four concentrations, starting with the fourth
IC50 on PANC-I to twice the IC50, were used to treat the cells. After 24 hrs. KA9, in a
concentration-dependent manner, inhibited the phosphorylation of pEGFR and pErk
compared to mTOR and pSTAT3, which confirms that the mechanism of action is similar
to the previously synthesized CIE analogs (Figure 5.8).

These results indicate the

specificity of KA9 in inhibition of pEGFR and pErk phosphorylation without affecting
different routes such as STAT3 and mTOR compared to the broad effect of cucurbitacin.
These results indicate that KA9 might have low toxicity compared to cucurbitacin
compounds.
In addition to the monolayer cell viability assays, results for the heterospheroids of PANC1/HPaSteC (2:1) (Table 5.4) were obtained, in spite of the reported chemoprotective effect
of myofibroblasts on pancreatic cancer cells in co-culture.
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Table 5.4. IC50 values* for 2D and 3D cell cultures of PANC-1 cells and their cocultures with HPaSteC.
2D
MTT assay

3D
CellTiter

Compound

CellTiter assay

assay
PANC1

PANC-1/
/HPaSteC
(2:1)

5.1

PANC1

PANC-1/
/HPaSteC
(2:1)

PANC-1

PANC-1/
120 /HPaSteC
cells, 120:60
2
cells, 2
weeks weeks
50.0

7.6

7.6

37.5

KA1

4.9

KA2

11.8

11.8

13.6

15.8

37.5

39.5

KA9

4.4

4.5

7.5

7.6

21.0

24.3

*All concentration values are given in µM.
Cancer spheroids are considered a more advanced cellular model for screening novel drug
candidates, since they mimic the tumor microenvironment to a higher extent and provides
better predictive values than cell monolayers.14 For the cytotoxicity evaluation of
cucurbitacin-derived compounds, we used pancreatic cancer homospheroids containing
PANC-1 cells, and heterospheroids comprised of PANC-1 and HPaSteC. Both types of
spheroids were cultivated for two weeks, reaching a size of approximately 450-500 µm in
diameter.
Upon activation in a tumor microenvironment, pancreatic stellate cells play an important
role in the progression of PDAC and significantly contribute to the development of the
desmoplastic reaction.15Here, we studied the expression and architecture of ECM
components in both types of spheroids. We found that heterospheroids more extensively
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produced collagen I, which form fibrous clusters in spheroid interstitium, whereas in
PANC-1 spheroids, it was distributed diffusely (Figure 5.8). Furthermore, PANC1/HPaSteC spheroids produced a fibronectin fibrillary scaffold, while homospheroids did
not express this ECM component.

Figure 5.8. Expression of ECM components in pancreatic cancer spheroids. Collagen
I (green), fibronectin (red), hyaluronan (purple) and laminin (yellow) in PANC-1 and
PANC-1/HPaSteC microtumors were defined in 10 µm-thick spheroid frozen section
by immunofluorescent staining. Sections were obtained from spheroids incubated for
2 weeks in growth medium. Scale bar is 100 µm.
To estimate the cytotoxic effects of cucurbitacin derivatives, we used CellTiter assay to
compare the values with those obtained for the monolayers of PANC-1 and the PANC1/HPaSteC co-culture. This test revealed that 3D spheroids are more resistant to all tested
compounds than cells in 2D cultures (Figure 5.9 A, B and Table 5.4). Moreover,
heterospheroids demonstrated slightly higher resistance to all drugs, as compared to
homospheroids. Interestingly, in the 3D models, the cytotoxicity trend of the drugs changed
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in comparison with the 2D models, resulting in KA9>KA1≈KA2>>GEM. According to
our results, KA9 displayed the highest toxicity. This trend was confirmed by another
experiment on the inhibition of the spheroid growth rate. We added drugs at final
concentrations of 10 µM to 5-day old spheroids and measured their growth. Only KA9 was
able to cause a regression of the spheroids, whereas other drugs, including GEM, merely
delayed their growth (Figure 5.9 C, D).

Figure 5.9. Cytotoxic efficacy of cucurbitacin-inspired estrone analogs for pancreatic
microtumors. CellTiter analysis of PANC-1 (A) and PANC-1/HPaSteC (B) spheroid
viability after 48 h exposure to cucurbitacin derivatives (KA1, KA2, and KA9) and
gemcitabine (GEM). For evaluation of spheroid growth inhibition, cucurbitacin
derivatives (KA1, KA2, KA9) or gemcitabine (GEM) were added to 5-days old
spheroids (day 0). Volumes of PANC-1 (C) or PANC-1/HPaSteC (D) pancreatic
tumor spheroids were calculated as L x W x W (length x width x width) every 2 days.
All spheroid images in (C) and (D) have a size of 650×450 microns. Data are given as
means±SD.
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5.3. Material and Methods
5.3.1. Molecular Modeling
The molecular modeling studies were carried using two OpenEye software programs, 13
Omega to generate the conformers of the compounds and FRED to allow rigid exhaustive
docking.14 The targets for the previously mentioned proteins were processed and generated
using MakeReceptor®. After the molecular docking was carried out, the consensus scores
were visualized using VIDA software.

5.3.2. Chemical Synthesis:
All chemicals and solvents (ACS grades) were purchased from Fisher Scientific or Sigma
Aldrich and used without any additional treatment. Before conducting the experiments, all
the glassware and tools were cleaned, washed and dried in 120 °C oven, followed by
closing and introducing nitrogen gas to the reaction vessel for all the reaction period, except
when mentioned during the experiment. TLC plates (Silica gel, 0.2-mm thick, polyester
backed, Sorbtech) were used to analyze the reaction conditions under UV254. All synthetic
intermediates and final compounds were purified using column chromatography packed
with silica gel 60A, 40-63 μm. 1H and 13C NMR spectra were carried out using Bruker
AVANCE-400 MHZ and 600 MHZ NMR spectrometers. The solvents used for the
compounds are CDCl3 and D-acetone, as will be indicated later. NMR chemical shifts were
presented in 𝛿(PPM) using residual solvent peaks as standards (CDCl3, 7.26 (1H), 77.16
(13C). High resolution mass (HRMS) was performed using a Thermofinnigan MAT 95XL
mass spectrometer at the Buffalo mass spectroscopy facility. X-ray crystallography was
conducted on KI 9 at the University of South Dakota using a Bruker APEXᴵᴵ diffractometer.
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To a solution of 0.22 mm of C11 hydroxy CIE analogs in DCM (2 mL), AlO3 (0.53 g) was
added, followed by PCC (0.659 g). The reaction mixture was heated to 45 for 4 hrs. Next,
the reaction mixture was filtered through silica using ethyl acetate, followed by
concentrating it under vacuu and purifying it through silica using (8:2) hexane: ethyl
acetate.
KA12

HO
HO

O

HO
O

OH
H
H

H

OH

H

AlO3/PCC/ 45 °C

O

O

CH2Cl2

H

H

O

1H NMR (600 MHz, CDCl3) δ 6.89 (s, 4H), 6.69 (d, J = 8.4 Hz, 11H), 6.66 – 6.63 (m,
24H), 4.34 (s, 8H), 3.72 (s, 32H), 2.84 – 2.71 (m, 39H), 2.56 (t, J = 9.1 Hz, 13H), 2.47 (d,
J = 12.5 Hz, 13H), 2.23 (tdd, J = 13.6, 6.2, 3.2 Hz, 23H), 2.19 – 2.12 (m, 25H), 2.02 (dt, J
= 12.5, 3.2 Hz, 17H), 1.99 (s, 31H), 1.93 (td, J = 12.1, 6.8 Hz, 20H), 1.80 – 1.71 (m,
45H), 1.31 (s, 15H), 0.62 (s, 31H).
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KA9

HO

O

HO

HO

O

O
H
H

H

H

CF3 AlO3/PCC/ 45 °C
CH2Cl2

O

H

CF3
H

O

1H NMR (600 MHz, CDCl3) δ 7.74 (d, J = 15.6 Hz, 3H), 7.62 (d, J = 8.3 Hz, 6H), 7.58
(d, J = 8.4 Hz, 6H), 6.91 – 6.87 (m, 4H), 6.72 (s, 2H), 6.69 – 6.67 (m, 3H), 6.63 (d, J = 2.5
Hz, 3H), 3.72 (s, 9H), 2.89 (d, J = 12.5 Hz, 3H), 2.73 (d, J = 5.7 Hz, 7H), 2.45 (d, J = 12.6
Hz, 3H), 2.29 – 2.19 (m, 5H), 2.18 (s, 2H), 2.04 (d, J = 12.5 Hz, 4H), 2.00 – 1.96 (m, 2H),
1.85 (dd, J = 17.1, 7.9 Hz, 8H), 1.72 – 1.68 (m, 5H), 1.67 – 1.57 (m, 11H), 1.37 (s, 9H),
1.33 (dd, J = 10.9, 4.9 Hz, 3H), 1.30 – 1.27 (m, 5H), 0.91 (s, 9H).
13C NMR (151 MHz, CDCl3) δ 213.04, 200.78, 159.32, 150.49, 140.38, 137.94, 130.64,
128.62, 127.39, 119.36, 115.55, 114.51, 113.35, 109.85, 78.40, 55.23, 53.66, 52.89, 47.84,
47.55, 41.15, 24.73, 24.05, 23.60, 22.27, 20.30, 14.65.
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KA8
HO

O

HO

HO

O
H
H

O

O

O
H

H

AlO3/PCC/ 45 °C
CH2Cl2

H

O
H

O

1H NMR (600 MHz, CDCl3) δ 7.71 (d, J = 15.5 Hz, 1H), 7.47 – 7.45 (m, 2H), 7.17 (d, J
= 8.7 Hz, 1H), 6.83 – 6.80 (m, 2H), 6.77 (d, J = 15.5 Hz, 1H), 6.64 (dd, J = 8.7, 2.8 Hz,
1H), 6.49 (d, J = 2.7 Hz, 1H), 4.13 (s, 1H), 3.74 (s, 3H), 3.65 (s, 3H), 3.37 (d, J = 11.5 Hz,
1H), 2.82 (d, J = 11.5 Hz, 1H), 2.71 (dd, J = 12.5, 4.9 Hz, 1H), 2.64 (dd, J = 16.9, 3.7 Hz,
1H), 2.59 (d, J = 11.5 Hz, 1H), 2.04 (t, J = 9.6 Hz, 1H), 1.90 – 1.84 (m, 1H), 1.80 (ddd, J
= 7.5, 5.6, 2.8 Hz, 1H), 1.71 – 1.57 (m, 3H), 1.38 (s, 3H), 1.32 – 1.16 (m, 3H), 0.83 (s, 3H).
13C NMR (151 MHz, CDCl3) δ 209.38, 201.26, 162.19, 158.00, 146.07, 138.47, 131.13,
130.62, 126.87, 123.71, 115.53, 114.52, 113.76, 111.62, 78.48, 57.92, 55.72, 55.50, 55.45,
55.23, 54.39, 49.05, 39.28, 30.05, 27.93, 24.26, 22.83, 22.52, 14.77.
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KA13

HO

O

HO

HO

O

O
H
H

Cl
H

H

AlO3/PCC/ 45 °C
CH2Cl2

O

H

Cl
H

O

1H NMR (600 MHz, CDCl3) δ 7.73 (d, J = 15.6 Hz, 1H), 7.40 (dd, J = 8.7, 2.4 Hz, 2H),
7.29 (dd, J = 8.7, 2.1 Hz, 2H), 6.79 – 6.76 (m, 1H), 6.64 (s, 1H), 6.61 (d, J = 1.1 Hz, 1H),
6.55 (s, 1H), 3.69 (s, 2H), 2.98 – 2.85 (m, 2H), 2.83 – 2.68 (m, 4H), 2.58 – 2.50 (m, 1H),
2.47 (dd, J = 15.0, 6.1 Hz, 1H), 2.24 – 2.21 (m, 1H), 2.20 – 2.08 (m, 3H), 1.67 – 1.55 (m,
3H), 1.25 (s, 2H), 0.82 – 0.78 (m, 3H), 0.71 (s, 3H).

13C NMR (151 MHz, CDCl3) δ 212.66, 201.65, 182.25, 159.19, 144.31, 137.18, 132.50,
129.94, 129.35, 128.62, 119.15, 114.49, 113.22, 112.63, 78.75, 55.25, 54.61, 51.23, 47.39,
46.89, 41.05, 31.14, 29.73, 26.27, 24.73, 22.94, 20.30, 14.35.
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KA10

HO

O

HO
O

HO
H
H

Cl

O

O
CH2Cl2

O

Cl

H

AlO3/PCC/ 45 °C
H

O

H

H

O

1H NMR (600 MHz, CDCl3) δ 7.36 (d, J = 15.2 Hz, 1H), 6.73 (d, J = 8.6 Hz, 1H), 6.68
(dd, J = 8.6, 2.7 Hz, 1H), 6.64 (s, 1H), 6.62 (s, 1H), 6.62 (d, J = 2.2 Hz, 1H), 6.24 (d, J =
3.5 Hz, 1H), 3.72 (s, 3H), 2.89 (d, J = 12.5 Hz, 1H), 2.78 (dd, J = 13.1, 5.7 Hz, 1H), 2.71
(dd, J = 17.5, 5.7 Hz, 1H), 2.47 (d, J = 12.6 Hz, 1H), 2.24 – 2.17 (m, 1H), 2.04 (dt, J = 12.5,
3.3 Hz, 1H), 1.89 – 1.82 (m, 2H), 1.73 – 1.54 (m, 4H), 1.34 (s, 3H), 1.32 – 1.21 (m, 3H),
0.90 (s, 3H).
13C NMR (151 MHz, CDCl3) δ 213.04, 200.78, 159.32, 150.49, 140.38, 137.94, 130.64,
128.62, 127.39, 119.36, 115.55, 114.51, 113.35, 109.85, 78.40, 55.23, 53.66, 52.89, 47.84,
47.55, 41.15, 24.73, 24.05, 23.60, 22.27, 20.30, 14.65.
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KA16

HO

O

HO

HO

O
H
H

H

O

1H

O

H

AlO3/PCC/ 45 °C
CH2Cl2

H

H

O

NMR (600 MHz, CDCl3 δ 7.73 (d, J = 8.4 Hz, 4H), 6.60 (dd, J = 8.7, 2.8 Hz, 4H),

6.54 (d, J = 2.8 Hz, 4H), 3.72 (s, 3H), 2.89 (d, J = 12.5 Hz, 1H), 2.78 (dd, J = 13.1, 5.7
Hz, 1H), 2.71 (dd, J = 17.5, 5.7 Hz, 1H), 2.47 (d, J = 12.6 Hz, 1H), 2.24 – 2.17 (m, 1H),
2.04 (dt, J = 12.5, 3.3 Hz, 1H), 1.89 – 1.82 (m, 2H), 1.73 – 1.54 (m, 4H), 1.34 (s, 3H),
1.32 – 1.21 (m, 3H), 0.90 (s, 3H).
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5.3.3. Biological Evaluations
In a 96-well plate, a total of 1x106 cells were seeded. After serial dilution of each CIE
analog (from 25 μM down to 1.625 μM as Quadruplicate for each concentration), they were
added with 0.05% DMSO (Acros Organics) as a negative control and cuc B as a positive
control. The mixtures were incubated at 37 °C with 5% CO2 for 48 hrs. Next, 20 μL of 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma Aldrich) (5
mg/mL PBS) was added to each well and the plate was incubated for 2 hrs. In each well,
the solutions were discarded and 200 μL of DMSO was added and mixed. The absorbance
was measured at 570 nm by Hidex Sense Microplate readers.

Cell Culture: Primary human pancreatic stellate cells HPaSteC (ScienCell Research
Laboratories, Carlsbad, CA) were cultured in an RPMI-1640 growth medium with 2%
fetal bovine serum, while PANC-1 (ATCC® CRL-1469™) cells were cultured in a
DMEM growth medium with 10% (v/v) fetal bovine serum. All cultured cells were
grown at 37 °С in a humidified 5% CO2 atmosphere.15

Generation of 3D Pancreatic Spheroids. To generate 3D spheroids, PANC-1 cells were
seeded onto round-bottomed 96-well plates with an ultra-low attachment coating
(Corning, Kennebunk, ME) at a density of 120 cells per well in a volume of 100 µL.
Heterospheroids of PANC-1 and HPaSteC cells were grown at an initial cell ratio of
120:60. After two weeks of incubation at 37 °С in a humidified 5% CO2 atmosphere, the
spheroids were processed for use in other experiments.16
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Immunostaining and Imaging of Spheroid Frozen Sections. Pancreatic cancer spheroids
were washed with PBS and embedded in HistoPrep™ tissue embedding medium, snapfrozen in liquid nitrogen, and kept at -80 °C. Then, the frozen tumor blocks were cut into
10 μm sections, fixed in an acetone-methanol (1:1) mixture for 15 min, and air-dried at
room temperature. To determine the ECM components, cryosections were immunostained
and imaged with antibodies against collagen I, fibronectin, hyaluronan, and laminin, as
described previously.17

Cell Viability Assays. The cell viability of pancreatic cells and their co-culture with
HPaSteC cells (in a ratio of 2:1) in either monolayers or spheroids was determined after 48
hours of incubation with cucurbitacin derivatives (KA1, KA2 and KA9) and gemcitabine
(GEM) at different concentrations. For monolayers, we used MTT and CellTiter assays. In
the case of MTT assay, after exposure to the tested compounds, cells were incubated in 0.5
mg mL-1 solution of thuazolyl blue tetrazolium bromide (Acros Organics, NJ) in PBS for
1.5-2 hours, followed by extraction of formazan crystals by DMSO:ethanol mixture (1:1,
v/v). Optical density was measured at a wavelength of 560 nm using the 96-well plate
reader SpectraMax M2 (Molecular Devices, Sunnyvale, CA). The CellTiter assay
(Promega, Madison, WI), which measures the content of cell-associated ATP, was carried
out in black-wall 96-well plates (Costar, Kennebunk, ME) for both monolayer and 3D cell
cultures, according to manufacturer’s protocol. Luminescence was measured using
GloMax-Multi Detection System (Promega, Madison, WI).
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Caspase 3/7 Activity Assay. The Caspase-Glo 3/7 assay (Promega, Madison, WI) was
used to measure the activation of caspase 3/7, according to the manufacturer’s protocol.
After 48 hours of incubation, the caspase 3/7 was measured in monolayers of pancreatic
cancer cells in the presence of different concentrations of cucurbitacin derivatives (KA1,
KA2 and KA9) and gemcitabine (GEM) (Acros Organics, NJ). Luminescence was
measured using the GloMax-Multi Detection System (Promega, Madison, WI).

Spheroid Growth Inhibition: For the evaluation of spheroid growth inhibition, several
cucurbitacin derivatives (KA1, KA2, KA9) or gemcitabine (GEM) in concentrations of 10
µM were added to 5-day old spheroids (day 0). Two dimensions (length and width) of
PANC-1 (120) or PANC-1/HPaSteC (120:60) pancreatic tumor spheroids were measured
every two days using an inverted Axio Observer A1 microscope (Carl Zeiss, Gӧttingen,
Germany) equipped with a ×20/0.4 objective lens microscope. The volumes of the
spheroids were calculated as L x W x W (length x width x width).

In-cell western assay (ICW): PANC-I Cell lines were seeded into clear-bottomed, blackwalled 96-well plates with a density of 0.5 × 106 cells per mL and allowed to grow to
conﬂuence. The next day, the cells were treated with various concentrations of KA9 (1.225,
2.45, 4.9, and 9.8 µM) for 24 h and DMSO was used as a –ve control. Cells were then fixed
with 3.7% formaldehyde in 1X PBS for 30 min and then washed, permeabilized with 0.1%
TritonX-100 in 1X PBS, and blocked with 1X PBS fish gel solution. Next, they were
incubated with an antibody to the following: EGFR (cell signaling technology), PhosphoEGFR (Santa Cruz Biotechnology), MAPK (Erk1/ 2; Santa Cruz Biotechnology),
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Phospho-MAPK (p-Erk1/2; Santa Cruz Biotechnology), STAT3 and pSTAT3 (Santa Cruz
Biotechnology), mTOR and phosphorylated mTOR (Santa Cruz Biotechnology), and
GAPDH (Santa Cruz Biotechnology). The mixtures received gentle shaking for 2 h. They
were then incubated overnight at 4 °C without shaking (i.e: stationary). The cells were then
washed with 0.1% Tween-20 in 1X PBS four times and then incubated with secondary
antibodies conjugated to IR dye for 1 h with gentle shaking (protected from light). Cells
were then washed with 0.1% Tween- 20 in 1X PBS four times. After the last wash, any
residual liquid was gently pipetted out and the plate was blotted dry using the In-cell
western protocol on an Odyssey® imager (LI-COR®), according to manufacturer's
directions.17 Phospho-proteins were normalized for total protein signals. Data are
expressed as mean values of at least two runs ± the standard deviation (SD).
5.4. Conclusion
Ligand-based drug discovery approach was used to synthesis 8 cucurbitacin estrone
analogs with ketone group at C11. Molecular modeling results indicate that there are some
of ketone-C11 CIE analogs score high in molecular targets of pancreatic ductal
adenocarcinoma such as EGFR, RAS, RAF, PI3K, and STAT3. KA9, CIE analog score
higher most of the previous CIE analogs modified with hydroxyl at C11 or desaturated at
C9 and C11. However, most of the ketone C11 analogs did not show high calculated affinity
against the used molecular targets. In-vitro MTT and was conducted for the synthesized
CIE analogs against 3 pancreatic ductal adenocarcinoma cell lines PANC-I, AsPC-I, and
BXPC-3. The results indicate that KA9 show IC50 value of 4.9, 4.17, and 5.7 µM’s,
respectively, which is the lowest IC50 among the synthesized 24 analogs which support the
conducted molecular docking against the indicated molecular targets. Comparing the best
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synthesized analogs, KA1, KA2, and KA9 different biological evaluation assays have been
conducted including 2D and 3D cellTiter assays, Caspase-3 activity assay, cell cycle
flowcytometery, and in-cell western assay. The results indicate that the cell viability assay
on 2D cells with CellTiter assay that the IC50 values for each of these analogs is slightly
higher compared to that of MTT assay. All the three analogs KA1, KA2, and KA9 show
an increase in caspase-3 activity which an indicated that these analogs induce cell necrosis
through cell apoptosis. KA9 appear to arrest cell cycle at G0/G1 phase in a time- and
concentration- dependent manner. Interestingly, 3D cellTiter assay experiment show that
KA9 was able to decrease the tumor size starting from day 4 of treatment compared to
gemcitabine and the hydoxylated analogs which although it has the same analog as KA1
which indicate that two factors is needed to achieve the highest activity through penetration
of the tumor spheroids, presence of oxygen and higher hydrophobicity. Our results indicate
that KA9 is candidate for in-vivo animal study and a promising novel treatment for
pancreatic ductal adenocarcinoma.
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Chapter Six
General Conclusion and Future Directions

In this project, a comprehensive investigation of the functionalization of C11 of cucurbitacin
inspired-estrone analogs was undertaken. This is part of our lab's investigation into this
novel group of compounds in relation to the natural products-based drug discovery process.
Initially, the project was based on previous results regarding the optimization of the analogs
that included C3 and C16. The targeted disease in this study is pancreatic ductal
adenocarcinoma, one of the most challenging diseases since it has acquired resistance to
the common chemotherapeutic options. This project focused on the C11 position, as it
previously indicated that it increases the anticancer potency of CIE analogs. Moreover, this
position was found to be critical in both CIE analogs and cucurbitacins, as it changes the
configuration of the molecule and hence its activity.
The molecular modeling step is an effective beginning step, utilizing putative pancreatic
ductal adenocarcinoma's known critical targets, including EGFR, Erk, Ras, JAKI and
STAT3 proteins. Upon docking these analogs against the known targets, it was found that
different functionalizations offer general trends regarding the affinity to these proteins. For
example, amine and oxygenated C11 analogs score better in EGFR and STAT3 proteins,
while C9 C11 dehydrogenated analogs score better in Erk, compared to the other analogs.
This difference in affinity in the functional groups at C11, although with a different 23, 24
α-unsaturated side chain, confirms the importance of this position in the structure-activity
relationship of CIE analogs.
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The chemical synthesis challenge was one of the main obstacles to overcome in order to
reach the proposed synthetic routes, as is the case in any chemical synthesis route.
However, the challenges included the optimization of the steps, the yield, the number of
synthetic steps, and the performance of different reactions in the hindered C11 position.
Among these challenges, the optimization of the DDQ reaction was a critical step. Five
conditions were tried in this regard and only one of them achieved the desired yield that
enabled us to continue. Hydroxylation, as well as three other conditions, were used to
achieve the desired product. Moreover, the optimizations of the steps was critical, as
working in more than one position delays the synthetic process, since many side reactions
can exist. The number of steps was also a challenge, since reaching the final oxygenated
products required 13 reactions.
After achieving the synthesis of 24 compounds, biological evaluations were conducted
with different pancreatic cancer cell lines. The main cell line used in this biological study
was PANC-I. Among the 24 synthesized analogs, 5 analogs indicated promising biological
activities on the PANC-I cell line: KA1, KA2, KA9, KA19, and KA20 with IC50’s of 5.52,
12.8, 4.3, 11.23, 7.64 μM, respectively. KA1, KA9, and KA20 all contain a phenyl paratrifluoro enone side chain, which indicates this side chain is involved in anticancer activity.
KA2 and KA19 contain a cuc D and a phenyl para-nitro enone side chain, respectively.
Since all CIE analogs containing a phenyl para-trifluoro enone side chain have
antiproliferative activity, this can be used in their C11 functionalization. Regarding C11
functionalization of KA9>KA1>KA20 in terms of IC50 against the PANC-I cell line, the
order of functionalizations is as follows: Ketone>hydroxyl>alkene.
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To further investigate the effects of active CIE analogs, cell cycle analysis was conducted
against the PANC-I cell line. Results showed that they accumulate the cells in the G1 phase,
which indicates that the mechanism of action is similar in these compounds. Moreover,
KA9 was shown to induce cell cycle arrest in a time- and concentration-dependent manner.
However, the 3D tests of KA1, KA2, and KA9 against the PANC-I cell line found that
KA9 was better able to penetrate cell accumulation than KA1, KA2 and gemcitabine,
which confirms the previously hypothesized data that these compounds are transferred to
the cells through diffusion.
In order to study the mechanism of action of these compounds in depth, in cell western
assay was conducted for KA9 using four proteins: pEGFR, pErk, pSTAT3, mTOR. The
results indicate that KA9 was able to inhibit the expression of pEGFR and pErk specifically
in a concentration-dependent manner compared to cucurbitacin that has non-specific effect
against its targets.
According to our results, then, KA9 appears to be a good candidate for animal study, as it
shows a promising IC50 and a promising penetration of 3D cells. Additionally, the targets
for this compound have been identified. This amount of preliminary data is usually not
available for the drugs that are promoted to animal study; however, with KA9, much data
can be estimated.

Future Directions and Recommendations
Based on the anticancer activity of the previously mentioned CIE analogs and the
molecular docking data, many further investigations are needed to address and investigate
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the unanswered questions. These areas include the optimization of C16 and C17, based on
the desaturation of C16 C17, which dramatically changed the anticancer activity of the
synthesized analogs. Our current study suggests that hydroxylation, animation, and ketone
substitutions may lead to more potent analogs against several cancer cell lines. Moreover,
functionalization should include C11 and C16, based on the previously obtained data and the
results from the recent study.
Another next step based on this investigation is the study of KA9 in an animal model. This
would allow further in-depth study of the anticancer activity and the toxicity profile, in
order to promote it to clinical trials.
Generally, the CIE analogs from the previously conducted studies should be investigated
in animal models in order to broaden the data prior to further in-depth studies.

